

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                     | DOSAGE FORM                 | STRENGTH                           | RLD/NDA                         | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-----------------------------|------------------------------------|---------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Abacavir Sulfate                              | Tablets                     | 300 mg                             | Ziagen<br>20977                 | 1/28/2009          | 1                         | Eligible       | 2/11/2020                     | 6/18/2012                        | 6/19/2012                                 | 5/14/2018                                 |
| Abacavir                                      | Oral Solution               | 20 mg/mL                           | Ziagen<br>20978                 | 12/27/2012         | 1                         | Eligible       | 2/11/2020                     | 9/26/2016                        | 9/15/2017                                 | 5/14/2018                                 |
| Abacavir Sulfate, Dolutegravir and Lamivudine | Tablets                     | 600 mg/50 mg/<br>300 mg            | Triumeq<br>205551               | 8/14/2017          | 5                         |                |                               |                                  |   | 12/8/2029                                 |
| Abacavir Sulfate, Dolutegravir and Lamivudine | Tablets for Oral Suspension | 60 mg/5 mg/30 mg                   | Triumeq PD<br>215413            | 3/31/2023          | 1                         |                |                               |                                  |   | 12/8/2029                                 |
| Abacavir Sulfate and Lamivudine               | Tablets                     | 600 mg/300 mg                      | Epzicom<br>21652                | 9/27/2007          | 1                         | Eligible       | 2/11/2020                     | 9/29/2016                        | 9/29/2016                                 | 5/14/2018                                 |
| Abacavir Sulfate, Lamivudine and Zidovudine   | Tablets                     | 300 mg/150 mg/<br>300 mg           | Trizivir<br>21205               | 3/22/2011          | 1                         | Eligible       | 2/11/2020                     | 12/5/2013                        | 12/17/2013                                | 5/14/2018                                 |
| Abaloparatide                                 | Subcutaneous Injection      | 3.12 mg/1.56 mL                    | Tymlos<br>208743                | 6/21/2022          | 1                         |                |                               |                                  |   | 1/10/2040                                 |
| Abiraterone Acetate                           | Tablets                     | 125 mg                             | Yonsa<br>210308                 | 7/23/2018          | 1                         | Deferred       | 7/25/2022                     | 6/24/2022                        |   | 3/17/2034                                 |
| Abiraterone Acetate                           | Tablets                     | 250 mg                             | Zytiga<br>202379                | 4/28/2015          | 13                        | Eligible       | 6/18/2019                     | 10/31/2018                       | 11/21/2018                                | 8/24/2027                                 |
| Abiraterone Acetate                           | Tablets                     | 500 mg                             | Zytiga<br>202379                | 8/23/2017          | 1                         | Extinguished   | 1/12/2021                     |                                  |   | 8/24/2027                                 |
| Acalabrutinib                                 | Capsules                    | 100 mg                             | Calquence<br>210259             | 11/1/2021          | 5                         |                |                               |                                  |   | 7/1/2036                                  |
| Acarbose                                      | Tablets                     | 25 mg, 50 mg and<br>100 mg         | Precose<br>20482                | 3/22/2005          | 1                         | Extinguished   | 2/11/2020                     | 5/7/2008                         |   | 9/6/2009                                  |
| Acetylcysteine                                | Injection                   | 200 mg/mL, 30 mL<br>vials          | Acetadote<br>21539              | 4/4/2012           | 3                         | Eligible       | 2/11/2020                     | 11/7/2012                        | 11/30/2012                                | 5/21/2026                                 |
| Acetaminophen                                 | Injection                   | 1000 mg/100 mL<br>(10 mg/mL)       | Ofirmev<br>22450                | 4/7/2011           | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 6/6/2021                                  |
| Acetaminophen                                 | Extended-release<br>Tablets | 650 mg                             | Tylenol<br>19872                | Pre-MMA            |                           |                |                               |                                  |   |   |
| Acetaminophen and Tramadol Hydrochloride      | Tablets                     | 325 mg/ 37.5 mg                    | Ultracet<br>21123               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Acetaminophen/ Aspirin/<br>Caffeine           | Tablets                     | 250 mg/ 250 mg/<br>65 mg           | Excedrin<br>(migraine)<br>20802 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Acyclovir Sodium                              | Injection                   | 50 mg/mL, 10 mL<br>and 20 mL vials | Zovirax<br>18603                | Pre-MMA            |                           |                |                               |                                  |   |   |
| Adapalene                                     | Topical Gel                 | 0.30%                              | Differin<br>21753               | 9/15/2009          | 1                         | Eligible       | 2/11/2020                     | 6/14/2012                        | 4/28/2014                                 | 2/23/2025                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| <b>DRUG NAME</b>                          | <b>DOSAGE FORM</b>       | <b>STRENGTH</b>                     | <b>RLD/NDA</b>           | <b>DATE OF SUBMISSION</b> | <b>NUMBER OF ANDAs SUBMITTED</b> | <b>180-DAY STATUS</b>   | <b>180-DAY DECISION POSTING DATE</b> | <b>DATE OF FIRST APPLICANT APPROVAL</b> | <b>DATE OF FIRST COMMERCIAL MARKETING BY FTF</b> | <b>EXPIRATION DATE OF LAST QUALIFYING PATENT</b> |
|---|--------------------------|-------------------------------------|--------------------------|---------------------------|----------------------------------|-------------------------|--------------------------------------|---|--|--|
| Adapalene and Benzoyl Peroxide            | Gel                      | 0.1%/2.5%                           | Epiduo 22320             | 12/30/2011                | 1                                | Eligible                | 2/11/2020                            | 9/30/2015                               | 7/27/2017  | 7/18/2027  |
| Adapalene and Benzoyl Peroxide            | Gel                      | 0.3%/2.5%                           | Epiduo Forte 207917      | 5/4/2016                  | 1                                | Eligible                | 6/18/2019                            | 10/17/2018                              | 12/1/2021  | 3/12/2023  |
| Adefovir Dipivoxil                        | Tablets                  | 10 mg                               | Hepsera 21449            | 6/8/2010                  | 1                                | Eligible                | 2/11/2020                            | 8/29/2013                               | 9/3/2013   | 7/23/2018  |
| Afatinib Dimaleate                        | Tablets                  | 20 mg, 30 mg and 40 mg              | Gilotrif 201292          | 7/12/2017                 | 7                                |                         |                                      |   |  | 12/19/2029                                       |
| Adenosine                                 | Injection                | 3 mg/mL, 20 mL and 30 mL vials      | Adenoscan 20059          | 4/18/2005                 | 1                                | Eligible                | 2/11/2020                            | 8/29/2013                               | 9/23/2013  | 3/24/2015  |
| Albuterol Sulfate                         | Oral Syrup               | 2 mg(base)/ 5 mL                    | Ventolin 19621           | Pre-MMA                   |                                  |                         |                                      |   |  |  |
| Albuterol Sulfate                         | Extended-release Tablets | 4 mg and 8 mg                       | Volmax 19604             | Pre-MMA                   |                                  |                         |                                      |   |  |  |
| Albuterol Sulfate                         | Inhalation Solution      | 0.021%                              | Accuneb 20949            | 10/19/2005                | 1                                | Eligible                | 2/11/2020                            | 9/25/2007                               |  | 12/28/2021                                       |
| Albuterol Sulfate                         | Inhalation Solution      | 0.042%                              | Accuneb 20949            | 4/6/2004                  | 1                                | Eligible                | 2/11/2020                            | 6/28/2004                               |  | 12/28/2021                                       |
| Albuterol Sulfate and Ipratropium Bromide | Inhalation Solution      | 0.083%/ 0.017%                      | Duoneb 20950             | Pre-MMA                   |                                  |                         |                                      |   |  |  |
| Albuterol Sulfate and Ipratropium Bromide | Inhalation Aerosol       | 100 mcg/20 mcg per actuation        | Combivent Respimat 21747 | 3/30/2023                 | 1                                |                         |                                      |   |  | 10/16/2030                                       |
| Albuterol Sulfate                         | Inhalation Aerosol       | 0.09 mg base per actuation          | Pro-Air HFA 21457        | 5/18/2012                 | 1                                | Non-Forfeiture Deferred | 8/24/2020<br>3/10/2020               | 2/24/2020                               | 2/26/2020  | 9/12/2023  |
| Albuterol Sulfate                         | Inhalation Aerosol       | 0.09 mg base per actuation          | Proventil HFA 20503      | 5/20/2015                 | 1                                | Extinguished            | 2/11/2020                            |   |  | 12/28/2016                                       |
| Alcaftadine                               | Ophthalmic Solution      | 0.25%                               | Lastacaft 22134          | 7/30/2014                 | 1                                | Extinguished            | 8/27/2019                            |   |  | 10/5/2029  |
| Alectinib                                 | Capsules                 | 150 mg                              | Alecensa 208434          | 12/11/2019                | 1                                |                         |                                      |   |  | 3/4/2032   |
| Alendronate Sodium                        | Oral Solution            | 70 mg/75 mL                         | Fosamax 21575            | 9/7/2007                  | 1                                | Extinguished            | 2/11/2020                            |   |  | 7/17/2018  |
| Alendronate Sodium                        | Tablets                  | 5 mg, 10 mg, 35 mg, 40 mg and 70 mg | Fosamax 20560            | Pre-MMA                   |                                  |                         |                                      |   |  |  |
| Alendronate Sodium and Cholecalciferol    | Tablets                  | 70 mg/2800 IU and 70 mg/5600 IU     | Fosamax Plus D 21762     | 11/20/2007                | 1                                | Extinguished            | 2/11/2020                            |   |  | 7/17/2018  |
| Alfuzosin Hydrochloride                   | Extended-release Tablets | 10 mg                               | Uroxatral 21287          | 6/12/2007                 | 9                                | Eligible                | 2/11/2020                            | 7/18/2011                               | 7/18/2011  | 8/22/2017  |
| Aliskiren Hemifumarate                    | Tablets                  | 150 mg and 300 mg                   | Tekturna 21985           | 1/27/2014                 | 1                                | Deferred                | 8/13/2019                            | 3/22/2019                               | 3/25/2019  | 2/19/2026  |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                      | DOSAGE FORM                      | STRENGTH   | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|----------------------------------|--|-----------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Aliskiren Hemifumarate and Hydrochlorothiazide | Tablets                          | 150 mg/12.5 mg<br>150 mg/25 mg<br>300 mg/12.5 mg<br>300 mg/25 mg | Tekturna HCT<br>22107 | 3/7/2014           | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 7/13/2028                                 |
| Almotriptan Malate                             | Tablets                          | 6.25 mg and<br>12.5 mg   | Axert<br>21001        | 12/8/2005          | 1                         | Extinguished             | 2/11/2020                     | 7/7/2015                         |   | 5/7/2015                                  |
| Alogliptin                                     | Tablets                          | 6.25 mg, 12.5 mg<br>and 25 mg                                    | Nesina<br>22271       | 1/25/2017          | 5                         |                          |                               |                                  |   | 6/16/2029                                 |
| Alogliptin and Metformin Hydrochloride         | Tablets                          | 12.5 mg/500 mg and<br>12.5 mg/1000 mg                            | Kazano<br>203414      | 1/25/2017          | 3                         |                          |                               |                                  |   | 5/24/2029                                 |
| Alosetron Hydrochloride                        | Tablets                          | 0.5 mg and 1 mg  | Lotronex<br>21107     | 12/2/2010          | 1                         | Deferred                 | 2/11/2020                     | 5/4/2015                         | 5/21/2015                                 | 10/5/2018                                 |
| Alprazolam                                     | Orally Disintegrating<br>Tablets | 0.25 mg, 0.5 mg,<br>1 mg and 2 mg                                | Niravam<br>21726      | 12/27/2005         | 1                         | Extinguished<br>Eligible | 7/2/2019<br>7/2/2019          | 1/9/2009                         | 1/14/2009                                 | 4/9/2018                                  |
| Alprazolam                                     | Tablets                          | 0.25 mg, 0.5 mg,<br>1 mg and 2 mg                                | Xanax<br>18276        | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Alvimopan                                      | Capsules                         | 12 mg  | Entereg<br>21775      | 6/16/2017          | 1                         | Deferred                 | 1/2/2020                      | 12/19/2019                       | 12/19/2019                                | 7/31/2030                                 |
| Amantadine                                     | Extended-release<br>Capsules     | 137 mg   | Gocovri<br>208944     | 1/16/2018          | 1                         |                          |                               |                                  |   | 12/2/2030                                 |
| Amantadine                                     | Extended-release<br>Capsules     | 68.5 mg  | Gocovri<br>208944     | 4/30/2020          | 1                         |                          |                               |                                  |   | 12/4/2034                                 |
| Ambrisentan                                    | Tablets                          | 5 mg and 10 mg   | Letairis<br>22081     | 2/9/2015           | 1                         | Extinguished             | 8/27/2019                     | 3/28/2019                        |   | 7/9/2018                                  |
| Amifampridine Phosphate                        | Tablets                          | 10 mg  | Firdapse<br>208078    | 11/28/2022         | 3                         |                          |                               |                                  |   | 2/25/2037                                 |
| Amifostine                                     | For Injection                    | 500 mg/vial  | Ethyol<br>20221       | 4/16/2004          | 1                         | Eligible                 | 2/11/2020                     | 3/14/2008                        | 3/27/2008                                 | 7/31/2012                                 |
| Amlodipine Benzoate                            | Oral Suspension                  | 1 mg/mL  | Katerzia<br>211340    | 12/29/2020         | 1                         | Eligible                 | 6/26/2023                     | 6/13/2023                        |   | 4/11/2039                                 |
| Amlodipine Besylate                            | Tablets                          | 2.5 mg, 5 mg and<br>10 mg  | Norvasc<br>19787      | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Amlodipine Besylate and Atorvastatin Calcium   | Tablets                          | 2.5 mg/10 mg<br>2.5 mg/20 mg<br>10 mg/40 mg                      | Caduet<br>21540       | 9/17/2009          | 1                         | Extinguished             | 2/11/2020                     | 11/29/2013                       | 2/1/2011                                  | 8/11/2018                                 |
| Amlodipine Besylate and Atorvastatin Calcium   | Tablets                          | 2.5 mg/40 mg   | Caduet<br>21540       | 9/17/2009          | 1                         | Extinguished             | 2/11/2020                     | 11/29/2013                       | 2/1/2011                                  | 8/11/2018                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM              | STRENGTH   | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|--|-----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Amlodipine Besylate and Atorvastatin Calcium     | Tablets                  | 5 mg/10 mg<br>5 mg/20 mg<br>5 mg/40 mg<br>10 mg/10 mg<br>10 mg/20 mg<br>10 mg/80 mg        | Caduet<br>21540       | 12/29/2006         | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 8/11/2018                                 |
| Amlodipine Besylate and Atorvastatin Calcium     | Tablets                  | 5 mg/80 mg   | Caduet<br>21540       | 4/7/2009           | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 8/11/2018                                 |
| Amlodipine Besylate and Benazepril Hydrochloride | Capsules                 | 2.5 mg/10 mg<br>5 mg/10 mg<br>5 mg/20 mg<br>10 mg/20 mg                                    | Lotrel<br>20364       | 6/9/2004           | 1                         | Eligible       | 2/11/2020                     | 3/18/2007                        |   | 12/19/2017                                |
| Amlodipine Besylate and Benazepril Hydrochloride | Capsules                 | 5 mg/40 mg and<br>10 mg/40 mg  | Lotrel<br>20364       | 11/17/2006         | 1                         | Eligible       | 2/11/2020                     | 7/29/2010                        | 1/3/2011                                  | 12/19/2017                                |
| Amlodipine Besylate and Celecoxib                | Tablets                  | 2.5 mg/200 mg,<br>5 mg/200 mg,<br>10 mg/200 mg   | Consensi<br>210045    | 6/29/2020          | 1                         |                |                               |                                  |   | 6/14/2038                                 |
| Amlodipine Besylate and Olmesartan Medoxomil     | Tablets                  | 5 mg/20 mg and<br>10 mg/40 mg  | Azor<br>22100         | 2/11/2008          | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 4/25/2016                                 |
| Amlodipine Besylate and Olmesartan Medoxomil     | Tablets                  | 10 mg/20 mg and<br>5 mg/40 mg  | Azor<br>22100         | 3/31/2008          | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 4/25/2016                                 |
| Amlodipine Besylate and Valsartan                | Tablets                  | 5 mg/160 mg  | Exforge<br>21990      | 10/22/2007         | 1                         | Eligible       | 2/11/2020                     | 3/28/2013                        | 9/30/2014                                 | 7/8/2019                                  |
| Amlodipine Besylate and Valsartan                | Tablets                  | 5 mg/320 mg  | Exforge<br>21990      | 11/26/2007         | 1                         | Eligible       | 2/11/2020                     | 3/28/2013                        | 9/30/2014                                 | 7/8/2019                                  |
| Amlodipine Besylate and Valsartan                | Tablets                  | 10 mg/160 mg   | Exforge<br>21990      | 10/1/2007          | 1                         | Eligible       | 2/11/2020                     | 3/28/2013                        | 9/30/2014                                 | 7/8/2019                                  |
| Amlodipine Besylate and Valsartan                | Tablets                  | 10 mg/320 mg   | Exforge<br>21990      | 11/9/2007          | 1                         | Eligible       | 2/11/2020                     | 3/28/2013                        | 9/30/2014                                 | 7/8/2019                                  |
| Amlodipine, Hydrochlorothiazide and Valsartan    | Tablets                  | 5 mg/12.5 mg/160 mg,<br>5 mg/25 mg/160 mg,<br>10 mg/25 mg/160 mg and<br>10 mg/25 mg/320 mg | Exforge HCT<br>22314  | 9/14/2009          | 1                         | Eligible       | 2/11/2020                     | 9/25/2012                        | 12/1/2014                                 | 7/18/2017                                 |
| Amlodipine, Hydrochlorothiazide and Valsartan    | Tablets                  | 10 mg/12.5 mg/<br>160 mg   | Exforge HCT<br>22314  | 10/22/2009         | 1                         | Eligible       | 2/11/2020                     | 9/25/2012                        | 12/1/2014                                 | 7/18/2017                                 |
| Amoxicillin and Clavulanate Potassium            | Extended-release Tablets | 1000 mg/62.5 mg  | Augmentin XR<br>50785 | 1/21/2009          | 1                         | Eligible       | 2/11/2020                     | 4/21/2010                        |   | 4/4/2020                                  |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                                    | STRENGTH  | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|--|---|-----------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Amphetamine   | Extended-release Orally Disintegrating Tablets | 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg | Adzenys XR-ODT 204326 | 5/10/2016          | 1                         | Deferred                 | 6/26/2023                     | 6/22/2023                        |   | 1/28/2032                                 |
| Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate | Extended-release Capsules                      | 37.5 mg and 50 mg                                 | Mydayis 22063         | 8/3/2017           | 1                         | Extinguished<br>Deferred | 9/4/2023<br>2/8/2022          | 1/31/2022                        |   | 8/24/2029                                 |
| Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate | Extended-release Capsules                      | 12.5 mg and 25 mg                                 | Mydayis 22063         | 8/7/2017           | 1                         | Extinguished<br>Deferred | 9/4/2023<br>2/8/2022          | 1/31/2022                        |   | 8/24/2029                                 |
| Angiotensin II Acetate  | Injection                                      | 2.5 mg/mL   | Giapreza 209360       | 12/21/2021         | 1                         |                          |                               |                                  |   | 12/18/2034                                |
| Apalutamide   | Tablets  | 60 mg   | Erleada 210951        | 2/14/2022          | 5                         |                          |                               |                                  |   | 4/30/2038                                 |
| Apixaban  | Tablets  | 2.5 mg and 5 mg                                   | Eliquis 202155        | 12/28/2016         | 25                        | Eligible                 | 1/14/2020                     | 12/23/2019                       |   | 2/24/2031                                 |
| Apremilast  | Tablets  | 10 mg, 20 mg and 30 mg                            | Otezla 205437         | 3/22/2018          | 10                        | Eligible                 | 2/22/2021                     | 2/17/2021                        |   | 5/29/2034                                 |
| Aprepitant  | Capsule  | 40 mg, 80 mg and 125 mg                           | Emend 21549           | 11/3/2008          | 1                         | Deferred                 | 2/11/2020                     | 9/24/2012                        | 12/27/2016                                | 4/17/2015                                 |
| Aprepitant  | for Oral Suspension                            | 125 mg/Kit  | Emend 207865          | 11/23/2016         | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 9/26/2027                                 |
| Aprepitant  | Intravenous Emulsion                           | 32 mg/4.4 mL                                      | Aponvie 216457        | 11/7/2023          | 1                         |                          |                               |                                  |   | 9/18/2035                                 |
| Aprepitant  | Intravenous Emulsion                           | 130 mg/18 mL                                      | Cinvanti 209296       | 4/29/2022          | 1                         |                          |                               |                                  |   | 9/18/2035                                 |
| Arformoterol Tartrate   | Inhalation Solution                            | Eq. 0.015 mg base/ 2 mL                           | Brovana 21912         | 10/1/2009          | 1                         | Extinguished             | 7/2/2019                      |                                  |   | 11/9/2021                                 |
| Argatroban  | Injection                                      | 100 mg/mL, 2.5 mL vials                           | Argatroban 20883      | 9/24/2007          | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 6/30/2014                                 |
| Argatroban in Sodium Chloride   | Injection                                      | 1 mg/mL, 50 mL vials                              | Argatroban 22434      | 12/16/2011         | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 9/26/2027                                 |
| Aripiprazole  | Oral Solution                                  | 1 mg/mL   | Abilify 21713         | 12/20/2007         | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 4/24/2022                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                              | DOSAGE FORM                            | STRENGTH                                  | RLD/NDA                     | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--|---|-----------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Aripiprazole                           | Tablets                                | 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg | Abilify 21436               | 11/15/2006         | 8                         | Extinguished   | 2/11/2020                     |                                  |   | 10/20/2014                                |
| Aripiprazole                           | Orally Disintegrating Tablets          | 10 mg, 15 mg, 20 mg and 30 mg             | Abilify 21729               | 11/15/2006         | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 10/20/2014                                |
| Aripiprazole                           | Extended-release Injectable Suspension | 300 mg/vial and 400 mg/vial               | Abilify Maintena Kit 202971 | 12/20/2021         | 1                         |                |                               |                                  |   | 9/24/2033                                 |
| Armodafinil                            | Tablets                                | 50 mg, 150 mg and 250 mg                  | Nuvigil 21875               | 7/24/2009          | 1                         | Eligible       | 2/11/2020                     | 6/1/2012                         | 6/1/2016                                  | 12/18/2024                                |
| Armodafinil                            | Tablets                                | 100 mg                                    | Nuvigil 21875               | 9/8/2009           | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 12/18/2023                                |
| Armodafinil                            | Tablets                                | 200 mg                                    | Nuvigil 21875               | 9/3/2009           | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 12/18/2023                                |
| Arsenic Trioxide                       | Injection                              | 1 mg/mL                                   | Trisenox 21248              | 8/11/2015          | 1                         | Deferred       | 2/11/2020                     | 8/31/2018                        |   | 11/10/2018                                |
| Asenapine Maleate                      | Sublingual Tablets                     | 5 mg and 10 mg                            | Saphris 22117               | 8/13/2013          | 4                         | Eligible       | 1/12/2021                     | 12/10/2020                       | 12/10/2020                                | 4/6/2026                                  |
| Asenapine Maleate                      | Sublingual Tablets                     | 2.5 mg                                    | Saphris 22117               | 7/27/2017          | 1                         | Deferred       | 1/12/2021                     | 12/10/2020                       | 12/10/2020                                | 4/6/2026                                  |
| Aspirin and Omeprazole                 | Delayed-release Tablets                | 81 mg/40 mg and 325 mg/40 mg              | Yosprala 205103             | 10/17/2016         | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 2/28/2023                                 |
| Aspirin and Dipyridamole               | Extended-release Capsules              | 25 mg and 200 mg                          | Aggrenox 20884              | 2/1/2007           | 1                         | Deferred       | 2/11/2020                     | 8/14/2009                        | 7/1/2015                                  | 1/18/2017                                 |
| Atazanavir Sulfate                     | Capsules                               | 100 mg and 150 mg                         | Reyataz 21567               | 3/19/2010          | 1                         | Eligible       | 2/11/2020                     | 4/22/2014                        | 12/27/2017                                | 12/21/2018                                |
| Atazanavir Sulfate                     | Capsules                               | 200 mg                                    | Reyataz 21567               | 2/16/2010          | 1                         | Eligible       | 2/11/2020                     | 4/22/2014                        | 12/27/2017                                | 12/21/2018                                |
| Atazanavir Sulfate                     | Capsules                               | 300 mg                                    | Reyataz 21567               | 7/20/2009          | 1                         | Eligible       | 2/11/2020                     | 4/22/2014                        | 12/27/2017                                | 12/21/2018                                |
| Atazanavir Sulfate and Cobicistat      | Tablets                                | 300 mg/150 mg                             | Evotaz 206353               | 9/13/2017          | 1                         |                |                               |                                  |   | 9/3/2029                                  |
| Atenolol                               | Tablets                                | 25 mg, 50 mg and 100 mg                   | Tenormin 18240              | Pre-MMA            |                           |                |                               |                                  |   |   |
| Atenolol/ Chlorthalidone               | Tablets                                | 50 mg/25 mg and 100 mg/25 mg              | Tenoretic 18760             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Atovaquone                             | Oral Suspension                        | 750 mg/5 mL                               | Mepron 20500                | 10/20/2009         | 1                         | Extinguished   | 2/11/2020                     |                                  |   |   |
| Atovaquone and Proguanil Hydrochloride | Tablets                                | 62.5 mg/25 mg                             | Malarone 21078              | 9/14/2010          | 1                         | Extinguished   | 2/11/2020                     | 5/27/2014                        |   | 11/25/2013                                |
| Atovaquone and Proguanil Hydrochloride | Tablets                                | 250 mg/100 mg                             | Malarone 21078              | 4/3/2009           | 1                         | Eligible       | 2/11/2020                     | 1/12/2011                        | 9/15/2011                                 | 11/25/2013                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM         | STRENGTH  | RLD/NDA                                 | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------|---|---|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Atomoxetine Hydrochloride                           | Capsules            | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | Strattera 21411                         | 5/29/2007          | 10                        | Extinguished   | 2/11/2020                     | 5/30/2017                        |   | 11/26/2016                                |
| Atorvastatin Calcium                                | Tablets             | 10 mg, 20 mg, 40 mg and 80 mg                       | Lipitor 20702                           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Avanafil  | Tablets             | 50 mg, 100 mg and 200 mg                            | Stendra 202276                          | 4/27/2016          | 1                         |                |                               |                                  |   | 4/27/2025                                 |
| Axitinib  | Tablets             | 1 mg and 5 mg                                       | Inlyta 202324                           | 2/23/2018          | 1                         |                |                               |                                  |   | 12/14/2030                                |
| Azacitidine   | Tablets             | 200 mg and 300 mg                                   | Onureg 214120                           | 9/30/2021          | 1                         |                |                               |                                  |   | 6/3/2030                                  |
| Azelaic Acid  | Gel                 | 15%   | Finacea 21470                           | 7/27/2012          | 1                         | Extinguished   | 2/11/2020                     | 11/19/2018                       |   | 11/18/2018                                |
| Azelaic Acid  | Topical Foam        | 15%   | Finacea 207071                          | 9/14/2017          | 1                         | Eligible       | 9/6/2022                      | 10/7/2020                        |   | 2/28/2029                                 |
| Azelastine Hydrochloride                            | Nasal Spray         | 0.125 mg base/spray                                 | Astelin 20114                           | 11/14/2005         | 1                         | Eligible       | 2/11/2020                     | 4/30/2009                        | 6/23/2010                                 | 5/1/2011                                  |
| Azelastine Hydrochloride                            | Nasal Spray         | 205.5 mcg/spray                                     | Astepro 22203                           | 12/15/2011         |                           |                |                               |                                  |   |   |
| Azelastine Hydrochloride                            | Nasal Spray         | 205.5 mcg/spray                                     | Astepro Allergy (OTC) 213872            | 7/12/2021          | 1                         |                |                               |                                  |   | 6/4/2028                                  |
| Azelastine Hydrochloride                            | Nasal Spray         | 205.5 mcg/spray                                     | Children's Astepro Allergy (OTC) 213872 | 7/12/2021          | 1                         |                |                               |                                  |   | 6/4/2028                                  |
| Azelastine Hydrochloride                            | Ophthalmic Solution | 0.05%   | Optivar 21127                           | 12/13/2006         | 1                         | Eligible       | 2/11/2020                     | 8/3/2009                         | 12/1/2009                                 | 5/1/2011                                  |
| Azelastine Hydrochloride and Fluticasone Propionate | Nasal Spray         | 137 mcg/50 mcg per spray                            | Dymista 202236                          | 6/13/2014          | 1                         | Eligible       | 6/18/2019                     | 4/28/2017                        | 3/2/2020                                  | 8/24/2026                                 |
| Azilsartan Kamedoxomil                              | Tablets             | 40 mg and 80 mg                                     | Edarbi 200796                           | 4/10/2020          | 1                         | Eligible       | 9/6/2022                      | 7/20/2022                        |   | 3/26/2028                                 |
| Azilsartan Kamedoxomil and Chlorthalidone           | Tablets             | 40 mg/12.5 mg and 40 mg/25 mg                       | Edarbyclor 202331                       | 4/19/2022          | 1                         |                |                               |                                  |   | 7/1/2031                                  |
| Azithromycin  | for Injection       | 500 mg/vial   | Zithromax 20733                         | 1/26/2009          | 2                         | Eligible       | 2/11/2020                     | 3/24/2009                        | 5/11/2009                                 | 7/31/2018                                 |
| Azithromycin  | Ophthalmic Solution | 1%  | Azasite 50810                           | 3/3/2011           | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 3/31/2019                                 |
| Baclofen  | Oral Solution       | 5 mg/5 mL   | Ozobax 208193                           | 7/26/2021          | 1                         |                |                               |                                  |   | 8/30/2039                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                   | DOSAGE FORM         | STRENGTH  | RLD/NDA                  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-----------------------------|---------------------|---|--------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Baclofen                    | Oral Suspension     | 25 mg/5 mL  | Fleqsuvy<br>215602       | 5/20/2022          | 1                         | Eligible                 | 6/12/2023                     | 6/8/2023                         | 6/19/2023                                 | 9/29/2037                                 |
| Baloxavir Marboxil          | Tablets             | 40 mg and 80 mg                                       | Xofluza<br>210854        | 10/24/2022         | 1                         |                          |                               |                                  |   | 9/25/2038                                 |
| Balsalazide Disodium        | Capsules            | 750 mg  | Colazal<br>20610         | 5/26/2022          | 1                         |                          |                               |                                  |   | 8/24/2026                                 |
| Balsalazide Disodium        | Tablets             | 1.1 g   | Giazo<br>22205           | 11/5/2013          | 1                         | Eligible                 | 2/11/2020                     | 9/8/2015                         |   | 6/23/2031                                 |
| Baricitinib                 | Tablets             | 1 mg and 2 mg   | Olumiant<br>207924       | 5/31/2022          | 2                         |                          |                               |                                  |   | 6/8/2030                                  |
| Baricitinib                 | Tablets             | 4 mg  | Olumiant<br>207924       | 10/3/2023          | 1                         |                          |                               |                                  |   | 6/8/2030                                  |
| Beclomethasone Dipropionate | Inhalation Aerosol  | 40 mcg/actuation and<br>80 mcg/actuation              | Qvar<br>20911            | 1/10/2020          | 1                         |                          |                               |                                  |   | 5/18/2031                                 |
| Beclomethasone Dipropionate | Inhalation Aerosol  | 40 mcg/actuation                                      | Qvar Redihaler<br>207921 | 10/30/2023         | 1                         |                          |                               |                                  |   | 8/19/2041                                 |
| Belinostat                  | Injection           | 500 mg/vial   | Beleodaq<br>206256       | 7/3/2018           | 1                         |                          |                               |                                  |   | 10/27/2027                                |
| Bendamustine Hydrochloride  | Injection           | 25 mg/vial and<br>100 mg/vial                         | Treanda<br>22249         | 6/4/2013           | 10                        | Eligible                 | 1/10/2023                     | 12/7/2022                        | 12/7/2022                                 | 10/26/2030                                |
| Bendamustine Hydrochloride  | Injection           | 90 mg/mL, 0.5 mL<br>and 2 mL in single-<br>dose vials | Treanda<br>22249         | 6/19/2014          | 1                         |                          |                               |                                  |   | 9/23/2029                                 |
| Bendamustine Hydrochloride  | Injection           | 100 mg/4 mL (25<br>mg/mL) multiple-dose<br>vials      | Bendeka<br>208194        | 5/4/2017           | 1                         |                          |                               |                                  |   | 3/15/2033                                 |
| Bendamustine Hydrochloride  | Injection           | 100 mg/4 mL (25<br>mg/mL) multiple-dose<br>vials      | Belrapzo<br>205580       | 7/17/2018          | 1                         |                          |                               |                                  |   | 1/28/2031                                 |
| Benzyl Alcohol              | Lotion              | 5%  | Ulesfia<br>22129         | 4/11/2016          | 1                         | Extinguished             | 6/15/2020                     |                                  |   | 5/19/2024                                 |
| Bepotastine Besilate        | Ophthalmic Solution | 1.5%  | Bepreve<br>22288         | 9/9/2013           | 3                         | Extinguished<br>Deferred | 2/11/2020<br>2/11/2020        | 3/5/219                          |   | 9/19/2019                                 |
| Betamethasone Valerate      | Foam                | 0.12%   | Luxiq<br>20934           | 8/10/2007          | 1                         | Deferred                 | 2/11/2020                     | 11/26/2012                       |   | 5/24/2017                                 |
| Betamethasone Dipropionate  | Topical Spray       | 0.05%   | Sernivo<br>208079        | 2/15/2018          | 1                         | Eligible                 | 7/13/2020                     | 6/17/2020                        |   | 8/31/2030                                 |
| Betaxolol                   | Ophthalmic Solution | 0.5%(base)  | Betoptic<br>19270        | Pre-MMA            |                           |                          |                               |                                  |   |   |



**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM         | STRENGTH                                   | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------|--|------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Bexarotene  | Capsules            | 75 mg                                      | Targretin 20155  | 6/6/2011           | 1                         | Eligible                 | 2/11/2020                     | 8/12/2014                        | 7/9/2015                                  | 10/5/2016                                 |
| Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate        | Tablets             | 15 mg/120 mg/15 mg                         | Biktarvy 210251  | 9/28/2023          | 1                         |                          |                               |                                  |   | 6/19/2035                                 |
| Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate        | Tablets             | 50 mg/200 mg/25 mg                         | Biktarvy 210251  | 2/7/2022           | 3                         |                          |                               |                                  |   | 11/8/2036                                 |
| Bimatoprost   | Ophthalmic Solution | 0.01%                                      | Lumigan 22184    | 4/5/2011           | 1                         |                          |                               |                                  |   | 6/13/2027                                 |
| Bimatoprost   | Ophthalmic Solution | 0.03%                                      | Lumigan 21275    | 12/22/2008         | 1                         | Extinguished             | 2/11/2020                     |                                  |   |   |
| Bimatoprost   | Topical Solution    | 0.03%                                      | Latisse 22369    | 5/3/2010           | 1                         | Extinguished<br>Deferred | 6/18/2019<br>6/18/2019        | 12/1/2014                        |   | 5/25/2024                                 |
| Binimetinib   | Tablets             | 15 mg                                      | Mektovi 210498   | 6/27/2022          | 3                         |                          |                               |                                  |   | 10/18/2033                                |
| Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride | Capsules            | 140 mg/125 mg/125 mg                       | Pylera 50786     | 8/12/2014          | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 12/14/2018                                |
| Bivalirudin   | For Injection       | 250 mg/vial                                | Angiomax 20873   | 9/1/2009           | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 7/27/2028                                 |
| Bosentan  | for Oral Suspension | 32 mg                                      | Tracleer 209279  | 2/8/2019           | 1                         |                          |                               |                                  |   | 12/28/2027                                |
| Bosutinib   | Tablets             | 100 mg and 500 mg                          | Bosulif 203341   | 9/6/2016           | 2                         |                          |                               |                                  |   | 11/23/2026                                |
| Bosutinib   | Tablets             | 400 mg                                     | Bosulif 203341   | 10/25/2018         | 1                         |                          |                               |                                  |   | 11/23/2026                                |
| Bortezomib  | For Injection       | 3.5 mg/vial                                | Velcade 21602    | 11/20/2008         | 1                         | Extinguished             | 1/27/2020                     |                                  |   | 1/25/2022                                 |
| Brexipiprazole  | Tablets             | 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg | Rexulti 205422   | 7/10/2019          | 18                        | Deferred                 | 9/6/2022                      | 8/11/2022                        |   | 10/12/2032                                |
| Brimonidine   | Topical Gel         | 0.33%                                      | Mirvaso 204708   | 12/15/2014         | 1                         | Extinguished             | 10/8/2019                     |                                  |   | 6/13/2031                                 |
| Brimonidine Tartrate  | Ophthalmic Solution | 0.1%                                       | Alphagan P 21770 | 12/20/2006         | 1                         | Extinguished             | 12/13/2022                    |                                  |   | 7/28/2021                                 |
| Brimonidine Tartrate  | Ophthalmic Solution | 0.15%                                      | Alphagan P 21262 | 11/03/2006         | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 1/28/2022                                 |
| Brimonidine Tartrate  | Ophthalmic Solution | 0.2%                                       | Alphagan 20613   | Pre-MMA            |                           |                          |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                    | DOSAGE FORM              | STRENGTH  | RLD/NDA                        | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|---|--------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Brimonidine Tartrate                         | Ophthalmic Solution      | 0.025%  | Lumify (OTC)<br>208144         | 7/12/2021          | 1                         |                |                               |                                  |   | 7/14/2030                                 |
| Brimonidine Tartrate and Timolol Maleate     | Ophthalmic Solution      | 0.2%/0.5%   | Combigan<br>21398              | 11/21/2008         | 1                         | Extinguished   | 5/5/2022                      |                                  |   | 4/19/2022                                 |
| Brinzolamide and Brimonidine Tartrate        | Ophthalmic Suspension    | 1%/0.2%   | Simbrinza<br>204251            | 8/1/2022           | 1                         |                |                               |                                  |   | 10/30/2030                                |
| Brivaracetam                                 | Injection                | 50 mg/5 mL  | Briviact<br>205837             | 5/12/2020          | 2                         |                |                               |                                  |   | 2/21/2026                                 |
| Brivaracetam                                 | Oral Solution            | 10 mg/mL  | Briviact<br>205838             | 5/12/2020          | 1                         |                |                               |                                  |   | 2/21/2026                                 |
| Brivaracetam                                 | Tablets                  | 10 mg, 25 mg,<br>50 mg, 75 mg and<br>100 mg                               | Briviact<br>205836             | 5/12/2020          | 7                         | Eligible       | 7/25/2022                     | 6/9/2022                         |   | 2/21/2026                                 |
| Bromfenac Sodium                             | Ophthalmic Solution      | 0.07%   | Prolensa<br>203168             | 7/26/2013          | 1                         | Non-Forfeiture | 11/19/2019                    | 11/22/2023                       | 1/8/2024                                  | 9/11/2025                                 |
| Bromfenac Sodium                             | Ophthalmic Solution      | 0.075%  | Bromsite<br>206911             | 10/25/2017         | 1                         | Deferred       | 2/19/2024                     | 2/2/2024                         | 2/12/2024                                 | 8/7/2029                                  |
| Budesonide                                   | Enteric Coated Capsules  | 3 mg  | Entocort EC<br>21324           | 2/1/2008           | 1                         | Extinguished   | 2/11/2020                     | 4/2/2014                         |   | 1/1/2015                                  |
| Budesonide                                   | Nasal Spray              | 0.032 mg<br>(32 mcg)/spray  | Rhinocort<br>20746             | 5/14/2007          | 1                         | Deferred       | 2/11/2020                     | 5/12/2014                        | 5/13/2014                                 | 10/29/2017                                |
| Budesonide                                   | Inhalation Suspension    | 0.25 mg/2 mL and<br>0.5 mg/2 mL   | Pulmicort<br>Respules<br>20929 | 9/15/2005          | 1                         | Extinguished   | 4/7/2020                      | 11/18/2008                       |   | 2/27/2006                                 |
| Budesonide                                   | Inhalation Suspension    | 1 mg/2 mL   | Pulmicort<br>Respules<br>20929 | 5/28/2010          | 1                         | Eligible       | 2/11/2020                     | 9/27/2013                        | 7/27/2015                                 | 12/23/2018                                |
| Budesonide                                   | Extended-release Tablets | 9 mg  | Uceris<br>203634               | 3/11/2013          | 1                         | Deferred       | 6/18/2019                     | 7/3/2018                         | 7/5/2018                                  | 6/9/2020                                  |
| Budesonide and Formoterol Fumarate Dihydrate | Metered Inhalation       | 80 mcg/4.5 mcg per<br>inhalation and<br>160 mcg/4.5 mcg per<br>inhalation | Symbicort<br>21929             | 6/26/2018          | 1                         | Deferred       | 3/18/2022                     | 3/15/2022                        | 7/31/2023                                 | 10/16/2028                                |
| Bupivacaine Liposome                         | Injectable Suspension    | 133 mg/10 mL  | Exparel<br>22496               | 12/28/2021         | 1                         |                |                               |                                  |   | 1/22/20241                                |
| Bupivacaine Liposome                         | Injectable Suspension    | 266 mg/20 mL  | Exparel<br>22496               | 8/20/2021          | 1                         |                |                               |                                  |   | 1/22/2041                                 |
| Buprenorphine and Naloxone                   | Buccal Film              | 2.1 mg/0.3 mg and<br>4.2 mg/0.7 mg  | Bunavail<br>205637             | 11/23/2016         | 1                         |                |                               |                                  |   | 8/20/2032                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM                 | STRENGTH                                    | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS                 | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-----------------------------|---|--------------------|--------------------|---------------------------|--------------------------------|-------------------------------|----------------------------------|---|---|
| Buprenorphine and Naloxone   | Buccal Film                 | 6.3 mg/1 mg                                 | Bunavail<br>205637 | 12/21/2015         | 1                         |                                |                               |                                  |   | 8/20/2032                                 |
| Buprenorphine Hydrochloride  | Buccal Film                 | 75 mcg and<br>150 mcg                       | Belbuca<br>207932  | 10/24/2016         | 1                         | Extinguished<br>Non-Forfeiture | 6/29/2021<br>2/9/2021         |                                  |   | 7/23/2027                                 |
| Buprenorphine Hydrochloride  | Buccal Film                 | 300 mcg, 450 mcg,<br>600 mcg and<br>750 mcg | Belbuca<br>207932  | 10/4/2016          | 1                         | Extinguished<br>Non-Forfeiture | 6/29/2021<br>2/9/2021         |                                  |   | 7/23/2027                                 |
| Buprenorphine Hydrochloride  | Buccal Film                 | 900 mcg                                     | Belbuca<br>207932  | 9/12/2016          | 1                         | Extinguished<br>Non-Forfeiture | 6/29/2021<br>2/9/2021         |                                  |   | 7/23/2027                                 |
| Buprenorphine Hydrochloride<br>and Naloxone Hydrochloride              | Sublingual Film             | 2 mg/0.5 mg* and<br>8 mg/2 mg               | Suboxone<br>22410  | 10/15/2012         | 1                         | Extinguished                   | 2/25/2020                     |                                  |   | 2/13/2023                                 |
| Buprenorphine Hydrochloride<br>and Naloxone Hydrochloride*             | Sublingual Film             | 4 mg/1 mg                                   | Suboxone<br>22410  | 5/14/2013          | 1                         | Extinguished                   | 2/25/2020                     |                                  |   | 2/13/2023                                 |
| Buprenorphine Hydrochloride<br>and Naloxone Hydrochloride              | Sublingual Film             | 12 mg/3 mg                                  | Suboxone<br>22410  | 5/14/2013          | 1                         | Extinguished                   | 2/25/2020                     |                                  |   | 2/13/2023                                 |
| Buprenorphine Hydrochloride<br>and Naloxone Hydrochloride<br>Dihydrate | Sublingual Tablets          | 1.4 mg/0.36 mg and<br>5.7 mg/1.4 mg         | Zubsolv<br>204242  | 10/22/2013         | 1                         |                                |                               |                                  |   | 5/22/2030                                 |
| Buprenorphine Hydrochloride<br>and Naloxone Hydrochloride<br>Dihydrate | Sublingual Tablets          | 8.6 mg/2.1 mg and<br>11.4 mg/2.9 mg         | Zubsolv<br>204242  | 7/24/2015          | 1                         |                                |                               |                                  |   | 9/18/2032                                 |
| Buprenorphine Hydrochloride<br>and Naloxone Hydrochloride<br>Dihydrate | Sublingual Tablets          | 2.9 mg/7.1 mg                               | Zubsolv<br>204242  | 12/21/2015         | 1                         |                                |                               |                                  |   | 9/18/2032                                 |
| Buprenorphine Hydrochloride<br>and Naloxone Hydrochloride<br>Dihydrate | Sublingual Tablets          | 0.7 mg/0.18 mg                              | Zubsolv<br>204242  | 5/4/2017           | 1                         |                                |                               |                                  |   | 9/18/2032                                 |
| Buprenorphine  | Transdermal System          | 5 mcg/hr<br>10 mcg/hr<br>20 mcg/hr          | Butrans<br>21306   | 6/6/2013           | 1                         | Extinguished                   | 6/18/2019                     | 11/20/2018                       |   | 9/29/2017                                 |
| Buprenorphine  | Transdermal System          | 15 mcg/hr                                   | Butrans<br>21306   | 12/16/2013         | 1                         | Extinguished                   | 6/18/2019                     | 11/20/2018                       |   | 9/29/2017                                 |
| Bupropion Hydrobromide   | Extended-release<br>Tablets | 174 mg                                      | Aplenzin<br>22108  | 9/28/2009          | 1                         | Extinguished                   | 2/25/2020                     |                                  |   | 6/27/2026                                 |
| Bupropion Hydrobromide   | Extended-release<br>Tablets | 348 mg                                      | Aplenzin<br>22108  | 9/24/2009          | 1                         | Extinguished                   | 2/25/2020                     |                                  |   | 6/27/2026                                 |
| Bupropion Hydrobromide   | Extended-release<br>Tablets | 522 mg                                      | Aplenzin<br>22108  | 12/24/2009         | 1                         | Extinguished                   | 2/25/2020                     |                                  |   | 6/27/2026                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                    | DOSAGE FORM              | STRENGTH                             | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS    | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|--------------------------------------|---------------------|--------------------|---------------------------|-------------------|-------------------------------|----------------------------------|---|---|
| Bupropion Hydrochloride                      | Extended-release Tablets | 100 mg, 150 mg and 200 mg            | Wellbutrin SR 20358 | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Bupropion Hydrochloride                      | Extended-release Tablets | 150 mg                               | Zyban 20711         | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Bupropion Hydrochloride                      | Extended-release Tablets | 150 mg and 300 mg                    | Wellbutrin XL 21515 | 9/21/2004          | 1                         | Eligible          | 2/25/2020                     | 12/14/2006                       | 5/30/2008 - 150 mg<br>12/4/2006 - 300 mg  | 10/30/2018                                |
| Bupropion Hydrochloride                      | Extended-release Tablets | 450 mg                               | Forfivo XL 22497    | 2/28/2013          | 1                         | Extinguished      | 2/25/2020                     |                                  | 10/1/2018                                 | 6/25/2027                                 |
| Bupropion Hydrochloride                      | Tablets                  | 75 mg and 100 mg                     | Wellbutrin 18644    | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Buspirone Hydrochloride                      | Tablets                  | 5 mg, 7.5 mg, 10 mg, 15 mg and 30 mg | Buspar 18731        | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Busulfan                                     | Injection                | 6 mg/mL                              | Busulfex 20954      | 12/26/2012         | 1                         | Extinguished      | 2/25/2020                     | 9/21/2018                        |   | 9/30/2013                                 |
| Butoconazole Nitrate                         | Vaginal Cream            | 2%                                   | Gynazole-1 19881    | 12/23/2009         | 1                         | Eligible          | 2/25/2020                     | 5/18/2012                        | 11/15/2012                                | 11/17/2017                                |
| Butorphanol Tartrate                         | Nasal Spray              | 10 mg/mL                             | Stadol NS 19890     | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Cabazitaxel                                  | Injection                | 60 mg/1.5 mL                         | Jevtana Kit 201023  | 6/17/2014          | 8                         | Eligible Deferred | 2/20/2023<br>7/25/2022        | 6/23/2022                        |   | 12/10/2025                                |
| Cabozantinib                                 | Tablets                  | 20 mg, 40 mg and 60 mg               | Cabometyx 208692    | 8/16/2019          | 1                         |                   |                               |                                  |   | 7/9/2033                                  |
| Calcipotriene                                | Topical Cream            | 0.005%                               | Dovonex 20554       | 12/2/2009          | 1                         | Eligible          | 2/25/2020                     | 5/30/2012                        | 7/27/2012                                 | 6/9/2015                                  |
| Calcipotriene                                | Topical Solution         | 0.005%                               | Dovonex 20611       | 5/19/2006          | 1                         | Eligible          | 2/25/2020                     | 5/6/2008                         | 5/6/2008                                  | 6/9/2015                                  |
| Calcipotriene and Betamethasone Dipropionate | Ointment                 | 0.005%/0.064%                        | Taclonex 21852      | 3/31/2010          | 1                         | Eligible          | 2/25/2020                     | 1/14/2013                        | 3/31/2014                                 | 1/27/2020                                 |
| Calcipotriene and Betamethasone Dipropionate | Topical Foam             | 0.005%/0.064%                        | Enstilar 207589     | 6/22/2020          | 1                         | Eligible          | 4/18/2023                     | 3/21/2023                        |   | 6/10/2031                                 |
| Calcitonin-Salmon                            | Nasal Spray              | 200 IU/spray                         | Miacalcin 20313     | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Calcitonin-Salmon (Recombinant)              | Nasal Spray              | 200 IU/spray                         | Fortical 21406      | 3/29/2006          | 1                         | Extinguished      | 4/7/2020                      |                                  |   | 2/2/2021                                  |
| Calcitriol                                   | Injection                | 1 mcg/mL and 2 mcg/mL, 1 mL vials    | Calcijex 18874      | Pre-MMA            |                           |                   |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM               | STRENGTH   | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|---------------------------|--|-----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Calcium Acetate  | Capsules                  | EQ 169 mg calcium  | PhosLo 21160          | 5/31/2005          | 1                         | Eligible       | 2/25/2020                     | 2/26/2008                        |   | 4/3/2021                                  |
| Calcium Acetate  | Oral Solution             | 667 mg/5 mL  | Phoslyra 22581        | 12/5/2013          | 2                         |                |                               |                                  |   | 2/23/2030                                 |
| Calcium Carbonate/<br>Famotadine/ Magnesium Hydroxide                    | Chewable Tablets          | 800 mg/10 mg/<br>165 mg (OTC)                                    | Pepcid Complete 20958 | 11/1/2004          | 1                         | Deferred       | 3/10/2020                     | 2/6/2008                         |   | 3/30/2016                                 |
| Calcium Oxybate, Magnesium Oxybate, Potassium Oxybate and Sodium Oxybate | Oral Solution             | 0.234 g/0.096 g/<br>013 g/0.04 g per mL                          | Xywav 212690          | 4/12/2021          | 1                         |                |                               |                                  |   | 3/15/2033                                 |
| Canagliflozin  | Tablets                   | 100 mg and 300 mg  | Invokana 204042       | 3/29/2017          | 10                        |                |                               |                                  |   | 2/26/2029                                 |
| Canagliflozin and Metformin Hydrochloride                                | Tablets                   | 50 mg/500 mg<br>50 mg/1000 mg<br>150 mg/500 mg<br>150 mg/1000 mg | Invokamet 204353      | 3/29/2017          | 6                         |                |                               |                                  |   | 2/26/2029                                 |
| Canagliflozin and Metformin Hydrochloride                                | Extended-release Tablets  | 50 mg/500 mg<br>50 mg/1000 mg<br>150 mg/500 mg<br>150 mg/1000 mg | Invokamet-XR 205879   | 11/21/2018         | 1                         |                |                               |                                  |   | 2/26/2029                                 |
| Candesartan Cilexetil  | Tablets                   | 4 mg, 8 mg, 16 mg<br>and 32 mg                                   | Atacand 20838         | 12/22/2006         | 1                         | Eligible       | 3/10/2020                     | 5/3/2013                         | 5/21/2013                                 | 1/9/2014                                  |
| Candesartan Cilexetil and Hydrochlorothiazide                            | Tablets                   | 16 mg/12.5 mg and<br>32 mg/12.5 mg                               | Atacand HCT 21093     | 6/25/2008          | 1                         | Extinguished   | 3/10/2020                     | 12/4/2012                        |   | 2/24/2015                                 |
| Candesartan Cilexetil and Hydrochlorothiazide                            | Tablets                   | 32 mg/25 mg  | Atacand HCT 21093     | 3/6/2009           | 1                         | Eligible       | 3/10/2020                     | 12/4/2012                        | 12/4/2012                                 | 2/24/2015                                 |
| Cangrelor  | For Injection             | 50 mg/vial   | Kengreal 204958       | 6/24/2019          | 2                         |                |                               |                                  |   | 7/10/2035                                 |
| Cannabidiol  | Oral Solution             | 100 mg/mL  | Epidiolex 210365      | 9/28/2022          | 10                        |                |                               |                                  |   | 3/1/2041                                  |
| Capecitabine   | Tablets                   | 150 mg and 500 mg  | Xeloda 20896          | 11/10/2008         | 1                         | Extinguished   | 3/10/2020                     | 8/8/2014                         |   | 12/14/2013                                |
| Captopril  | Tablets                   | 12.5 mg, 25 mg,<br>50 mg, and 100 mg                             | Capoten 18343         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Carbamazepine  | Extended-release Capsules | 100 mg and 200 mg  | Carbatrol 20712       | 2/2/2006           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 6/15/2016                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                          | DOSAGE FORM               | STRENGTH  | RLD/NDA                                 | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------------------|---------------------------|---|---|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Carbamazepine                      | Extended-release Capsules | 200 mg and 300 mg   | Equetro 21710                           | 8/21/2007          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 5/19/2024                                 |
| Carbamazepine                      | Extended-release Capsules | 100 mg  | Equetro 21710                           | 5/23/2014          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 5/19/2024                                 |
| Carbamazepine                      | Extended-release Capsules | 300 mg  | Carbatrol 20712                         | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Carbamazepine                      | Extended-release Tablets  | 100 mg  | Tegretol-XR 20234                       | 12/30/2005         | 1                         | Deferred                 | 3/10/2020                     | 3/31/2009                        |   | 2/8/2011                                  |
| Carbamazepine                      | Extended-release Tablets  | 200 mg and 400 mg   | Tegretol-XR 20234                       | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Carbidopa, Levodopa and Entacapone | Tablets                   | 12.5 mg, 50 mg and 200 mg                                   | Stalevo 50 21485                        | 8/5/2008           | 1                         | Extinguished<br>Deferred | 3/10/2020<br>3/10/2020        | 11/20/2012                       |   | 6/29/2020                                 |
| Carbidopa, Levodopa and Entacapone | Tablets                   | 18.75 mg/75 mg/<br>200 mg and<br>31.25 mg/125 mg/<br>200 mg | Stalevo 75 and<br>Stalevo 125<br>21485  | 5/19/2009          | 1                         | Deferred                 | 3/10/2020                     | 11/20/2012                       |   | 6/29/2020                                 |
| Carbidopa, Levodopa and Entacapone | Tablets                   | 25/100/200 mg and<br>37.5/150/200 mg                        | Stalevo 100 and<br>Stalevo 150<br>21485 | 6/29/2007          | 1                         | Extinguished             | 4/7/2020                      | 5/10/2012                        |   | 6/29/2020                                 |
| Carbidopa, Levodopa and Entacapone | Tablets                   | 50 mg/200 mg/<br>200 mg                                     | Stalevo 200<br>21485                    | 8/28/2008          | 1                         | Deferred                 | 3/10/2020                     |                                  |   |   |
| Carbidopa/ Levodopa                | Extended-release Tablets  | 25 mg/100 mg and<br>50 mg/200 mg                            | Sinemet CR<br>19856                     | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Carbidopa and Levodopa             | Extended-release Capsules | 61.25 mg/245 mg   | Rytary<br>203312                        | 6/10/2015          | 1                         | Non-Forfeiture           | 8/10/2020                     |                                  |   | 12/26/2028                                |
| Carbidopa and Levodopa             | Extended-release Capsules | 23.75 mg/95 mg,<br>36.25 mg/145 mg,<br>48.75 mg/195 mg      | Rytary<br>203312                        | 6/24/2015          | 1                         | Non-Forfeiture           | 8/10/2020                     |                                  |   | 12/26/2028                                |
| Carboplatin                        | For Injection             | 50 mg/vial,<br>150 mg/vial and<br>450 mg/vial               | Paraplatin<br>19880                     | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Carboplatin                        | Injection                 | 50 mg/vial,<br>150 mg/vial and<br>450 mg/vial               | Paraplatin<br>20452                     | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Carfilzomib                        | For Injection             | 10 mg/vial  | Kyprolis<br>202714                      | 11/28/2018         | 1                         | Deferred                 | 7/13/2021                     | 6/11/2021                        |   | 2/27/2033                                 |
| Carfilzomib                        | For Injection             | 60 mg/vial  | Kyprolis<br>202714                      | 7/20/2016          | 9                         | Eligible                 | 7/13/2021                     | 9/9/2019                         |   | 12/7/2027                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                  | STRENGTH                                | RLD/NDA                                   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|------------------------------|---|---|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Carfilzomib   | For Injection                | 30 mg/vial                              | Kyprolis<br>202714                        | 10/5/2017          | 1                         | Eligible       | 7/25/2022                     | 3/20/2020                        |   | 2/27/2033                                 |
| Cariprazine   | Capsules                     | 1.5 mg, 3 mg,<br>4.5 mg and 6 mg        | Vraylar<br>204370                         | 9/17/2019          | 3                         | Eligible       | 10/4/2022                     | 9/9/2022                         |   | 7/16/2029                                 |
| Carisoprodol/ Aspirin                                     | Tablets                      | 200 mg/ 325 mg                          | Soma<br>Compound<br>12365                 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Carisoprodol/ Aspirin/ Codeine                            | Tablets                      | 200 mg/325 mg/<br>16 mg                 | Soma<br>Compound with<br>Codeine<br>12366 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Carvedilol  | Tablets                      | 3.125 mg, 6.25 mg,<br>12.5 mg and 25 mg | Coreg<br>20297                            | Pre-MMA            |                           |                |                               |                                  |   |   |
| Carvedilol Phosphate                                      | Extended-release<br>Capsules | 10 mg and 20 mg                         | Coreg CR<br>22012                         | 3/18/2008          | 1                         | Deferred       | 4/7/2020                      | 10/25/2017                       | 11/8/2017                                 | 12/27/2023                                |
| Carvedilol Phosphate                                      | Extended-release<br>Capsules | 40 mg                                   | Coreg CR<br>22012                         | 12/21/2007         | 1                         | Deferred       | 4/7/2020                      | 10/25/2017                       | 11/8/2017                                 | 12/27/2023                                |
| Carvedilol Phosphate                                      | Extended-release<br>Capsules | 80 mg                                   | Coreg CR<br>22012                         | 11/19/2007         | 1                         | Deferred       | 4/7/2020                      | 10/25/2017                       | 11/8/2017                                 | 12/27/2023                                |
| Caspofungin Acetate                                       | for Injection                | 50 mg/vial and<br>70 mg/vial            | Cancidas<br>21227                         | 6/26/2009          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 3/28/2017                                 |
| Cefixime  | for Oral Suspension          | 500 mg/5 mL                             | Suprax<br>202091                          | 7/22/2016          | 1                         | Deferred       | 4/7/2020                      | 2/6/2017                         |   | 12/14/2028                                |
| Ceftaroline Fosamil                                       | for Injection                | 400 mg/vial and<br>600 mg/vial          | Teflaro<br>200327                         | 10/29/2014         | 2                         | Deferred       | 10/19/2021                    | 9/21/2021                        |   | 2/10/2031                                 |
| Celecoxib   | Capsules                     | 50 mg                                   | Celebrex<br>20998                         | 3/21/2008          | 1                         | Extinguished   | 3/10/2020                     | 5/30/2014                        |   | 4/14/2018                                 |
| Celecoxib   | Capsules                     | 100 mg, 200 mg and<br>400 mg            | Celebrex<br>20998                         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Cetirizine Hydrochloride                                  | Syrup                        | 5 mg/5 mL                               | Zyrtec<br>20346                           | 3/19/2007          | 1                         | Extinguished   | 4/7/2020                      | 5/11/2012                        |   | 6/25/2007                                 |
| Cetirizine Hydrochloride                                  | Chewable Tablets             | 5 mg and 10 mg                          | Zyrtec<br>21621                           | 3/25/2005          |                           |                |                               |                                  |   |   |
| Cetirizine Hydrochloride and<br>Pseudoephedrine           | Extended-release<br>Tablets  | 5 mg/120 mg                             | Zyrtec-D<br>21150                         | 6/2/2004           | 1                         | Extinguished   | 4/7/2020                      | 2/25/2008                        |   | 7/13/2019                                 |
| Cevimeline Hydrochloride                                  | Capsules                     | 30 mg                                   | Evoxac<br>20989                           | 2/27/2009          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 7/7/2013                                  |
| Chlorhexidine Gluconate                                   | Scrub brush/sponge           | 4%                                      | Hibiclens<br>18423                        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Chlorpheniramine Polistirex<br>and Hydrocodone Polistirex | Extended-release<br>Capsules | 8 mg/10 mg and<br>4 mg/5 mg             | Tussionex<br>19111                        | 9/10/2004          | 1                         | Extinguished   | 4/7/2020                      | 10/4/2007                        |   | 8/9/2005                                  |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                  | DOSAGE FORM              | STRENGTH                                       | RLD/NDA              | DATE OF SUBMISSION             | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|--|----------------------|--------------------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Ciclesonide                                | Nasal Spray              | 50 mcg   | Omnaris<br>22004     | 2/13/2012                      | 1                         | Extinguished   | 2/22/2021                     |                                  |   | 10/21/2020                                |
| Ciclopirox                                 | Gel                      | 0.77%  | Loprox<br>20519      | 5/10/2006                      | 1                         | Extinguished   | 4/7/2020                      | 1/7/2009                         | 12/3/2007                                 | 9/5/2018                                  |
| Cinacalcet Hydrochloride                   | Tablets                  | 30 mg, 60 mg and 90 mg                         | Sensipar<br>21688    | 3/10/2008                      | 1                         | Extinguished   | 8/27/2019                     |                                  |   | 12/14/2016                                |
| Ciprofloxacin                              | Oral Suspension          | 250 mg/5 mL and 500 mg/ 5 mL                   | Cipro<br>20780       | 10/16/2009                     | 1                         | Deferred       | 4/7/2020                      | 3/5/2014                         |   | 12/9/2014                                 |
| Ciprofloxacin Hydrochloride                | Tablets                  | 100 mg, 250 mg, 500 mg and 750 mg              | Cipro<br>19537       | Pre-MMA                        |                           |                |                               |                                  |   |   |
| Ciprofloxacin and Dexamethasone            | Otic Suspension          | 0.3%/0.1%                                      | Ciprodex<br>21537    | 7/31/2012                      | 1                         | Extinguished   | 11/17/2020                    |                                  |   | 8/10/2020                                 |
| Cisatracurium Besylate (multi-dose)        | Injection                | 2 mg/mL, 10 mL vial                            | Nimbex<br>20551      | 8/12/2009                      | 1                         | Eligible       | 4/7/2020                      | 2/3/2012                         |   | 9/26/2012                                 |
| Cisatracurium Besylate (preserve free)     | Injection                | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial    | Nimbex<br>20551      | 8/4/2009                       | 1                         | Eligible       | 4/7/2020                      | 2/3/2012                         |   | 9/26/2012                                 |
| Cisplatin                                  | Injection                | 1 mg/mL, 10 mL, 50 mL, 100 mL and 200 mL vials | Platinol-AQ<br>18057 | Pre-MMA                        |                           |                |                               |                                  |   |   |
| Cisplatin                                  | For Injection            | 10 mg/vial and 50 mg/vial                      | Platinol<br>18057    | Pre-MMA                        |                           |                |                               |                                  |   |   |
| Cladribine                                 | Tablets                  | 10 mg  | Mavenclad<br>22561   | 4/7/2022                       | 1                         |                |                               |                                  |   | 10/16/2026                                |
| Clarithromycin                             | Extended-release Tablets | 500 mg   | Biaxin XL<br>50775   | PIV received prior to 2/5/2009 |                           |                |                               |                                  |   |   |
| Clevidipine                                | Injectable Emulsion      | 25 mg/50 mL and 50 mg/100 mL                   | Cleviprex<br>22156   | 7/2/2019                       | 1                         |                |                               |                                  |   | 10/10/2031                                |
| Clindamycin Phosphate                      | Foam                     | 1%   | Evoclin<br>50801     | PIV received prior to 2/5/2009 | 1                         | Eligible       | 3/10/2020                     | 3/31/2010                        | 3/31/2010                                 | 8/9/2026                                  |
| Clindamycin Phosphate                      | Vaginal Cream            | 2%   | Clindesse<br>50793   | 2/5/2015                       | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 4/27/2023                                 |
| Clindamycin Phosphate and Tretinoin        | Gel                      | 1.2%/0.025%                                    | Ziana<br>50802       | 12/17/2010                     | 1                         | Deferred       | 6/18/2019                     | 6/12/2015                        | 7/5/2016                                  | 8/3/2020                                  |
| Clindamycin Phosphate and Benzoyl Peroxide | Gel                      | 1% / 5%  | Duac<br>50741        | 12/11/2008                     | 1                         | Deferred       | 6/18/2019                     | 6/26/2012                        | 6/26/2012                                 | 11/14/2012                                |



**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                  | DOSAGE FORM                   | STRENGTH                               | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-------------------------------|--|--------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Clindamycin Phosphate and Benzoyl Peroxide | Gel                           | 1.2%/2.5%                              | Acanya 50819       | 12/20/2012         | 1                         | Eligible       | 6/18/2019                     | 6/19/2015                        | 2/19/2019                                 | 8/5/2029                                  |
| Clindamycin Phosphate and Benzoyl Peroxide | Gel                           | 1.2%/3.75%                             | Onexton 50819      | 9/30/2015          | 1                         | Eligible       | 6/18/2019                     | 6/5/2018                         | 10/2/2023                                 | 8/5/2029                                  |
| Clobetasol Propionate                      | Emulsion Foam                 | 0.05%                                  | Olux-E 22013       | 2/25/2010          | 1                         | Eligible       | 4/7/2020                      | 8/14/2012                        | 2/1/2013                                  | 9/8/2019                                  |
| Clobetasol Propionate                      | Topical Foam                  | 0.05%                                  | Olux 21142         | 6/27/2005          | 1                         | Eligible       | 4/7/2020                      | 3/10/2008                        |   | 10/3/2017                                 |
| Clobetasol Propionate                      | Lotion                        | 0.05%                                  | Clobex 21535       | 3/27/2006          | 1                         | Eligible       | 4/7/2020                      | 12/4/2008                        | 1/2/2012                                  | 9/22/2017                                 |
| Clobetasol Propionate                      | Spray                         | 0.05%                                  | Clobex 21835       | 9/29/2008          | 1                         | Eligible       | 4/7/2020                      | 6/16/2011                        | 1/1/2015                                  | 3/24/2018                                 |
| Clobetasol Propionate                      | Topical Shampoo               | 0.05%                                  | Clobex 21644       | 1/9/2008           | 1                         | Non-Forfeiture | 4/7/2020                      | 6/7/2011                         | 1/2/2012                                  | 6/17/2019                                 |
| Clobetasol Propionate                      | Cream                         | 0.025%                                 | Impoyz 209483      | 12/6/2019          | 1                         |                |                               |                                  |   | 3/11/2035                                 |
| Clofarabine                                | Injection                     | 1 mg/mL, 20 mL vial                    | Clolar 21673       | 2/23/2012          | 1                         | Eligible       | 4/7/2020                      | 5/9/2017                         | 5/9/2017                                  | 1/14/2018                                 |
| Clonidine Hydrochloride                    | Extended-release Tablets      | 0.1 mg and 0.2 mg                      | Jenloga 22331      | 3/4/2011           | 1                         | Extinguished   | 4/7/2020                      | 4/2/2014                         |   | 10/13/2013                                |
| Clonidine Hydrochloride                    | Extended-release Tablets      | 0.1 mg and 0.2 mg                      | Kapvay 22331       | 3/4/2011           | 1                         | Eligible       | 4/7/2020                      | 9/30/2013                        | 10/7/213                                  | 10/13/2013                                |
| Clonidine Hydrochloride                    | Transdermal System            | 0.1 mg/day<br>0.2 mg/day<br>0.3 mg/day | Catapres-TTS 18891 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Clopidogrel Bisulfate                      | Tablets                       | 75 mg                                  | Plavix 20839       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Clopidogrel Bisulfate                      | Tablets                       | 300 mg                                 | Plavix 20839       | 3/4/2009           | 1                         | Eligible       | 4/7/2020                      | 5/17/2012                        | 5/17/2012                                 | 6/10/2019                                 |
| Clozapine                                  | Orally Disintegrating Tablets | 12.5 mg                                | Fazaclo 21590      | 6/5/2008           | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 4/9/2018                                  |
| Clozapine                                  | Orally Disintegrating Tablets | 25 mg and 100 mg                       | Fazaclo 21590      | 4/28/2008          | 1                         | Extinguished   | 4/7/2020                      | 11/25/2015                       | 8/30/2012                                 | 4/9/2018                                  |
| Clozapine                                  | Orally Disintegrating Tablets | 150 mg                                 | Fazaclo 21590      | 4/8/2011           | 1                         | Deferred       | 4/7/2020                      | 11/25/2015                       | 5/4/2015                                  | 4/9/2018                                  |
| Clozapine                                  | Orally Disintegrating Tablets | 200 mg                                 | Fazaclo 21590      | 4/18/2011          | 1                         | Deferred       | 4/7/2020                      | 11/25/2015                       | 5/4/2015                                  | 4/9/2018                                  |
| Cobicistat                                 | Tablets                       | 150 mg                                 | Tybest 203094      | 11/14/2016         | 1                         |                |                               |                                  |   | 9/3/2029                                  |
| Colchicine                                 | Capsules                      | 0.6 mg                                 | Mitigare 204820    | 6/10/2016          | 1                         | Eligible       | 8/27/2019                     | 11/29/2018                       | 11/1/2023                                 | 8/22/2033                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                | STRENGTH   | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS                 | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|----------------------------|--|---------------------|--------------------|---------------------------|--------------------------------|-------------------------------|----------------------------------|---|---|
| Colchicine  | Tablets                    | 0.3 mg   | Colcrys<br>22352    | 7/19/2019          | 1                         | Eligible                       | 4/7/2020                      | 11/14/2019                       |   | 2/17/2029                                 |
| Colchicine  | Tablets                    | 0.6 mg   | Colcrys<br>22352    | 12/23/2011         | 1                         | Extinguished                   | 4/7/2020                      |                                  | 7/2/2018                                  | 2/17/2029                                 |
| Colchicine  | Oral Solution              | 0.6 mg/5 mL  | Gloperba<br>210942  | 4/2/2020           | 1                         | Non-Forfeiture                 | 1/10/2023                     |                                  |   | 12/20/2037                                |
| Colesevelam Hydrochloride                                       | Powder for Oral Suspension | 1.875 g/Package and<br>3.75 g/Package                    | Welchol<br>22362    | 4/9/2010           | 1                         | Extinguished                   | 3/10/2020                     |                                  |   | 12/2/2014                                 |
| Colesevelam Hydrochloride                                       | Tablets                    | 625 mg   | Welchol<br>21176    | 7/1/2009           | 1                         | Extinguished                   | 4/7/2020                      | 5/16/2018                        |   | 12/10/2014                                |
| Colestipol Hydrochloride  | Tablets                    | 1 g  | Colestid<br>02222   | 8/23/2005          | 1                         |                                |                               | 10/24/2006                       |   |   |
| Conjugated Estrogen (Synthetic A)                               | Tablets                    | 0.3 mg, 0.45 mg and<br>0.9 mg                            | Cenestin<br>20992   | 3/19/2009          | 1                         | Extinguished                   | 4/7/2020                      |                                  |   | 7/26/2015                                 |
| Conjugated Estrogen (Synthetic A)                               | Tablets                    | 1.25 mg  | Cenestin<br>20992   | 11/3/2008          | 1                         | Extinguished                   | 4/7/2020                      |                                  |   | 7/26/2015                                 |
| Conjugated Estrogen (Synthetic A)                               | Tablets                    | 0.625 mg   | Cenestin<br>20992   | 3/2/2009           | 1                         | Extinguished                   | 4/7/2020                      |                                  |   | 7/26/2015                                 |
| Conjugated Estrogens  | Tablets                    | 0.3 mg and<br>0.625 mg                                   | Premarin<br>04782   | Pre-MMA            |                           |                                |                               |                                  |   |   |
| Cyanocobalamin  | Nasal Spray                | 500 mcg/spray  | Nascobal<br>21642   | 4/28/2017          | 1                         | Extinguished                   | 4/6/2021                      |                                  |   | 8/1/2024                                  |
| Crisaborole   | Topical Ointment           | 2%   | Eucrisa<br>207695   | 6/14/2021          | 5                         |                                |                               |                                  |   | 1/20/2030                                 |
| Cupric Sulfate, Magnesium Sulfate, Selenious Acid, Zinc Sulfate | Injection                  | 60 mcg/mL,<br>3 mcg/mL,<br>6 mcg/mL,<br>1000 mcg/mL      | Multrys<br>209376   | 11/16/2023         | 3                         |                                |                               |                                  |   | 7/1/2041                                  |
| Cupric Sulfate, Magnesium Sulfate, Selenious Acid, Zinc Sulfate | Injection                  | 0.3 mg/mL,<br>55 mcg/mL,<br>60 mcg/mL,<br>3 mg/mL (1 mL) | Tralement<br>209376 | 11/16/2023         | 2                         |                                |                               |                                  |   | 7/1/2041                                  |
| Cupric Sulfate, Magnesium Sulfate, Selenious Acid, Zinc Sulfate | Injection                  | 0.3 mg/mL,<br>55 mcg/mL,<br>60 mcg/mL,<br>3 mg/mL (5 mL) | Tralement<br>209376 | 11/16/2023         | 1                         |                                |                               |                                  |   | 7/1/2041                                  |
| Cyclobenzaprine Hydrochloride                                   | Tablets                    | 10 mg  | Flexeril<br>17821   | Pre-MMA            |                           |                                |                               |                                  |   |   |
| Cyclobenzaprine Hydrochloride                                   | Extended-release Capsule   | 15 mg and 30 mg  | Amrix<br>21777      | 8/11/2008          | 1                         | Extinguished<br>Non-Forfeiture | 4/7/2020<br>4/7/2020          |                                  | 5/13/2011                                 | 2/26/2025                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                 | DOSAGE FORM                 | STRENGTH  | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-----------------------------|---|---------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Cyclophosphamide                          | For Injection               | 100 mg/vial<br>200 mg/vial<br>500 mg/vial<br>1 g/vial<br>2 g/vial | Cytoxan<br>12142    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Cyclophosphamide                          | Injection                   | 500 mg/2.5 mL and<br>1 g/5 mL                                     | Cyclophos<br>212501 | 3/7/2022           | 1                         |                |                               |                                  |   | 2/15/2036                                 |
| Cyclophosphamide                          | Injection                   | 2 g/10 mL   | Cyclophos<br>212501 | 1/17/2023          | 1                         |                |                               |                                  |   | 2/15/2036                                 |
| Cyclosporine                              | Ophthalmic Emulsion         | 0.05%   | Restasis<br>50790   | 1/13/2014          | 1                         | Extinguished   | 2/8/2022                      |                                  |   | 5/17/2014                                 |
| Cysteamine Bitartrate                     | Delayed-release<br>Capsules | 25 mg and 75 mg   | Procysbi<br>203389  | 5/11/2020          | 1                         |                |                               |                                  |   | 8/16/2036                                 |
| Cysteamine Bitartrate                     | Delayed-release<br>Granules | 75 mg/Package and<br>300 mg/Package                               | Procysbi<br>213491  | 12/16/2021         | 1                         |                |                               |                                  |   | 8/16/2036                                 |
| Cysteine Hydrochloride                    | Injection                   | 500 mg/10 mL  | Elcys<br>210660     | 12/10/2019         | 1                         | Eligible       | 5/5/2022                      | 4/8/2022                         |   | 1/15/2039                                 |
| Dabigatran Etexilate Mesylate             | Capsules                    | eq. to 75 mg base<br>and 150 mg base                              | Pradaxa<br>22512    | 10/20/2014         | 17                        | Eligible       | 6/15/2020                     | 5/6/2020                         | 75 mg - 7/1/2022<br>150 mg-3/11/2020      | 8/31/2027                                 |
| Dabigatran Etexilate Mesylate             | Capsules                    | eq. to 110 mg base  | Pradaxa<br>22512    | 12/15/2015         | 2                         | Deferred       | 1/8/2024                      | 12/15/2023                       | 2/13/2024                                 | 1/20/2031                                 |
| Dalbavancin Hydrochloride                 | Powder For Injection        | 500 mg/vial   | Dalvance            | 5/23/2023          | 3                         |                |                               |                                  |   | 5/23/2028                                 |
| Dalfampridine                             | Extended-release<br>Tablets | 10 mg   | Ampyra<br>22250     | 1/22/2014          | 8                         | Eligible       | 11/19/2019                    | 1/23/2017                        | 9/10/2018                                 | 5/26/2027                                 |
| Dapagliflozin                             | Tablets                     | 5 mg and 10 mg  | Farxiga<br>202293   | 1/8/2018           | 20                        | Deferred       | 3/22/2022                     | 2/22/2022                        |   | 5/26/2030                                 |
| Dapagliflozin and Saxagliptan             | Tablets                     | 5 mg/5 mg   | Qtern<br>209091     | 7/29/2020          | 1                         |                |                               |                                  |   | 12/16/2029                                |
| Dapagliflozin and Saxagliptan             | Tablets                     | 10 mg/5 mg  | Qtern<br>209091     | 1/8/2018           | 5                         |                |                               |                                  |   | 12/16/2029                                |
| Dapagliflozin and Metformin Hydrochloride | Extended-release<br>Tablets | 2.5 mg/1000 mg  | Xigduo XR<br>205649 | 10/29/2018         | 1                         |                |                               |                                  |   | 12/16/2029                                |
| Dapagliflozin and Metformin Hydrochloride | Extended-release<br>Tablets | 5 mg/500 mg<br>5 mg/1000 mg<br>10 mg/500 mg<br>10 mg/1000 mg      | Xigduo XR<br>205649 | 1/8/2018           | 10                        |                |                               |                                  |   | 5/26/2030                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                 | STRENGTH                          | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS             | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-----------------------------|-----------------------------------|---------------------|--------------------|---------------------------|----------------------------|-------------------------------|----------------------------------|---|---|
| Dapsone   | Gel                         | 7.5%                              | Aczone<br>207154    | 2/13/2017          | 1                         | Eligible                   | 7/2/2019                      | 6/26/2019                        | 6/26/2019                                 | 11/18/2033                                |
| Daptomycin  | For Injection               | 500 mg/vial                       | Cubicin<br>21572    | 11/19/2008         | 1                         | Extinguished               | 11/19/2019                    |                                  |   | 9/24/2019                                 |
| Darifenacin Hydrobromide  | Extended-release<br>Tablets | 7.5 mg and 15 mg                  | Enablex<br>21513    | 12/22/2008         | 3                         | Deferred                   | 4/7/2020                      | 3/13/2015                        | 3/15/2016                                 | 8/21/2016                                 |
| Darolutamide  | Tablets                     | 300 mg                            | Nubeqa<br>212099    | 7/31/2023          | 1                         |                            |                               |                                  |   | 2/27/2038                                 |
| Darunavir Ethanolate  | Tablets                     | 75 mg, 150 mg and<br>300 mg       | Prezista<br>21976   | 6/23/2010          | 1                         |                            |                               |                                  |   | 12/26/2026                                |
| Darunavir Ethanolate  | Tablets                     | 400 mg                            | Prezista<br>21976   | 6/23/2010          | 3                         | Deferred                   | 11/13/2023                    | 9/14/2023                        |   | 12/26/2026                                |
| Darunavir Ethanolate  | Tablets                     | 600 mg                            | Prezista<br>21976   | 6/23/2010          | 4                         | Deferred                   | 7/2/2019                      | 11/21/2017                       | 6/1/2023                                  | 12/26/2026                                |
| Darunavir Ethanolate  | Tablets                     | 800 mg                            | Prezista<br>21976   | 5/14/2013          | 1                         | Eligible                   | 10/4/2022                     | 9/29/2022                        | 6/1/2023                                  | 12/26/2026                                |
| Darunavir and Cobicistat  | Tablets                     | 800 mg/150 mg                     | Prezcobix<br>205395 | 7/24/2020          | 1                         |                            |                               |                                  |   | 10/6/2032                                 |
| Darunavir, Cobicistat,<br>Emtricitabine, Tenofovir<br>Alafenamide | Tablets                     | 800 mg/150 mg/<br>200 mg/10 mg    | Symtuza<br>210455   | 8/16/2021          | 1                         |                            |                               |                                  |   | 7/19/2038                                 |
| Dasatinib   | Tablets                     | 80 mg and 140 mg                  | Sprycel<br>21986    | 6/17/2011          | 1                         | Non-Forfeiture             | 10/2/2021                     | 11/23/2021                       |   | 3/28/2026                                 |
| Dasatinib   | Tablets                     | 20 mg, 50 mg,<br>70 mg and 100 mg | Sprycel<br>21986    | 6/28/2010          | 1                         | Non-Forfeiture<br>Deferred | 10/19/2021<br>4/7/2020        | 6/10/2016                        |   | 3/28/2026                                 |
| Deferasirox   | Tablets for<br>Suspension   | 125 mg, 250 mg, and<br>500 mg     | Exjade<br>21882     | 10/28/2011         | 1                         | Eligible                   | 7/2/2019                      | 1/26/2016                        | 3/22/2019                                 | 4/5/2019                                  |
| Deferasirox   | Tablets                     | 90 mg and 360 mg                  | Jadenu<br>206910    | 10/19/2015         | 1                         | Extinguished               | 7/16/2019                     |                                  |   | 4/5/2019                                  |
| Deferasirox   | Tablets                     | 180 mg                            | Jadenu<br>206910    | 4/21/2016          | 1                         | Eligible                   | 7/16/2019                     | 12/13/2019                       | 12/17/2019                                | 11/21/2034                                |
| Deferiprone   | Tablets                     | 500 mg                            | Ferriprox<br>21825  | 1/29/2016          | 1                         | Eligible                   | 8/13/2019                     | 2/8/2019                         | 9/28/2020                                 | 6/28/2021                                 |
| Degarelix Acetate   | Powder for Injection        | 80 mg/vial and<br>120 mg/vial     | Firmagon<br>22201   | 12/20/2019         | 1                         |                            |                               |                                  |   | 4/27/2032                                 |
| Deoxycholic Acid  | Injection                   | 10 mg/mL (2 mL)                   | Kybella<br>206333   | 7/13/2018          | 1                         | Deferred                   | 5/4/2021                      | 4/2/2021                         |   | 3/2/2030                                  |
| Desflurane  | Inhalation                  | 99.9%                             | Suprane<br>20118    | 9/11/2008          | 1                         | Extinguished               | 4/7/2020                      |                                  |   | 4/8/2014                                  |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                 | DOSAGE FORM                   | STRENGTH                         | RLD/NDA                     | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-------------------------------|----------------------------------|-----------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Desloratadine                             | Tablets                       | 5 mg                             | Clarinet<br>21165           | 6/21/2006          | 11                        | Extinguished             | 4/7/2020                      | 10/25/2010                       |   | 7/7/2019                                  |
| Desloratadine                             | Orally Disintegrating Tablets | 2.5 mg and 5 mg                  | Clarinet<br>21165           | 6/21/2006          | 3                         | Extinguished             | 4/7/2020                      | 7/12/2010                        |   | 7/7/2019                                  |
| Desloratadine                             | Oral Solution                 | 0.5 mg/mL                        | Clarinet Syrup<br>21300     | 5/8/2008           | 1                         | Extinguished             | 4/7/2020                      |                                  |   | 6/1/2018                                  |
| Desloratadine and Pseudoephedrine Sulfate | Extended-release Tablets      | 2.5 mg/120 mg                    | Clarinet-D 24 Hour<br>21313 | 6/1/2007           | 1                         | Extinguished             | 4/7/2020                      |                                  |   | 2/18/2021                                 |
| Desloratadine and Pseudoephedrine Sulfate | Extended-release Tablets      | 5 mg/240 mg                      | Clarinet-D 24 Hour<br>21313 | 6/21/2006          | 1                         | Extinguished             | 4/7/2020                      | 4/26/2011                        |   | 3/28/2022                                 |
| Desmopressin Acetate                      | Injection                     | 4 mcg/mL, 1 mL and 10 mL vials   | DDAVP<br>18938              | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Desmopressin Acetate                      | Nasal Spray                   | 0.01%                            | DDAVP<br>17922              | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Desmopressin Acetate                      | Tablets                       | 0.1 mg and 0.2 mg                | DDAVP<br>19955              | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Desogestrel; Ethinyl Estradiol Tablets    | Tablets                       | 0.15mg/ 0.02 mg and 0.01 mg      | Mircette<br>20713           | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Desonide                                  | Gel                           | 0.05%                            | Desonate<br>21844           | 12/1/2010          | 1                         | Deferred                 | 6/15/2020                     | 5/11/2020                        | 7/9/2020                                  | 8/3/2020                                  |
| Desoximetasone                            | Topical Spray                 | 0.25%                            | Topicort<br>204141          | 12/18/2013         | 1                         | Extinguished             | 4/7/2020                      | 1/20/2017                        |   | 4/23/2028                                 |
| Desvenlafaxine Succinate                  | Extended-release Tablets      | 50 mg and 100 mg                 | Pristiq<br>21992            | 2/29/2012          | 12                        | Eligible                 | 6/18/2019                     | 6/29/2015                        | 2/28/2017                                 | 2/11/2022                                 |
| Desvenlafaxine Succinate                  | Extended-release Tablets      | 25 mg                            | Pristiq<br>21992            | 5/8/2015           | 1                         | Eligible                 | 4/7/2020                      | 7/29/2016                        | 7/29/2016                                 | 7/5/2027                                  |
| Deutetrabenazine                          | Tablets                       | 6 mg, 9 mg and 12 mg             | Austedo<br>208082           | 4/5/2021           | 2                         |                          |                               |                                  |   | 3/7/2036                                  |
| Dexlansoprazole                           | Delayed-release Capsules      | 30 mg                            | Dexilant<br>22287           | 11/30/2010         | 1                         | Extinguished             | 4/7/2020                      |                                  |   | 8/2/2026                                  |
| Dexlansoprazole                           | Delayed-release Capsules      | 60 mg                            | Dexilant<br>2287            | 8/25/2010          | 1                         | Extinguished<br>Deferred | 9/20/2022<br>4/7/2020         | 4/19/2017                        | 11/22/2022                                | 8/2/2026                                  |
| Dexmedetomidine                           | Injection                     | 100 mcg/mL                       | Precedex<br>21038           | 4/8/2009           | 1                         | Eligible                 | 4/7/2020                      | 6/14/2016                        | 9/22/2014                                 | 3/31/2019                                 |
| Dexmedetomidine                           | Injection                     | 4 mcg/mL, 50 mL and 100 mL vials | Precedex<br>21038           | 12/26/2013         | 1                         | Extinguished             | 8/13/2019                     | 1/30/2020                        |   | 1/4/2032                                  |
| Dexmedetomidine                           | Injection                     | 4 mcg/mL, 20 mL vials            | Precedex<br>21038           | 9/30/2015          | 1                         | Eligible                 | 7/2/2019                      | 11/29/2018                       | 6/3/2019                                  | 1/4/2032                                  |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                 | STRENGTH                                   | RLD/NDA           | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-----------------------------|--|-------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Dexmethylphenidate Hydrochloride  | Tablets                     | 2.5 mg                                     | Focalin 21278     | 7/27/2004          | 1                         | Eligible       | 4/7/2020                      | 1/29/2007                        |   | 12/4/2015                                 |
| Dexmethylphenidate Hydrochloride  | Tablets                     | 5 mg and 10 mg                             | Focalin 21278     | 5/27/2004          | 1                         | Eligible       | 4/7/2020                      | 1/29/2007                        |   | 12/4/2015                                 |
| Dexmethylphenidate Hydrochloride  | Extended-release Capsules   | 15 mg                                      | Focalin XR 21802  | 5/14/2007          | 1                         | Eligible       | 1/27/2020                     | 11/18/2013                       |   | 11/1/2019                                 |
| Dexmethylphenidate Hydrochloride  | Extended-release Capsules   | 5 mg, 10 mg and 20 mg                      | Focalin XR 21802  | 3/30/2007          | 1                         | Eligible       | 1/27/2020                     | 11/19/2013                       | 11/10/2014                                | 11/1/2019                                 |
| Dexmethylphenidate Hydrochloride  | Extended-release Capsules   | 30 mg                                      | Focalin XR 21802  | 12/15/2010         | 1                         | Eligible       | 1/27/2020                     | 8/28/2013                        | 11/18/2013                                | 11/1/2019                                 |
| Dexmethylphenidate Hydrochloride  | Extended-release Capsules   | 40 mg                                      | Focalin XR 21802  | 12/20/2010         | 1                         | Eligible       | 1/27/2020                     | 11/19/2013                       | 11/22/2013                                | 11/1/2019                                 |
| Dexmethylphenidate  | Extended-release Capsules   | 35 mg                                      | Focalin XR 21802  | 9/29/2011          | 1                         | Eligible       | 1/27/2020                     | 11/30/2016                       | 1/5/2017                                  | 11/1/2019                                 |
| Dexmethylphenidate  | Extended-release Capsules   | 25 mg                                      | Focalin XR 21802  | 9/30/2011          | 1                         | Eligible       | 1/27/2020                     | 11/30/2016                       | 1/5/2017                                  | 11/1/2019                                 |
| Dexrazoxane   | For Injection               | 250 mg/vial                                | Zinecard 20212    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Dextroamphetamine saccharate; Amphetamine aspartate; Dextroamphetamine Sulfate; Amphetamine Sulfate | Extended-release Capsules   | 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg | Adderall XR 21303 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Dextroamphetamine saccharate; Amphetamine aspartate; Dextroamphetamine Sulfate; Amphetamine Sulfate | Tablets                     | 5 mg, 10 mg, 20 mg, 30 mg                  | Adderall 11522    | 11/18/2009         | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 7/6/2020                                  |
| Dextroamphetamine saccharate; Amphetamine aspartate; Dextroamphetamine Sulfate; Amphetamine Sulfate | Tablets                     | 7.5 mg, 12.5 mg and 15 mg                  | Adderall 11522    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Dextromethorphan Polistirex   | Extended-release Suspension | 30 mg/5 mL                                 | Delsym 18658      | 1/12/2009          | 1                         | Eligible       | 4/7/2020                      | 5/25/2012                        | 8/27/2012                                 | 4/16/2017                                 |
| Dextromethorphan Hydrobromide and Bupropion Hydrochloride   | Extended-release Tablet     | 45 mg/105 mg                               | Auvelity 215430   | 12/22/2022         | 1                         |                |                               |                                  |   | 1/7/2040                                  |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM               | STRENGTH   | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------|--|-----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Dextromethorphan Hydrobromide and Quinidine Sulfate | Capsules                  | 20 mg/10 mg  | Nuedexta 21879        | 3/7/2011           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 8/13/2026                                 |
| Diazepam  | Tablets                   | 2 mg, 5 mg and 10 mg   | Valium 13263          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Diazepam  | Rectal Gel                | 2.5 mg/0.5 mL<br>5 mg/mL<br>10 mg/2 mL<br>15 mg/3 mL<br>20 mg/4 mL | Diastat 20648         | 3/23/2004          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 10/31/2012                                |
| Diazepam  | Rectal Gel                | 5 mg/mL, 4mL pre-filled syringe                                    | Diastat Acudial 20648 | 12/8/2008          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 9/17/2013                                 |
| Diazepam  | Rectal Gel                | 5 mg/mL, 2mL pre-filled syringe                                    | Diastat Acudial 20648 | 12/23/2008         | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 9/17/2013                                 |
| Diclofenac Potassium                                | Oral Solution (Sachet)    | 50 mg  | Cambia 22165          | 1/24/2011          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 6/16/2026                                 |
| Diclofenac Potassium                                | Capsules                  | 25 mg  | Zipsor 22202          | 11/14/2012         | 1                         | Extinguished   | 2/11/2020                     | 2/23/2016                        |   | 2/24/2029                                 |
| Diclofenac Sodium                                   | Injection                 | 37.5 mg/mL, 1 mL single-dose vials                                 | Dyloject 22396        | 12/15/2015         | 1                         | Eligible       | 7/2/2019                      | 6/18/2019                        |   | 3/22/2027                                 |
| Diclofenac Sodium                                   | Topical Gel               | 3%   | Solaraze 21005        | 12/16/2009         | 1                         | Deferred       | 4/7/2020                      | 10/28/2013                       | 11/21/2013                                | 8/11/2015                                 |
| Diclofenac Sodium                                   | Topical Solution          | 1.5%   | Pennsaid 20947        | 7/11/2012          | 1                         | Eligible       | 4/7/2020                      | 5/27/2014                        | 5/27/2014                                 | 7/10/2029                                 |
| Diclofenac Sodium                                   | Topical Solution          | 2.0%   | Pennsaid 204623       | 6/3/2014           | 1                         | Extinguished   | 5/5/2022                      |                                  |   | 8/9/2030                                  |
| Diclofenac  | Capsules                  | 18 mg and 35 mg  | Zorvolex 204592       | 6/6/2014           | 1                         |                |                               |                                  |   | 4/23/2030                                 |
| Diclofenac Epolamine                                | Topical Patch             | 1.3%   | Flector 21234         | 6/26/2015          | 1                         | Extinguished   | 7/2/2019                      |                                  |   | 4/13/2019                                 |
| Diclofenac Sodium and Misoprostol                   | Delayed-release Tablets   | 50 mg/0.2 mg   | Arthrotec 20607       | 6/29/2009          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 2/11/2014                                 |
| Diclofenac Sodium and Misoprostol                   | Delayed-release Tablets   | 75 mg/0.2 mg   | Arthrotec 20607       | 11/28/2008         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 2/11/2014                                 |
| Didanosine  | Delayed-release Capsules  | 200 mg, 250 mg and 400 mg  | Videx EC 21183        | 6/1/2004           | 1                         | Eligible       | 4/7/2020                      | 12/3/2004                        |   | 3/1/2007                                  |
| Difluprednate                                       | Ophthalmic Emulsion       | 0.05%  | Durezol 22212         | 5/1/2014           | 1                         | Extinguished   | 7/2/2019                      |                                  |   | 5/18/2019                                 |
| Diltiazem Hydrochloride                             | Extended-release Capsules | 60 mg, 90 mg and 120 mg  | Cardizem SR 19471     | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                           | DOSAGE FORM                   | STRENGTH  | RLD/NDA           | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------------|-------------------------------|---|-------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Diltiazem Hydrochloride             | Extended-release Capsules     | 120 mg, 180 mg and 240 mg                         | Dilacor XR 20092  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Diltiazem Hydrochloride             | Extended-release Capsules     | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg         | Cardizem CD 20062 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Diltiazem Hydrochloride             | Extended-release Capsules     | 120 mg, 180 mg, 240 mg, 300 mg, 360 mg and 420 mg | Tiazac 20401      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Diltiazem Hydrochloride             | Extended-release Tablets      | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg         | Cardizem LA 21392 | 8/30/2005          | 1                         | Deferred       | 11/19/2019                    | 3/15/2010                        | 3/15/2010                                 | 6/25/2013                                 |
| Diltiazem Hydrochloride             | Extended-release Tablets      | 420 mg  | Cardizem LA 21392 | 4/25/2005          | 1                         | Deferred       | 11/19/2019                    | 3/15/2010                        | 3/15/2010                                 | 6/25/2013                                 |
| Dimethyl Fumarate                   | Delayed-release Capsules      | 120 mg and 240 mg                                 | Tecfidera 204063  | 3/27/2017          | 29                        | Deferred       | 8/24/2020                     | 8/17/2020                        | 8/18/2020                                 | 2/7/2028                                  |
| Diroximel Fumarate                  | Delayed-release Capsules      | 231 mg  | Vumerity 211855   | 12/23/2020         | 1                         |                |                               |                                  |   | 9/20/2033                                 |
| Divalproex Sodium                   | Delayed-release Tablets       | 125 mg, 250 mg and 500 mg                         | Depakote 18723    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Divalproex Sodium*                  | Extended-release Tablets      | 250 mg  | Depakote ER 21168 | 5/3/2004           |                           |                |                               |                                  |   |   |
| Divalproex Sodium                   | Extended-release Tablets      | 500 mg  | Depakote ER 21168 | 2/8/2005           |                           |                |                               |                                  |   |   |
| Docetaxel                           | Injection                     | 40 mg/mL, 0.5 mL and 2 mL vials                   | Taxotere 20449    | 6/30/2009          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 11/22/2013                                |
| Dofetilide                          | Capsules                      | 0.125 mg, 0.25 mg, and 0.5 mg                     | Tikosyn 20931     | 5/1/2014           | 1                         | Eligible       | 8/13/2019                     | 6/6/2016                         | 6/7/2016                                  | 10/9/2018                                 |
| Dolutegravir Sodium                 | Tablets                       | 10 mg, 25 mg and 50 mg                            | Tivicay 204790    | 8/14/2017          | 4                         |                |                               |                                  |   | 12/8/2029                                 |
| Dolutegravir Sodium                 | Tablets for Suspension        | 5 mg  | Tivicay PD 213983 | 7/21/2021          | 1                         |                |                               |                                  |   | 12/8/2029                                 |
| Dolutegravir Sodium and Lamivudine  | Tablets                       | 50 mg/300 mg                                      | Dovato 211994     | 7/30/2019          | 1                         |                |                               |                                  |   | 12/8/2029                                 |
| Dolutegravir Sodium and Rilpivirine | Tablets                       | 50 mg/25 mg                                       | Juluca 210192     | 11/19/2019         | 1                         |                |                               |                                  |   | 1/24/2031                                 |
| Donepezil Hydrochloride             | Tablets                       | 5 mg and 10 mg                                    | Aricept 20690     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Donepezil Hydrochloride             | Orally Disintegrating Tablets | 5 mg and 10 mg                                    | Aricept ODT 21720 | 6/30/2010          | 1                         | Extinguished   | 4/7/2020                      | 11/26/2010                       |   | 6/23/2022                                 |



**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM                 | STRENGTH                       | RLD/NDA             | DATE OF SUBMISSION                   | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-----------------------------|--------------------------------|---------------------|--------------------------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Donepezil Hydrochloride                                  | Tablets                     | 23 mg                          | Aricept<br>22568    | 7/9/2013                             |                           | Eligible                 | 4/7/2020                      | 7/24/2013                        | 7/26/2013                                 | 10/4/2026                                 |
| Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate | Tablets                     | 100 mg/300 mg/<br>300 mg       | Delstrigo<br>210807 | 8/30/2022                            | 1                         |                          |                               |                                  |   | 11/29/2036                                |
| Doripenem  | Injection                   | 250 mg/vial and<br>500 mg/vial | Doribax<br>22106    | 10/12/2011                           | 1                         | Extinguished             | 4/7/2020                      |                                  |   | 6/5/2015                                  |
| Dorzolamide Hydrochloride                                | Ophthalmic Solution         | 2%                             | Trusopt<br>20408    | 10/11/2005                           | 1                         | Extinguished             | 4/7/2020                      | 10/28/2008                       |   | 4/28/2008                                 |
| Dorzolamide Hydrochloride and Timolol Maleate            | Ophthalmic Solution         | 2%/0.5%                        | Cosopt<br>20869     | 10/11/2005                           | 1                         | Extinguished             | 4/7/2020                      | 10/28/2008                       |   | 4/28/2008                                 |
| Doxazosin Mesylate                                       | Tablets                     | 1 mg, 2 mg, 4 mg<br>and 8 mg   | Cardura<br>19668    | Pre-MMA                              |                           |                          |                               |                                  |   |   |
| Doxepin Hydrochloride                                    | Tablets                     | 3 mg and 6 mg                  | Silenor<br>22036    | 9/16/2010                            | 2                         | Extinguished<br>Eligible | 7/27/2020<br>6/18/2019        | 7/26/2013                        |   | 2/17/2020                                 |
| Doxercalciferol  | Capsules                    | 1 mcg                          | Hectorol<br>20862   | 2/12/2010                            | 1                         | Extinguished             | 4/7/2020                      | 9/9/2016                         |   | 2/11/2014                                 |
| Doxercalciferol  | Capsules                    | 0.5 mcg and<br>2.5 mcg         | Hectorol<br>20862   | 3/25/2009                            | 1                         | Eligible                 | 4/7/2020                      | 1/14/2014<br>9/23/2011           |   | 7/18/2021                                 |
| Doxercalciferol  | Injection                   | 2 mcg/mL,<br>2 mL ampules      | Hectorol<br>21027   | 10/15/2007                           | 1                         | Extinguished             | 11/19/2019                    |                                  |   |   |
| Doxercalciferol  | Injection                   | 2 mcg/mL, 1 mL in<br>2 mL vial | Hectorol<br>21027   | 12/28/2011                           | 1                         | Extinguished             | 11/19/2019                    |                                  |   |   |
| Doxycycline  | Delayed-release<br>Capsules | 40 mg                          | Oracea<br>50805     | 12/12/2008                           | 1                         | Extinguished             | 8/24/2022                     |                                  |   | 4/5/2022                                  |
| Doxycycline Hyclate                                      | Delayed-release<br>Tablets  | 75 mg and 100 mg               | Doryx<br>50795      | PIV received<br>prior to<br>2/5/2009 | 1                         | Eligible                 | 4/7/2020                      | 12/28/2010                       | 12/30/2010                                | 12/15/2022                                |
| Doxycycline Hyclate                                      | Delayed-release<br>Tablets  | 150 mg                         | Doryx<br>50795      | 12/19/2008                           | 1                         | Extinguished             | 4/7/2020                      |                                  |   | 12/15/2022                                |
| Doxycycline Hyclate                                      | Delayed-release<br>Tablets  | 200 mg                         | Doryx<br>50795      | 5/19/2014                            | 1                         | Eligible                 | 4/7/2020                      | 5/19/2016                        | 5/19/2016                                 | 12/15/2022                                |
| Doxycycline Hyclate                                      | Delayed-release<br>Tablets  | 80 mg                          | Doryx<br>50795      | 7/1/2015                             | 1                         | Extinguished<br>Eligible | 4/18/2023<br>4/7/2020         | 4/29/2016                        |   | 12/15/2022                                |
| Doxycycline Hyclate                                      | Delayed-release<br>Tablets  | 50 mg                          | Doryx<br>50795      | 11/5/2015                            | 1                         | Eligible                 | 4/7/2020                      | 5/23/2016                        | 5/23/2016                                 | 2/3/2028                                  |
| Doxycycline Hyclate                                      | Delayed-release<br>Tablets  | 60 mg and 120 mg               | Doryx MPC<br>50795  | 9/28/2017                            | 1                         | Extinguished             | 8/7/2023                      |                                  |   | 12/23/2034                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM              | STRENGTH                                  | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|---|---------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Doxylamine Succinate and Pyridoxine Hydrochloride                                    | Delayed-release Tablets  | 10 mg/10 mg                               | Diclegis 21876      | 8/1/2013           | 1                         | Extinguished             | 7/2/2019                      | 8/19/2016                        | 6/21/2019                                 | 6/21/2021                                 |
| Doxylamine Succinate and Pyridoxine Hydrochloride                                    | Extended-release Tablets | 20 mg/20 mg                               | Bonjesta 209661     | 8/28/2018          | 1                         | Deferred                 | 5/5/2022                      | 3/1/2022                         |   | 2/18/2033                                 |
| Dronabinol   | Oral Solution            | 5 mg/mL                                   | Syndros 205525      | 4/17/2017          | 1                         | Extinguished             | 1/12/2021                     |                                  |   | 8/6/2028                                  |
| Dronedarone Hydrochloride  | Tablets                  | 400 mg                                    | Multaq 22425        | 7/1/2013           | 7                         | Deferred                 | 2/6/2024                      | 1/31/2024                        |   | 4/16/2029                                 |
| Drospirenone and Estradiol   | Tablets                  | 0.5 mg/1 mg                               | Angeliq 21355       | 12/26/2007         | 1                         | Extinguished             | 4/7/2020                      |                                  |   | 8/11/2017                                 |
| Drospirenone and Estradiol   | Tablets                  | 0.25 mg/0.5 mg                            | Angeliq 21355       | 1/8/2015           | 1                         | Extinguished             | 4/7/2020                      |                                  |   | 10/22/2031                                |
| Drospirenone and Ethinyl Estradiol   | Tablets                  | 3 mg/0.02 mg                              | Yaz 21676           | 9/29/2006          | 1                         | Extinguished<br>Deferred | 11/17/2022<br>11/17/2022      | 3/30/2009                        | 6/1/2010                                  | 12/20/2021                                |
| Drospirenone and Ethinyl Estradiol   | Tablets                  | 3 mg/0.03 mg                              | Yasmin 21098        | 1/7/2005           | 1                         | Extinguished             | 4/7/2020                      | 5/9/2008                         |   | 8/31/2020                                 |
| Drospirenone and Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium | Tablets                  | 3 mg/0.03 mg/<br>0.451 mg and<br>0.451 mg | Safyral 22574       | 9/28/2012          | 1                         | Extinguished             | 4/7/2020                      | 10/11/2016                       |   | 3/3/2022                                  |
| Drospirenone and Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium | Tablets                  | 3 mg/0.02 mg/<br>0.451 mg and<br>0.451 mg | Beyaz 22532         | 11/13/2012         | 1                         | Eligible                 | 4/7/2020                      | 10/11/2016                       | 10/11/2016                                | 3/3/2022                                  |
| Drospirenone   | Tablets                  | 4 mg                                      | Slynd 211367        | 1/7/2022           | 1                         |                          |                               |                                  |   | 6/28/2031                                 |
| Duloxetine Hydrochloride   | Delayed-release Capsules | 20 mg, 30 mg and 60 mg                    | Cymbalta 21427      | 8/4/2008           | 16                        | Eligible                 | 4/7/2020                      | 12/11/2013                       |   | 7/18/2014                                 |
| Duloxetine Hydrochloride   | Delayed-release Capsules | 40 mg                                     | Cymbalta 21427      | 5/10/2012          | 1                         | Eligible                 | 4/7/2020                      | 12/11/2013                       | 7/15/2015                                 | 7/18/2014                                 |
| Dutasteride  | Capsules                 | 0.5 mg                                    | Avodart 21319       | 10/29/2007         | 1                         | Deferred                 | 4/7/2020                      | 12/21/2010                       | 10/9/2015                                 | 11/20/2015                                |
| Dutasteride and Tamsulosin Hydrochloride   | Capsules                 | 0.5 mg/0.4 mg                             | Jalyn 22460         | 10/26/2010         | 1                         | Eligible                 | 4/7/2020                      | 2/26/2014                        | 11/18/2015                                | 11/20/2015                                |
| Edaravone  | Oral Suspension          | 105 mg/5 mL                               | Radicava ORS 215446 | 4/20/2023          | 1                         |                          |                               |                                  |   | 11/1/2039                                 |
| Edoxaban Tosylate  | Tablets                  | 15 mg, 30 mg and 60 mg                    | Savaysa 206316      | 1/28/2019          | 1                         |                          |                               |                                  |   | 3/28/2028                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM         | STRENGTH   | RLD/NDA                            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|---------------------|--|------------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Efavirenz  | Tablets             | 600 mg   | Sustiva<br>21360                   | 4/9/2009           | 1                         | Eligible       | 4/7/2020                      | 2/17/2016                        | 1/30/2018                                 | 1/20/2018                                 |
| Efavirenz  | Capsules            | 50 mg, 100 mg and<br>200 mg                                      | Sustiva<br>20972                   | 11/3/2016          | 1                         | Eligible       | 7/2/2019                      | 12/15/2017                       | 12/21/2017                                | 4/6/2019                                  |
| Efavirenz, Emtricitabine and<br>Tenofovir Disoproxil Fumarate                | Tablets             | 600 mg/200 mg/300<br>mg  | Atripla<br>21937                   | 12/29/2008         | 1                         | Extinguished   | 4/7/2020                      | 11/9/2018                        |   | 3/9/2021                                  |
| Efinaconazole  | Topical Solution    | 10%  | Jublia<br>203567                   | 6/6/2018           | 19                        | Eligible       | 2/9/2021                      | 12/16/2020                       |   | 10/2/2034                                 |
| Elagolix Sodium  | Tablets             | 150 mg and 200 mg  | Orilissa<br>210450                 | 7/25/2022          | 9                         |                |                               |                                  |   | 9/1/2036                                  |
| Elagolix Sodium, Estradiol,<br>Norethindrone Acetate;<br>Elagolix Sodium     | Capsules            | 300 mg/1 mg/<br>0.5 mg;<br>300 mg                                | Oriahnn<br>(Co-Packaged)<br>213388 | 11/3/2022          | 1                         |                |                               |                                  |   | 3/14/2034                                 |
| Eletriptan Hydrobromide  | Tablets             | 20 mg and 40 mg  | Relpax<br>21016                    | 3/29/2010          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 8/29/2017                                 |
| Eliglustat Tartrate  | Capsules            | 84 mg  | Cerdelga<br>205494                 | 8/20/2018          | 6                         | Deferred       | 10/5/2021                     | 9/8/2021                         |   | 6/26/2026                                 |
| Eltrombopag Olamine  | Tablets             | 50 mg and 75 mg  | Promacta<br>22291                  | 1/7/2014           | 1                         |                |                               |                                  |   | 2/1/2028                                  |
| Eltrombopag Olamine  | Tablets             | 12.5 mg and 25 mg  | Promacta<br>22291                  | 2/4/2014           | 1                         |                |                               |                                  |   | 2/1/2028                                  |
| Eltrombopag Olamine  | For Oral Suspension | 12. mg/packet and<br>25 mg/packet                                | Promacta Kit<br>207027             | 4/22/2022          | 1                         |                |                               |                                  |   | 7/13/2025                                 |
| Elvitegravir, Cobicistat,<br>Emtricitabine, Tenofovir<br>Disoproxil Fumarate | Tablets             | 150 mg/150 mg/<br>200 mg/300 mg                                  | Stribild<br>203100                 | 10/4/2018          | 1                         |                |                               |                                  |   | 4/24/2030                                 |
| Elvitegravir, Cobicistat,<br>Emtricitabine, Tenofovir<br>Alafenamide         | Tablets             | 150 mg/150 mg/<br>200 mg/10 mg                                   | Genvoya<br>207561                  | 4/12/2023          | 1                         |                |                               |                                  |   | 10/6/2032                                 |
| Eluxadoline  | Tablets             | 75 mg and 100 mg   | Viberzi<br>206940                  | 5/28/2019          | 6                         |                |                               |                                  |   | 3/14/2033                                 |
| Empagliflozin  | Tablets             | 10 mg and 25 mg  | Jardiance<br>204629                | 8/1/2018           | 14                        | Eligible       | 9/6/2022                      | 8/3/2022                         |   | 6/11/2034                                 |
| Empagliflozin and Metformin<br>Hydrochloride                                 | Tablets             | 5 mg/500 mg<br>5 mg/1000 mg<br>12.5 mg/500 mg<br>12.5 mg/1000 mg | Synjardy<br>206111                 | 8/1/2018           | 4                         | Eligible       | 9/6/2022                      | 7/7/2022                         |   | 4/3/2034                                  |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM              | STRENGTH   | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|--------------------------|--|-----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Empagliflozin and Metformin Hydrochloride                                   | Extended-release Tablets | 5 mg/1000 mg<br>10 mg/1000 mg<br>12.5 mg/1000 mg<br>25 mg/1000 mg          | Synjardy XR<br>208658 | 8/1/2018           | 3                         |                |                               |                                  |   | 6/11/2034                                 |
| Empagliflozin and Linagliptin   | Tablets                  | 10 mg/5 mg and<br>25 mg/5 mg   | Glyxambi<br>206073    | 8/1/2018           | 9                         |                |                               |                                  |   | 6/11/2034                                 |
| Empagliflozin, Linagliptan and Metformin Hydrochloride                      | Extended-release Tablets | 5 mg/2.5 mg/1 g,<br>10 mg/5 mg/1 g,<br>12.5 mg/5 mg/1 g,<br>25 mg/5 mg/1 g | Trijardy XR<br>212614 | 5/26/2020          | 1                         |                |                               |                                  |   | 4/3/2034                                  |
| Emtricitabine   | Capsules                 | 200 mg   | Emtriva<br>21500      | 7/16/2012          | 1                         | Eligible       | 11/17/2020                    | 7/2/2018                         | 8/31/2020                                 | 3/9/2021                                  |
| Emtricitabine and Tenofovir Alafenamide Fumarate                            | Tablets                  | 120 mg/15 mg   | Descovy<br>208215     | 10/31/2022         | 1                         |                |                               |                                  |   | 8/15/2032                                 |
| Emtricitabine and Tenofovir Alafenamide Fumarate                            | Tablets                  | 200 mg/25 mg   | Descovy<br>208215     | 11/5/2019          | 6                         |                |                               |                                  |   | 8/15/2032                                 |
| Emtricitabine and Tenofovir Disoproxil Fumarate                             | Tablets                  | 200 mg/300 mg  | Truvada<br>21752      | 9/26/2008          | 1                         | Extinguished   | 8/13/2019                     | 6/8/2017                         |   | 3/9/2021                                  |
| Emtricitabine and Tenofovir Disoproxil Fumarate                             | Tablets                  | 100 mg/150 mg<br>133 mg/200 mg<br>167 mg/250 mg                            | Truvada<br>21752      | 5/19/2017          | 1                         | Eligible       | 8/13/2019                     | 8/22/2018                        | 1/18/2021                                 | 3/9/2021                                  |
| Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Disoproxil Fumarate  | Tablets                  | 200 mg/25 mg/<br>300 mg  | Complera<br>202123    | 5/20/2015          | 1                         |                |                               |                                  |   | 12/9/2025                                 |
| Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate | Tablets                  | 200 mg/25 mg/<br>25 mg   | Odefsey<br>208351     | 11/5/2019          | 3                         |                |                               |                                  |   | 8/15/2032                                 |
| Enalapril Maleate   | Tablets                  | 2.5 mg, 5 mg,<br>10 mg and 20 mg   | Vasotec<br>18998      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Enalapril Maleate   | Powder for Oral Solution | 1 mg/mL  | Epaned Kit<br>204308  | 6/21/2016          | 1                         |                |                               |                                  |   | 11/6/2032                                 |
| Enalapril Maleate   | Oral Solution            | 1 mg/mL  | Epaned<br>208686      | 8/31/2018          | 1                         | Eligible       | 9/7/2021                      | 8/10/2021                        | 8/17/2021                                 | 3/25/2036                                 |
| Encorafenib   | Capsules                 | 75 mg  | Braftovi<br>210496    | 6/27/2022          | 3                         |                |                               |                                  |   | 11/21/2032                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                | DOSAGE FORM               | STRENGTH  | RLD/NDA                      | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS          | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--------------------------|---------------------------|---|------------------------------|--------------------|---------------------------|-------------------------|-------------------------------|----------------------------------|---|---|
| Enoxaparin Sodium        | Injection                 | 100 mg/mL, 0.3 mL, 0.4 mL, 0.6 mL, 0.8 mL and 1 mL prefilled syringes | Lovenox 20164                | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Enoxaparin Sodium        | Injection                 | 150 mg/mL, 0.6 mL, 0.8 mL and 1 mL prefilled syringes                 | Lovenox 20164                | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Enoxaparin Sodium        | Injection                 | 100 mg/mL, 3 mL vials   | Lovenox 20164                | 12/7/2006          | 1                         | Non-Forfeiture          | 4/7/2020                      | 11/28/2011                       |   | 2/14/2012                                 |
| Entacapone               | Tablets                   | 200 mg  | Comtan 20796                 | 4/11/2007          | 1                         | Extinguished            | 4/7/2020                      | 8/16/2012                        |   | 9/14/2018                                 |
| Entecavir                | Tablets                   | 0.5 mg and 1 mg   | Baraclude 21797              | 6/14/2010          | 1                         | Eligible                | 4/7/2020                      | 8/26/2014                        | 9/4/2014                                  | 8/21/2015                                 |
| Enzalutamide             | Capsules                  | 40 mg   | Xtandi 203415                | 8/31/2016          | 3                         | Non-Forfeiture Deferred | 9/18/2023<br>6/15/2021        | 5/14/2021                        |   | 8/13/2027                                 |
| Enzalutamide             | Tablets                   | 40 mg and 80 mg   | Xtandi 213674                | 3/31/2021          | 1                         |                         |                               |                                  |   | 8/13/2027                                 |
| Ephedrine Sulfate        | Injection                 | 50 mg/10 mL   | Emerphed 213407              | 10/14/2021         | 1                         |                         |                               |                                  |   | 5/16/2040                                 |
| Ephedrine Sulfate        | Injection                 | 25 mg/5 mL and 50 mg/10 mL  | Ephedrine Sulfate 213994     | 3/17/2023          | 1                         |                         |                               |                                  |   | 1/22/2040                                 |
| Epinastine Hydrochloride | Ophthalmic Solution       | 0.05%   | Elestat 21565                | 10/14/2008         | 1                         | Eligible                | 4/7/2020                      | 3/14/2011                        | 5/2/2011                                  | 11/29/2020                                |
| Epinephrine              | Injection (Auto-injector) | 0.15 mg/0.3 mL and 0.3 mg/0.3 mL                                      | Epipen and Epipen Jr. 19430  | 7/20/2009          | 1                         | Deferred                | 8/27/2019                     | 8/16/2018                        | 8/19/2019                                 | 9/11/2025                                 |
| Epinephrine              | Injection                 | 1 mg/mL ampules   | Adrenalin 204200             | 3/9/2016           | 1                         | Deferred                | 4/7/2020                      | 7/6/2018                         |   | 3/13/2035                                 |
| Epinephrine              | Injection                 | 30 mg/30 mL   | Adrenalin 204640             | 8/20/2018          | 1                         | Eligible                | 9/6/2022                      | 4/24/2020                        | 5/19/2020                                 | 3/13/2035                                 |
| Epinephrine              | Injection                 | 1 mg/mL   | Epinephrine Injection 205029 | 8/13/2020          | 1                         |                         |                               |                                  |   | 8/15/2034                                 |
| Eplerenone               | Tablets                   | 25 mg and 50 mg   | Inspra 21437                 | 9/27/2006          | 2                         | Eligible                | 4/7/2020                      | 7/30/2008                        | 7/30/2008                                 | 4/10/2020                                 |
| Epoprostenol Sodium      | Injection                 | 0.5 mg/vial and 1.5 mg/vial   | Veletri 22260                | 3/31/2017          | 1                         | Deferred                | 2/9/2021                      | 1/15/2021                        | 1/27/2021                                 | 3/15/2027                                 |
| Eptifibatide             | Injection                 | 0.75 mg/mL, 100 mL vial   | Integrilin 21437             | 6/5/2009           | 1                         | Eligible                | 4/7/2020                      | 6/5/2015                         | 12/14/2015                                | 9/15/2015                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                | DOSAGE FORM              | STRENGTH  | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--------------------------|--------------------------|---|---------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Eptifibatide             | Injection                | 2 mg/mL, 10 mL vial   | Integrilin 20718    | 9/30/2008          | 1                         | Extinguished   | 4/7/2020                      | 6/12/2015                        |   | 9/15/2015                                 |
| Eptifibatide             | Injection                | 2 mg/mL, 100 mL vial  | Integrilin 20718    | 12/18/2008         | 1                         | Extinguished   | 4/7/2020                      | 6/12/2015                        |   | 9/15/2015                                 |
| Eprosartan Mesylate      | Tablets                  | 400 mg and 600 mg   | Teveten 20738       | 5/10/2010          | 1                         | Eligible       | 4/7/2020                      | 11/16/2011                       | 12/20/2011                                | 8/12/2014                                 |
| Erdafitinib              | Tablets                  | 3 mg, 4 mg and 5 mg   | Balversa 212018     | 4/12/2023          | 1                         |                |                               |                                  |   | 2/2/2038                                  |
| Eribulin Mesylate        | Injection                | 1 mg/2 mL   | Halaven 201532      | 12/20/2019         | 1                         |                |                               |                                  |   | 1/8/2027                                  |
| Erlotinib Hydrochloride  | Tablets                  | 100 mg and 150 mg   | Tarceva 21743       | 11/18/2008         | 2                         | Eligible       | 6/18/2019                     | 6/11/2014                        | 5/9/2019                                  | 11/9/2020                                 |
| Erlotinib Hydrochloride  | Tablets                  | 25 mg   | Tarceva 21743       | 11/18/2008         | 1                         | Eligible       | 6/18/2019                     | 6/11/2014                        | 5/9/2019                                  | 11/9/2020                                 |
| Ertapenem                | Injection                | 1 g/vial  | Invanz 21337        | 12/21/2012         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 5/15/2017                                 |
| Ertugliflozin            | Tablets                  | 5 mg and 15 mg  | Steglatro 209803    | 12/20/2021         | 3                         | Eligible       | 8/7/2023                      | 7/13/2023                        |   | 7/13/2030                                 |
| Escitalopram Oxalate     | Capsules                 | 5 mg  | Lexapro 21323       | 8/17/2005          | 1                         | Eligible       | 4/7/2020                      | 8/3/2007                         |   | 7/25/2022                                 |
| Escitalopram Oxalate     | Capsules                 | 10 mg and 20 mg   | Lexapro 21323       | 3/30/2005          | 1                         | Eligible       | 4/7/2020                      | 8/3/2007                         |   | 7/25/2022                                 |
| Escitalopram Oxalate     | Tablets                  | 5 mg, 10 mg and 20 mg   | Lexapro 21323       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Esketamine Hydrochloride | Nasal Spray              | 28 mg   | Spravato 211243     | 3/6/2023           | 3                         |                |                               |                                  |   | 9/10/2035                                 |
| Eslicarbazepine Acetate  | Tablets                  | 200 mg, 400 mg, 600 mg and 800 mg                                 | Aptiom 22416        | 11/8/2017          | 7                         | Deferred       | 7/13/2021                     | 6/29/2021                        |   | 8/24/2032                                 |
| Esmolol Hydrochloride    | Injection                | 10 mg/mL, 10 mL vial  | Brevibloc 19386     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Esmolol Hydrochloride    | Injection                | 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags | Brevibloc 19386     | 1/31/2014          | 1                         | Extinguished   | 4/7/2020                      | 6/8/2016                         |   | 1/12/2021                                 |
| Esomeprazole Magnesium   | Delayed-release Capsules | 20 mg and 40 mg   | Nexium 21153        | 8/5/2005           | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 3/1/2008                                  |
| Esomeprazole Magnesium   | Delayed-release Capsules | 20 mg   | Nexium (OTC) 204655 | 4/24/2014          |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                             | DOSAGE FORM                         | STRENGTH  | RLD/NDA                  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------------------|-------------------------------------|---|--------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Esomeprazole Magnesium                | Delayed-release for Oral Suspension | 20 mg and 40 mg   | Nexium 21957             | 8/1/2013           | 1                         | Extinguished   | 10/4/2022                     |                                  |   | 11/3/2019                                 |
| Esomeprazole Magnesium                | Delayed-release for Oral Suspension | 10 mg   | Nexium 22101             | 7/6/2018           | 1                         | Extinguished   | 1/27/2020                     | 3/23/2020                        |   | 11/3/2019                                 |
| Esomeprazole Magnesium                | Delayed-release for Oral Suspension | 2.5 mg and 5 mg   | Nexium 21957             | 9/24/2018          | 1                         | Extinguished   | 1/27/2020                     |                                  |   | 11/3/2019                                 |
| Esomeprazole                          | Delayed-release Tablets             | 20 mg   | Nexium 24HR (OTC) 207920 | 9/9/2016           | 1                         | Eligible       | 7/2/2019                      | 3/5/2019                         |   | 11/3/2019                                 |
| Esomeprazole Sodium                   | For Injection                       | 20 mg/vial and 40 mg/vial   | Nexium IV 21689          | 11/23/2009         | 1                         | Deferred       | 4/7/2020                      | 3/18/2013                        | 1/15/2014                                 | 5/27/2014                                 |
| Estradiol                             | Transdermal System                  | 0.025 mg/day<br>0.0375 mg/day<br>0.05 mg/days<br>0.075 mg/day<br>0.1 mg/day | Vivelle Dot 20538        | 4/27/2010          | 1                         | Extinguished   | 4/7/2020                      | 12/19/2014                       |   | 8/12/2014                                 |
| Estradiol                             | Transdermal System                  | 0.0375 mg/day and 0.06 mg/day   | Climara 20375            | Pre-MMA            |                           |                |                               |                                  |   |   |
| Estradiol                             | Transdermal System                  | 0.05 mg/day and 0.1 mg/day  | Climara 20375            | 9/12/2005          |                           |                |                               |                                  |   |   |
| Estradiol                             | Vaginal Tablets                     | 10 mcg  | Vagifem 20908            | 1/2/2013           | 1                         | Eligible       | 4/7/2020                      | 5/29/2015                        | 10/17/2016                                | 9/17/2022                                 |
| Estradiol                             | Vaginal Inserts                     | 4 mcg and 10 mcg  | Imvexxy 208564           | 12/30/2019         | 1                         |                |                               |                                  |   | 12/20/2033                                |
| Estradiol                             | Transdermal System                  | 0.0375 mg/day<br>0.05 mg/day<br>0.075 mg/day<br>0.1 mg/day                  | Minivelle 203752         | 8/18/2014          | 1                         | Deferred       | 10/8/2019                     | 8/15/2018                        | 11/1/2018                                 | 7/4/2030                                  |
| Estradiol                             | Transdermal System                  | 0.025 mg/day  | Minivelle 203752         | 5/8/2015           | 1                         | Deferred       | 10/8/2019                     | 8/15/2018                        | 11/1/2018                                 | 7/4/2030                                  |
| Estradiol; Estradiol and Norgestimate | Tablets                             | 1 mg; 1 mg and 0.09 mg  | Prefest 21040            | Pre-MMA            |                           |                |                               |                                  |   |   |
| Estradiol and Progesterone            | Capsules                            | 1 mg/100 mg   | Bijuva NDA 210132        | 1/6/2020           | 1                         | Eligible       | 5/31/2022                     | 5/16/2022                        |   | 11/21/2032                                |
| Estradiol Valerate and Dienogest      | Tablets                             | 3 mg;2 mg/2 mg;<br>2 mg/3 mg and 1 mg                                       | Natazia 22252            | 10/22/2010         | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 10/25/2016                                |
| Eszopiclone                           | Tablets                             | 1 mg, 2 mg and 3 mg   | Lunesta 21476            | 12/15/2008         | 10                        | Eligible       | 4/7/2020                      | 5/23/2011                        | 4/15/2014                                 | 8/30/2012                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                          | DOSAGE FORM                 | STRENGTH   | RLD/NDA                    | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------------------|-----------------------------|--|----------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Etelcalcetide                      | Injection                   | 2.5 mg/0.5 mL<br>5 mg/mL<br>10 mg/2 mL                   | Parsabiv<br>208325         | 2/8/2021           | 2                         |                          |                               |                                  |   | 6/27/2034                                 |
| Ethinyl Estradiol and Etonogestrel | Vaginal Ring                | 0.015 mg/24 hour<br>0.12 mg/24 hour                      | Nuvaring<br>21187          | 6/17/2013          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 4/8/2018                                  |
| Etodolac                           | Extended-release Tablets    | 400 mg, 500 mg and 600 mg                                | Lodine XL<br>20584         | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Everolimus                         | Tablets                     | 0.25 mg, 0.5 mg, and 0.75 mg                             | Zortress<br>21560          | 9/30/2013          | 3                         | Extinguished<br>Deferred | 4/7/2020<br>4/7/2020          | 4/12/2018                        |   | 3/9/2020                                  |
| Everolimus                         | Tablets                     | 10 mg  | Afinitor<br>22334          | 6/18/2014          | 1                         | Extinguished             | 2/25/2020                     |                                  |   | 12/6/2019                                 |
| Everolimus                         | Tablets                     | 2.5 mg, 5 mg, and 7.5 mg                                 | Afinitor<br>22334          | 12/10/2014         | 1                         | Extinguished             | 2/25/2020                     | 12/9/2019                        |   | 12/6/2019                                 |
| Everolimus                         | Tablets for Oral Suspension | 2 mg, 3 mg and 5 mg                                      | Afinitor Disperz<br>203985 | 12/30/2016         | 1                         | Eligible                 | 1/27/2020                     | 4/19/2019                        | 10/1/2021                                 | 9/27/2022                                 |
| Exenatide                          | Injection                   | 250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe           | Byetta<br>21773            | 6/11/2014          | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 1/14/2020                                 |
| Ezetimibe                          | Tablets                     | 10 mg  | Zetia<br>21445             | 10/25/2006         | 1                         | Eligible                 | 6/18/2019                     | 6/26/2015                        | 12/12/2016                                | 1/25/2022                                 |
| Ezetimibe and Simvastatin          | Tablets                     | 10 mg/10 mg<br>10 mg/20 mg<br>10 mg/40 mg<br>10 mg/80 mg | Vytorin<br>21687           | 7/27/2009          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 10/25/2016                                |
| Famciclovir                        | Tablets                     | 125 mg, 250 mg and 500 mg                                | Famvir<br>20363            | 12/28/2004         | 1                         | Eligible                 | 5/19/2020                     | 8/24/2007                        |   | 9/1/2015                                  |
| Famotidine                         | Injection                   | 10 mg/mL, 2 mL vials; unpreserved                        | Pepcid                     | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Famotidine                         | Injection                   | 10 mg/mL, 4 mL and 20 mL vials; preserved                | Pepcid                     | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Famotidine                         | Injection                   | 10 mg/mL, 50 mL vial, pharmacy bulk package; unpreserved | Pepcid                     | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Famotidine                         | Tablets                     | 10 mg (OTC)  | Pepcid AC                  | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Famotidine                         | Tablets                     | 20 mg and 40 mg  | Pepcid<br>19462            | Pre-MMA            |                           |                          |                               |                                  |   |   |



**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                  | DOSAGE FORM                       | STRENGTH  | RLD/NDA                    | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|----------------------------|-----------------------------------|---|----------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Famotidine                 | Tablets (Chewable)                | 10 mg (OTC)   | Pepcid AC (chewable) 20801 | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Febuxostat                 | Tablets                           | 40 mg and 80 mg   | Uloric 21856               | 2/13/2013          | 10                        | Eligible                 | 8/27/2019                     | 7/1/2019                         | 7/1/2019                                  | 3/8/2024                                  |
| Fedratinib Hydrochloride   | Capsules                          | 100 mg  | Inrebic 212327             | 8/16/2023          | 1                         |                          |                               |                                  |   | 9/24/2039                                 |
| Felodipine                 | Extended-release Tablets          | 2.5 mg, 5 mg and 10 mg  | Plendil ER 19834           | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Fenfluramine Hydrochloride | Oral Solution                     | 2.2 mg/mL   | Fintepla NDA 212102        | 6/21/2021          | 1                         |                          |                               |                                  |   | 6/29/2038                                 |
| Fenofibrate                | Tablets                           | 40 mg and 120 mg  | Fenoglide 22118            | 3/17/2010          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 12/9/2024                                 |
| Fenofibrate                | Capsules                          | 43 mg and 130 mg  | Antara 21695               | 9/15/2008          | 1                         | Extinguished             | 5/19/2020                     | 3/1/2012                         |   | 8/20/2020                                 |
| Fenofibrate Choline        | Delayed-release Capsules          | 45 mg   | Trilipix 22224             | 9/2/2009           | 1                         | Extinguished             | 5/19/2020                     | 9/7/2016                         |   | 1/7/2025                                  |
| Fenofibrate Choline        | Delayed-release Capsules          | 135 mg  | Trilipix 22224             | 9/1/2009           | 1                         | Extinguished             | 5/19/2020                     | 9/7/2016                         |   | 1/7/2025                                  |
| Fenofibrate                | Capsules                          | 67 mg, 134 mg and 200 mg  | Tricor 19304               | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Fenofibrate                | Tablets                           | 48 mg   | Tricor 21656               | 7/1/2008           | 1                         | Extinguished             | 4/7/2020                      | 4/5/2012                         |   | 2/21/2023                                 |
| Fenofibrate                | Tablets                           | 54 mg, 107 mg and 160 mg  | Tricor 21203               | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Fenofibrate                | Tablets                           | 145 mg  | Tricor 21656               | 10/19/2007         | 1                         | Extinguished             | 4/7/2020                      |                                  |   | 2/21/2023                                 |
| Fentanyl                   | Transdermal Extended-release Film | 0.6 mg/24 hr<br>1.2 mg/ 24 hr<br>1.8 mg/ 24 hr<br>2.4 mg/ 24 hr | Duragesic 19813            | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Fentanyl Citrate           | Buccal Tablets                    | 0.1 mg, 0.2 mg,<br>0.3 mg, 0.4 mg,<br>0.6 mg and 0.8 mg         | Fentora 21947              | 11/13/2007         | 1                         | Extinguished<br>Deferred | 3/10/2020<br>3/10/2020        | 1/7/2011                         |   | 3/26/2019                                 |
| Fentanyl Citrate           | Lozenges                          | 0.2 mg  | Actiq 20747                | 10/29/2004         |                           |                          |                               |                                  |   |   |
| Fentanyl Citrate           | Lozenges                          | 0.4 mg  | Actiq 20747                | 10/6/2004          |                           |                          |                               |                                  |   |   |
| Fentanyl Citrate           | Lozenges                          | 0.6 mg  | Actiq 20747                | 12/20/2004         |                           |                          |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM              | STRENGTH   | RLD/NDA                 | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|--|-------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Fentanyl Citrate   | Lozenges                 | 0.8 mg, 1.2 mg and 1.6 mg  | Actiq 20747             | 11/22/2004         |                           |                |                               |                                  |   |   |
| Fentanyl   | Sublingual Spray         | 0.4 mg/spray   | Subsys 202788           | 5/22/2017          | 1                         | Extinguished   | 9/4/2023                      |                                  |   | 4/27/2030                                 |
| Fentanyl   | Sublingual Spray         | 0.1 mg/spray, 0.2 mg/spray, 0.6 mg/spray, 0.8 mg/spray, 1.2 mg/spray, 1.6 mg/spray | Subsys 202788           | 12/7/2017          | 1                         | Extinguished   | 9/4/2023                      |                                  |   | 4/27/2030                                 |
| Fentanyl Citrate   | Sublingual Tablets       | 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg                                  | Abstral 22510           | 6/19/2014          | 1                         | Deferred       | 5/19/2020                     | 11/17/2017                       |   | 9/24/2019                                 |
| Ferric Carboxymaltose  | Injection                | 100 mg/2 mL  | Injectafer 203565       | 9/23/2022          | 1                         |                |                               |                                  |   | 2/15/2028                                 |
| Ferric Carboxymaltose  | Injection                | 750 mg/15 mL   | Injectafer 203565       | 3/27/2019          | 1                         |                |                               |                                  |   | 2/15/2028                                 |
| Ferric Carboxymaltose  | Injection                | 1 g/20 mL  | Injectafer 203565       | 2/15/2022          | 1                         |                |                               |                                  |   | 2/15/2028                                 |
| Ferumoxytol  | Injection                | 30 mg/mL, 17 mL single-use vials   | Feraheme 22180          | 12/4/2015          | 1                         | Deferred       | 2/9/2021                      | 1/15/2021                        | 7/15/2021                                 | 6/30/2023                                 |
| Fesoterodine Fumarate  | Extended-release Tablets | 4 mg and 8 mg  | Toviaz 22030            | 10/31/2012         | 16                        | Eligible       | 5/19/2020                     | 12/10/2015                       | 7/3/2022                                  | 6/7/2027                                  |
| Fexofenadine Hydrochloride                                   | Oral Suspension (OTC)    | 30 mg/5 mL   | Allegra 201373          | 1/25/2010          | 1                         | Eligible       | 11/19/2019                    | 11/18/2014                       | 12/22/2014                                | 3/14/2017                                 |
| Fexofenadine Hydrochloride                                   | Capsules                 | 60 mg  | Allegra 20625           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fexofenadine Hydrochloride                                   | Tablets                  | 30 mg, 60 mg and 180 mg  | Allegra 20872           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride | Extended-release Tablets | 60 mg/120 mg   | Allegra-D 20786         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride | Extended-release Tablets | 180 mg/240 mg  | Allegra-D 24 Hour 21704 | 6/6/2007           | 1                         | Eligible       | 5/19/2020                     | 6/22/2011                        | 1/28/2011                                 | 12/25/2020                                |
| Fidaxomicin  | Tablets                  | 200 mg   | Dificid 201699          | 5/27/2015          | 1                         | Deferred       | 1/22/2024                     | 1/16/2024                        |   | 7/31/2027                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                | DOSAGE FORM                 | STRENGTH                            | RLD/NDA   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--------------------------|-----------------------------|-------------------------------------|---|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Finasteride              | Tablets                     | 1 mg                                | Propecia<br>20788                               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Finasteride              | Tablets                     | 5 mg                                | Proscar<br>20180                                | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fingolimod               | Capsules                    | 0.5 mg                              | Gilenya<br>22527                                | 9/22/2014          | 19                        | Deferred       | 1/2/2020                      | 12/4/2019                        | 9/21/2022                                 | 3/29/2026                                 |
| Fingolimod               | Capsules                    | 0.25 mg                             | Gilenya<br>22527                                | 7/19/2018          | 1                         | Eligible       | 11/15/2021                    | 11/12/2021                       |   | 3/30/2032                                 |
| Flecainide Acetate       | Tablets                     | 50 mg, 100 mg and<br>150 mg         | Tambocor<br>18830                               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluconazole              | For Oral Suspension         | 50 mg/5 mL and<br>200 mg/5 mL       | Diflucan for Oral<br>Suspension<br>20090        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluconazole              | Tablets                     | 50 mg, 100 mg,<br>150 mg and 200 mg | Diflucan<br>19949                               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Flunisolide              | Nasal Solution              | 0.025%                              | Nasalide<br>18148                               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluocinonide             | Cream                       | 0.1%                                | Vanos<br>21758                                  | 1/31/2008          | 1                         | Eligible       | 6/1/2020                      | 1/14/2014                        | 1/14/2014                                 | 12/21/2021                                |
| Fluocinonide             | Ointment                    | 0.05%                               | Lidex<br>16909                                  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluorouracil             | Cream                       | 0.5%                                | Carac<br>20985                                  | 7/29/2011          | 1                         | Deferred       | 6/1/2020                      | 4/20/2015                        | 11/1/2014                                 | 6/2/2021                                  |
| Fluoxetine Hydrochloride | Tablets                     | 10 mg and 20 mg                     | Prozac<br>20974                                 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluoxetine Hydrochloride | Capsules                    | 10 mg, 20 mg and 40<br>mg           | Prozac<br>18936                                 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluoxetine Hydrochloride | Delayed-release<br>Capsules | 90 mg                               | Prozac Weekly<br>21235                          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluoxetine Hydrochloride | Oral Solution               | 20 mg (base)/5 mL                   | Prozac<br>20101                                 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluoxetine Hydrochloride | Capsules                    | 10 mg and 20 mg                     | Sarafem<br>18936                                | Pre-MMA            |                           |                |                               |                                  |   |   |
| Flutamide                | Capsules                    | 125 mg                              | Eulexin<br>18554                                | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluticasone Furoate      | Nasal Spray                 | 27.5 mcg                            | Flonase<br>Sensimist Allergy<br>Relief<br>22051 | 7/15/2011          | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 8/3/2021                                  |
| Fluticasone Propionate   | Lotion                      | 0.05%                               | Cutivate<br>21152                               | 7/28/2008          | 1                         | Eligible       | 6/15/2020                     | 5/2/2011                         | 3/26/2012                                 | 10/20/2019                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM               | STRENGTH                          | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------|-----------------------------------|--------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Fluticasone Propionate  | Inhalation Aerosol        | 0.11 mcg/inh                      | Flovent HFA 21433  | 12/23/2016         | 1                         |                |                               |                                  |   | 2/26/2026                                 |
| Fluticasone Propionate  | Inhalation Aerosol        | 0.22 mcg/inh                      | Flovent HFA 21433  | 10/29/2021         | 1                         |                |                               |                                  |   | 2/26/2026                                 |
| Fluvastatin   | Capsules                  | 20 mg and 40 mg                   | Lescol 20261       | 6/4/2008           | 1                         | Extinguished   | 6/15/2020                     | 4/11/2012                        |   | 12/12/2011                                |
| Fluvastatin Sodium  | Extended-release Tablets  | 80 mg                             | Lescol XL 21192    | 3/15/2007          | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 4/13/2020                                 |
| Fluvoxamine Maleate   | Extended-release Capsules | 100 mg                            | Luvox CR 22033     | 4/20/2009          | 1                         | Extinguished   | 6/15/2020                     | 3/13/2013                        |   | 5/10/2020                                 |
| Fluvoxamine Maleate   | Extended-release Capsules | 150 mg                            | Luvox CR 22033     | 4/13/2009          | 1                         | Non-Forfeiture | 6/15/2020                     | 3/13/2013                        | 3/13/2013                                 | 5/10/2020                                 |
| Fomepizole  | Injection                 | 1.5 g/1.5 mL                      | Antizol 20696      | 4/14/2014          | 1                         | Extinguished   | 8/7/2023                      |                                  |   | 6/30/2027                                 |
| Formoterol Fumarate   | Inhalation Solution       | 0.02 mg/2 mL                      | Perforomist 22007  | 1/21/2009          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 6/22/2021                                 |
| Fosamprenavir Calcium   | Tablets                   | 700 mg                            | Lexiva 21548       | 1/18/2012          | 1                         | Extinguished   | 6/15/2020                     | 11/20/2019                       |   | 7/15/2019                                 |
| Fosaprepitant Dimeglumine   | Injection                 | 115 mg/vial                       | Emend 22023        | 1/25/2012          | 1                         | Extinguished   | 3/10/2020                     | 9/5/2019                         |   | 2/10/2015                                 |
| Fosaprepitant Dimeglumine   | Injection                 | 150 mg/vial                       | Emend 22023        | 1/25/2012          | 2                         | Extinguished   | 3/10/2020                     |                                  |   | 3/4/2019                                  |
| Fosinopril Sodium   | Tablets                   | 10 mg, 20 mg and 40 mg            | Monopril 19915     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fosinopril Sodium and Hydrochlorothiazide                           | Tablets                   | 10 mg/12.5 mg and 20 mg/12.5 mg   | Monopril HCT 20286 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fosnetupitant Chloride Hydrochloride and Palonosetron Hydrochloride | Solution in SDV           | 235 mg/0.25 mg per 20 mL          | Akynzeo 210493     | 4/19/2022          | 1                         |                |                               |                                  |   | 6/2/2037                                  |
| Fostamatinib Disodium   | Tablets                   | 100 mg and 150 mg                 | Tavalisse 209299   | 4/18/2022          | 1                         |                |                               |                                  |   | 7/27/2032                                 |
| Frovatriptan Succinate  | Tablets                   | 2.5 mg                            | Frova 21006        | 3/9/2011           | 1                         | Eligible       | 6/15/2020                     | 7/8/2014                         | 4/29/2016                                 | 11/7/2015                                 |
| Fulvestrant   | Injection                 | 50 mg/mL, 2.5 mL and 5 mL syringe | Faslodex 21344     | 10/1/2009          | 1                         | Extinguished   | 7/16/2019                     |                                  |   | 1/9/2021                                  |
| Gabapentin  | Capsules                  | 100 mg, 300 mg and 400 mg         | Neurontin 20235    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Gabapentin  | Tablets                   | 100 mg, 300 mg and 400 mg         | Neurontin 20235    | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM               | STRENGTH  | RLD/NDA                 | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|---------------------------|---|-------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Gabapentin                                       | Oral Solution             | 250 mg/5 mL                                     | Neurontin 21129         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Gabapentin                                       | Tablets                   | 600 mg and 800 mg                               | Neurontin 20882         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Gabapentin                                       | Tablets                   | 300 mg and 600 mg                               | Gralise 22544           | 10/31/2011         | 1                         | Extinguished   | 1/22/2024                     |                                  |   | 2/26/2024                                 |
| Gabapentin Enacarbil                             | Extended-release Tablets  | 300 mg and 600 mg                               | Horizant 22399          | 4/29/2019          | 1                         |                |                               |                                  |   | 6/10/2029                                 |
| Galantamine Hydrobromide                         | Extended-release Capsules | 8 mg  | Razadyne ER 21615       | 3/2/2006           | 1                         | Eligible       | 6/15/2020                     | 9/15/2008                        | 10/15/2008                                | 12/20/2019                                |
| Galantamine Hydrobromide                         | Extended-release Capsules | 16 mg and 24 mg                                 | Razadyne ER 21615       | 3/11/2006          | 1                         | Eligible       | 6/15/2020                     | 9/15/2008                        | 10/15/2008                                | 12/20/2019                                |
| Galantamine Hydrobromide                         | Tablets                   | 4 mg, 8 mg and 12 mg                            | Razadyne 21169          | 2/28/2005          | 14                        | Eligible       | 6/15/2020                     | 8/28/2008                        | 8/28/2008                                 | 6/6/2017                                  |
| Ganciclovir Sodium                               | Capsules                  | 250 mg and 500 mg                               | Cytovene 20460          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ganirelix Acetate                                | Injection                 | 250 mcg/0.5 mL, 1 mL PFS                        | Ganirelix Acetate 21057 | 3/30/2012          | 1                         | Extinguished   | 1/27/2020                     | 11/30/2018                       |   | 6/16/2015                                 |
| Gatifloxacin                                     | Injection                 | 10 mg/mL, 20 mL and 40 mL vials                 | Tequin                  | 11/24/2004         | 1                         | Extinguished   | 6/15/2020                     |                                  |   |   |
| Gatifloxacin                                     | Ophthalmic Solution       | 0.3 %   | Zymar 21493             | 7/19/2007          | 1                         | Eligible       | 6/15/2020                     | 8/19/2011                        |   | 8/20/2019                                 |
| Gatifloxacin                                     | Ophthalmic Solution       | 0.5 %   | Zymaxid 22548           | 12/7/2010          | 1                         | Eligible       | 6/15/2020                     | 8/28/2013                        | 10/1/2013                                 | 8/20/2019                                 |
| Gatifloxacin                                     | Tablets                   | 200 mg and 400 mg                               | Tequin                  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Gatifloxacin in Dextrose 5% in Plastic Container | Injection                 | 2 mg/mL, 100 mL and 200 mL containers (plastic) | Tequin                  | 12/13/2004         | 2                         |                |                               |                                  |   |   |
| Gemcitabine                                      | For Injection             | 200 mg/vial                                     | Gemzar 20509            | 11/1/2005          | 1                         | Eligible       | 6/15/2020                     | 12/18/2008                       |   | 11/7/2012                                 |
| Gemcitabine                                      | For Injection             | 1g/vial   | Gemzar 20509            | 11/14/2005         | 1                         | Eligible       | 6/15/2020                     | 1/25/2011                        |   | 11/7/2012                                 |
| Gemcitabine                                      | For Injection             | 2 g/vial  | Gemzar                  | 8/24/2007          | 1                         | Eligible       | 6/15/2020                     | 11/15/2010                       | 11/15/2010                                | 11/7/2012                                 |
| Gemifloxacin Mesylate                            | Tablets                   | 320 mg  | Factive 21158           | 3/4/2008           | 1                         | Eligible       | 6/18/2019                     | 6/15/2015                        |   | 9/21/2019                                 |
| Gilteritinib Fumarate                            | Tablets                   | 40 mg   | Xospata 211349          | 11/28/2022         | 1                         |                |                               |                                  |   | 7/1/2036                                  |
| Glatiramer Acetate                               | Injection                 | 20 mg/mL, 1mL pre-filled syringe                | Copaxone 20622          | 12/27/2007         | 1                         | Extinguished   | 2/25/2020                     | 4/16/2015                        |   | 5/24/2014                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                             | DOSAGE FORM              | STRENGTH                                      | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------------------|--------------------------|---|---------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Glatiramer Acetate                    | Injection                | 40 mg/mL, 1 mL pre-filled syringe             | Copaxone 20622      | 2/26/2014          | 2                         | Deferred       | 2/25/2020                     | 10/3/2017                        | 10/4/2017                                 | 8/19/2030                                 |
| Glimepiride and Rosiglitazone Maleate | Tablets                  | 1 mg/4 mg<br>2 mg/4 mg<br>4 mg/4 mg           | Avandaryl 21700     | 12/22/2006         | 1                         | Extinguished   | 6/15/2020                     | 4/1/2016                         |   | 10/21/2015                                |
| Glimepiride and Rosiglitazone Maleate | Tablets                  | 8 mg/2 mg<br>8 mg/4 mg                        | Avandaryl 21700     | 5/30/2008          | 1                         | Eligible       | 6/15/2020                     | 4/1/2016                         |   | 10/19/2020                                |
| Glipizide                             | Extended-release Tablets | 2.5 mg, 5 mg and 10 mg                        | Glucotrol XL 20329  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Glyburide                             | Tablets                  | 1.5 mg, 3 mg, 4.5 mg and 6 mg                 | Glynase 20051       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Glyburide/<br>Metformin Hydrochloride | Tablets                  | 1.25mg/250 mg<br>2.5 mg/500 mg<br>5 mg/500 mg | Glucovance 21178    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Glycerol Phenylbutyrate               | Oral Liquid              | 1.1 g/mL                                      | Ravicti 203284      | 11/19/2013         | 1                         | Eligible       | 1/11/2022                     | 12/2/2021                        |   | 3/9/2032                                  |
| Glycopyrrolate                        | Tablets                  | 1 mg  | Robinul 12827       | 8/14/2009          | 1                         | Extinguished   | 3/10/2020                     | 2/3/2014                         |   | 4/24/2024                                 |
| Glycopyrrolate                        | Tablets                  | 1.5 mg  | Robinul Forte       | 5/6/2009           | 1                         | Deferred       | 6/15/2020                     | 3/12/2012                        |   | 4/24/2024                                 |
| Glycopyrrolate                        | Tablets                  | 2 mg  | Robinul Forte 12827 | 10/12/2010         | 1                         | Eligible       | 6/15/2020                     | 2/3/2014                         | 12/21/2015                                | 4/24/2024                                 |
| Glycopyrrolate                        | Oral Solution            | 1 mg/5 mL                                     | Cuvposa 22571       | 6/20/2012          | 1                         | Eligible       | 8/24/2021                     | 8/9/2021                         | 1/4/2022                                  | 8/20/2023                                 |
| Glycopyrronium Tosylate               | Topical Cloth            | 2.4%  | Qbrexza 210361      | 1/13/2020          | 1                         |                |                               |                                  |   | 2/28/2033                                 |
| Granisetron Hydrochloride             | Injection                | 0.1 mg/mL, 1 mL single dose vial              | Kytril 20239        | 3/8/2007           | 1                         |                |                               |                                  |   |   |
| Granisetron Hydrochloride             | Injection                | 1 mg/mL, 1 mL vials                           | Kytril 20239        | 6/1/2004           | 1                         | Eligible       | 6/15/2020                     | 12/31/2007                       | 12/31/2007                                | 5/4/2019                                  |
| Granisetron Hydrochloride             | Injection                | 1 mg/mL, 4 mL multi-dose vials                | Kytril 20239        | 7/19/2004          | 1                         | Eligible       | 6/15/2020                     | 12/31/2007                       | 12/31/2007                                | 5/4/2019                                  |
| Granisetron Hydrochloride             | Transdermal System       | 3.1 mg/24 hrs                                 | Sancuso 22198       | 10/9/2015          | 1                         |                |                               |                                  |   | 10/22/2024                                |
| Guaifenesin                           | Extended-release Tablets | 600 mg and 1.2 gm                             | Mucinex 21282       | 6/9/2006           | 1                         | Extinguished   | 11/19/2019                    |                                  |   | 4/28/2020                                 |
| Guaifenesin and Dextromethorphan      | Extended-release Tablets | 600 mg/30 mg and 1200 mg/60 mg                | Mucinex DM 21620    | 12/17/2008         | 1                         | Deferred       | 6/15/2020                     | 8/31/2015                        | 4/5/2016                                  | 4/28/2020                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                     | DOSAGE FORM               | STRENGTH                                     | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------|--|------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Guaifenesin and Pseudoephedrine Hydrochloride | Extended-release Tablets  | 600 mg/60 mg and 1200 mg/120 mg              | Mucinex-D 21585        | 12/29/2008         | 1                         | Deferred       | 6/15/2020                     | 5/27/2015                        | 12/16/2015                                | 4/28/2020                                 |
| Guanfacine Hydrochloride                      | Extended-release Tablets  | 1 mg, 2 mg, 3 mg and 4 mg                    | Intuniv 22037          | 12/29/2009         | 1                         | Eligible       | 6/29/2020                     | 10/5/2012                        | 12/1/2014                                 | 7/4/2022                                  |
| Halobetasol Propionate                        | Lotion                    | 0.05%  | Ultavate 208183        | 1/24/2018          | 1                         | Eligible       | 7/13/2020                     | 6/4/2020                         |   | 6/19/2033                                 |
| Halobetasol Propionate                        | Lotion                    | 0.01%  | Bryhali 209355         | 5/15/2019          | 1                         |                |                               |                                  |   | 11/2/2031                                 |
| Halobetasol Propionate                        | Topical Foam              | 0.05%  | Lexette 210566         | 1/28/2021          | 1                         | Eligible       | 9/4/2023                      | 8/11/2023                        | 12/27/2023                                | 11/30/2036                                |
| Halobetasol Propionate and Tazarotene         | Lotion                    | 0.01%/0.045%                                 | Duobrii 209354         | 6/11/2020          | 1                         |                |                               |                                  |   | 6/6/2036                                  |
| Hydrocodone Bitartrate                        | Extended-release Capsules | 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 50 mg | Zohydro ER 202880      | 2/26/2014          | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 11/1/2019                                 |
| Hydrocodone Bitartrate and Ibuprofen          | Tablets                   | 2.5 mg/200 mg                                | Vicoprofen 20716       | 2/24/2006          | 1                         | Eligible       | 7/25/2022                     | 10/19/2007                       |   | 6/10/2017                                 |
| Hydrocodone Bitartrate and Ibuprofen          | Tablets                   | 5 mg/200 mg                                  | Vicoprofen             | 5/27/2005          | 1                         |                |                               | 3/18/2004                        |   | 6/10/2017                                 |
| Hydrocodone Bitartrate and Ibuprofen          | Tablets                   | 7.5 mg/200 mg                                | Vicoprofen 20716       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Hydrocodone Bitartrate and Ibuprofen          | Tablets                   | 10 mg/200 mg                                 | Vicoprofen 20716       | 3/20/2006          | 1                         | Eligible       | 6/15/2020                     | 11/6/2006                        |   | 6/10/2017                                 |
| Hydrocodone Bitartrate                        | Extended-release Tablets  | 20 mg, 60 mg, and 120 mg                     | Hysingla ER 206627     | 4/15/2015          | 1                         | Deferred       | 3/9/2021                      | 3/1/2021                         | 3/1/2021                                  | 12/21/2031                                |
| Hydrocodone Bitartrate                        | Extended-release Tablets  | 30 mg, 40 mg, 80 mg, and 100 mg              | Hysingla ER 206627     | 5/8/2015           | 1                         | Deferred       | 3/9/2021                      | 3/1/2021                         | 3/1/2021                                  | 12/21/2031                                |
| Hydrocortisone Butyrate                       | Cream                     | 0.10%  | Locoid Lipocream 20769 | 6/28/2010          | 1                         | Eligible       | 6/29/2020                     | 9/27/2013                        | 12/5/2013                                 | 6/3/2014                                  |
| Hydrocortisone Butyrate                       | Lotion                    | 0.10%  | Locoid 22076           | 8/31/2016          | 1                         | Eligible       | 6/29/2020                     | 11/21/2017                       | 2/12/2018                                 | 12/19/2026                                |
| Hydromorphone Hydrochloride                   | Extended-release Tablets  | 8 mg and 12 mg                               | Exlago 21217           | 9/2/2010           | 1                         | Deferred       | 6/29/2020                     | 5/12/2014                        |   | 7/7/2014                                  |
| Hydromorphone Hydrochloride                   | Extended-release Tablets  | 16 mg  | Exlago 21217           | 8/2/2010           | 1                         | Deferred       | 6/29/2020                     | 5/12/2014                        |   | 7/7/2014                                  |
| Hydromorphone Hydrochloride                   | Oral Solution             | 5 mg/5mL                                     | Dilaudid 19891         | 2/25/2011          | 1                         | Extinguished   | 1/27/2020                     |                                  |   | 11/9/2020                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                    | DOSAGE FORM               | STRENGTH             | RLD/NDA                                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------------|---------------------------|----------------------|--|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Hydromorphone Hydrochloride  | Injection                 | 10 mg/mL             | Dilaudid-HP 19034                      | 11/4/2011          | 1                         | Extinguished   | 6/29/2020                     |                                  |   |   |
| Hydromorphone Hydrochloride  | Injection                 | 2 mg/mL              | Dilaudid 19034                         | 6/22/2011          | 1                         | Deferred       | 1/8/2024                      | 4/27/2018                        | 10/1/2018                                 | 11/9/2020                                 |
| Hydromorphone Hydrochloride  | Injection                 | 1 mg/mL              | Dilaudid 19034                         | 12/13/2022         | 1                         |                |                               |                                  |   | 3/12/2034                                 |
| Hydromorphone Hydrochloride  | Injection                 | 0.5 mg/0.5 mL        | Dilaudid 19034                         | 12/13/2022         | 1                         |                |                               |                                  |   | 3/12/2034                                 |
| Hydromorphone Hydrochloride  | Injection                 | 0.2 mg/mL            | Dilaudid 19034                         | 12/19/2023         | 1                         |                |                               |                                  |   | 3/12/2034                                 |
| Hydromorphone Hydrochloride  | Tablets                   | 2 mg, 4 mg, and 8 mg | Dilaudid 19892                         | 8/5/2013           | 1                         | Deferred       | 6/29/2020                     | 5/13/2016                        |   | 11/9/2020                                 |
| Hydroxyprogesterone Caproate | Injection (Auto-injector) | 275 mg/1.1 mL        | Makena 21945                           | 9/28/2020          | 1                         |                |                               |                                  |   | 5/2/2036                                  |
| Ibandronate Sodium           | Injection                 | 1 mg/mL, 3 mL Vial   | Boniva 21858                           | 8/31/2007          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 9/2/2014                                  |
| Ibandronate Sodium           | Tablets                   | 150 mg               | Boniva 21455                           | 5/16/2007          | 8                         | Deferred       | 6/29/2020                     | 3/19/2012                        | 3/19/2012                                 | 5/6/2023                                  |
| Ibandronate Sodium           | Tablets                   | 2.5 mg               | Boniva 21455                           | 5/16/2007          | 1                         | Extinguished   | 6/29/2020                     |                                  |   | 5/6/2023                                  |
| Ibrutinib                    | Capsules                  | 70 mg                | Imbruvica 205552                       | 12/14/2018         | 1                         | Eligible       | 4/6/2021                      | 3/31/2021                        |   | 10/30/2033                                |
| Ibrutinib                    | Capsules                  | 140 mg               | Imbruvica 205552                       | 11/13/2017         | 8                         | Deferred       | 4/6/2021                      | 3/31/2021                        |   | 10/24/2034                                |
| Ibrutinib                    | Tablets                   | 140 mg and 560 mg    | Imbruvica 210563                       | 11/5/2018          | 1                         |                |                               |                                  |   | 3/3/2036                                  |
| Ibrutinib                    | Tablets                   | 280 mg and 420 mg    | Imbruvica 210563                       | 12/14/2018         | 1                         |                |                               |                                  |   | 3/3/2036                                  |
| Ibuprofen                    | Oral Drops                | 40 mg/mL             | Children's Motrin Drops 20603          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ibuprofen                    | Oral Suspension           | 50 mg/1.25 mL        | Concentrated Motrin Infant Drops 20812 | 6/29/2007          | 1                         |                |                               |                                  |   | 12/20/2011                                |
| Ibuprofen                    | Oral Suspension           | 100 mg/5 mL (Rx)     | Motrin                                 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ibuprofen                    | Oral Suspension           | 100 mg/5 mL (OTC)    | Children's Motrin                      | Pre-MMA            |                           |                |                               |                                  |   |   |



**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                     | STRENGTH  | RLD/NDA   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------------|---|---|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Ibuprofen   | Chewable Tablets                | 50 mg and 100 mg  | Children's Motrin, Junior Strength Motrin 20601 | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Ibuprofen Lysine                                      | Injection                       | 10 mg/mL, 2 mL vials  | Neoprofen 21903                                 | 10/1/2010          | 1                         | Extinguished<br>Deferred | 4/18/2023<br>6/29/2020        | 3/30/2016                        |   | 3/20/2021                                 |
| Ibuprofen and Diphenhydramine Hydrochloride           | Capsules                        | 200 mg/25 mg  | Advil PM 21393                                  | 2/16/2016          |                           |                          |                               |                                  |   |   |
| Ibuprofen and Diphenhydramine Citrate                 | Tablets                         | 200 mg/38 mg  | Advil PM 21394                                  | 12/28/2017         | 1                         | Extinguished             | 4/18/2023                     |                                  |   | 5/30/2022                                 |
| Ibuprofen and Famotidine                              | Tablets                         | 800 mg/26.6 mg  | Duexis 22519                                    | 12/6/2011          | 1                         | Extinguished             | 8/24/2021                     |                                  |   | 7/18/2026                                 |
| Ibuprofen and Pseudoephedrine Hydrochloride           | Oral Suspension                 | 100 mg/ 15 mg per 5 mL  | Children's Motrin Cold                          | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Ibuprofen and Pseudoephedrine Hydrochloride           | Tablets                         | 200 mg/30 mg  | Advil Cold and Sinus                            | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Ibuprofen Potassium and Pseudoephedrine Hydrochloride | Capsules                        | 200 mg/30 mg  | Advil Cold and Sinus                            | 12/27/2004         | 1                         | Extinguished             | 6/29/2020                     |                                  |   |   |
| Icatibant   | Injection                       | 10 mg/mL  | Firazyr 22150                                   | 8/25/2015          | 2                         | Extinguished             | 8/13/2019                     |                                  |   | 7/15/2019                                 |
| Icosapent Ethyl                                       | Capsules                        | 1 g   | Vascepa 202057                                  | 7/26/2016          | 4                         | Deferred                 | 6/15/2020                     | 5/21/2020                        | 11/4/2020                                 | 4/29/2030                                 |
| Icosapent Ethyl                                       | Capsules                        | 500 mg  | Vascepa 202057                                  | 8/29/2017          | 1                         | Non-Forfeiture           | 12/1/2020                     | 9/11/2020                        | 9/9/2022                                  | 4/29/2030                                 |
| Idelalisib  | Tablets                         | 100 mg and 150 mg   | Zydelig 205858                                  | 3/23/2022          | 1                         |                          |                               |                                  |   | 9/2/2033                                  |
| Ifosfamide  | For Injection                   | 1 g/vial and 3 g/vial   | Ifex 19763                                      | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Ifosfamide  | Injection                       | 50 mg/mL, 20 mL vials and 60 mL vials                                 | Ifex  | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Ifosfamide/ Mesna                                     | For Injection/<br>Injection Kit | 1 g/vial; 100 mg/mL, 10 mL vials and 3 g/vial; 100 mg/mL, 10 mL vials | Ifex/ Mesnex Kit 19763                          | Pre-MMA            |                           |                          |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                          | DOSAGE FORM               | STRENGTH   | RLD/NDA                    | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------------------|---------------------------|--|----------------------------|--------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Ifosfamide/ Mesna                  | Injection/ Injection Kit  | 50 mg/mL, 20 mL and 60 mL vials; 100 mg/mL, 10 mL vial | Ifex/ Mesnex Kit           | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Iloperidone                        | Tablets                   | 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg         | Fanapt 22192               | 5/6/2013           | 1                         | Extinguished          | 6/18/2019                     |                                  |   | 11/15/2016                                |
| Imatinib Mesylate                  | Tablets                   | 100 mg and 400 mg                                      | Gleevec 21588              | 3/12/2007          | 1                         | Non-forfeiture        | 6/18/2019                     | 12/3/2015                        | 2/1/2016                                  | 11/23/2019                                |
| Imatinib Mesylate                  | Capsules                  | 400 mg   | Gleevec                    | 1/24/2014          | 1                         | Extinguished          | 3/10/2020                     |                                  |   | 1/16/2019                                 |
| Imiquimod                          | Cream                     | 5%   | Aldara 20723               | 10/17/2006         | 1                         | Eligible              | 6/29/2020                     | 2/25/2010                        | 2/25/2010                                 | 8/24/2010                                 |
| Imiquimod                          | Cream                     | 2.5%   | Zyclara 22483              | 6/17/2014          | 1                         |                       |                               |                                  |   | 12/11/2029                                |
| Imiquimod                          | Cream                     | 3.75%  | Zyclara 22483              | 8/8/2012           | 1                         | Non-Forfeiture        | 7/16/2019                     |                                  | 7/30/2020                                 | 12/11/2029                                |
| Indocyanine Green                  | For Injection             | 25 mg/vial   | Spy Agent Green Kit 211580 | 11/28/2022         | 1                         |                       |                               |                                  |   | 8/4/2035                                  |
| Indomethacin                       | Extended-release Capsules | 75 mg  | Indocin SR 18185           | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Ingenol Mebutate                   | Gel                       | 0.05%  | Picato 202833              | 1/27/2016          | 2                         | Eligible              | 8/13/2019                     | 1/9/2019                         |   | 7/6/2027                                  |
| Ingenol Mebutate                   | Gel                       | 0.015%   | Picato 202833              | 1/27/2016          | 2                         | Eligible              | 8/13/2019                     | 1/7/2019                         |   | 7/6/2027                                  |
| Irbesartan                         | Tablets                   | 75 mg, 150 mg and 300 mg                               | Avapro 20757               | 5/25/2004          | 1                         | Non-Forfeiture        | 6/29/2020                     | 3/30/2012                        | 3/30/2012                                 | 6/7/2015                                  |
| Irbesartan and Hydrochlorothiazide | Tablets                   | 150 mg/12.5 mg and 300 mg/12.5 mg                      | Avalide 20758              | 11/10/2004         | 1                         | Eligible              | 6/29/2020                     | 3/30/2012                        | 3/30/2012                                 | 6/7/2015                                  |
| Irbesartan and Hydrochlorothiazide | Tablets                   | 300 mg/25 mg   | Avalide 20758              | 6/6/2006           | 1                         | Eligible              | 6/29/2020                     | 3/30/2012                        |   | 6/7/2015                                  |
| Irinotecan Hydrochloride           | Injection                 | 20 mg/mL, 2 mL and 5 mL vials                          | Camptosar 20571            | 7/26/2004          | 1                         | Extinguished          | 6/29/2020                     | 2/20/2008                        |   | 5/1/2020                                  |
| Isotretinoin                       | Capsules                  | 30 mg  | Absorica 21951             | 12/31/2012         | 1                         | Eligible Deferred     | 4/20/2021<br>4/6/2021         | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |
| Isotretinoin                       | Capsules                  | 40 mg  | Absorica 21951             | 12/31/2012         | 1                         | Extinguished Deferred | 4/20/2021<br>4/6/2021         | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |
| Isotretinoin                       | Capsules                  | 20 mg  | Absorica 21951             | 1/7/2013           | 1                         | Eligible Deferred     | 4/20/2021<br>4/6/2021         | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME              | DOSAGE FORM         | STRENGTH   | RLD/NDA              | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS       | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------|---------------------|--|----------------------|--------------------|---------------------------|----------------------|-------------------------------|----------------------------------|---|---|
| Isotretinoin           | Capsules            | 10 mg  | Absorica<br>21951    | 6/20/2013          | 1                         | Eligible<br>Deferred | 4/20/2021<br>4/6/2021         | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |
| Isotretinoin           | Capsules            | 35 mg  | Absorica<br>21951    | 11/25/2015         | 1                         | Deferred             | 4/6/2021                      | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |
| Isotretinoin           | Capsules            | 25 mg  | Absorica<br>21951    | 5/16/2016          | 1                         | Deferred             | 4/6/2021                      | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |
| Itraconazole           | Capsules            | 100 mg   | Sporanox<br>20083    | Pre-MMA            |                           |                      |                               |                                  |   |   |
| Itraconazole           | Oral Solution       | 10 mg/mL   | Sporanox<br>20657    | 5/3/2013           | 1                         | Eligible             | 6/29/2020                     | 10/30/2015                       | 9/18/2018                                 | 6/18/2019                                 |
| Ivabradine             | Tablets             | 5 mg and 7.5 mg                                    | Corlanor<br>206143   | 10/15/2019         | 6                         | Eligible             | 1/11/2022                     | 12/30/2021                       |   | 2/22/2026                                 |
| Ivacaftor              | Tablets             | 150 mg   | Kalydeco<br>203188   | 6/10/2020          | 1                         |                      |                               |                                  |   | 8/13/2029                                 |
| Ivacaftor              | Oral Granules       | 25 mg, 50 mg and<br>75 mg                          | Kalydeco<br>207925   | 4/13/2022          | 1                         |                      |                               |                                  |   | 2/27/2033                                 |
| Ivermectin             | Lotion              | 0.50%  | Sklice<br>202736     | 9/1/2017           | 1                         | Eligible             | 6/15/2020                     | 5/6/2020                         | 11/30/2020                                | 10/12/2027                                |
| Ivermectin             | Cream               | 1%   | Soolantra<br>206255  | 12/30/2016         | 1                         | Eligible             | 1/2/2020                      | 9/13/2019                        | 10/14/2019                                | 3/13/2034                                 |
| Ivosidenib             | Tablets             | 250 mg   | Tibsovo<br>211192    | 7/20/2022          | 1                         |                      |                               |                                  |   | 6/7/2039                                  |
| Ixabepilon             | Injection           | 15 mg/vial and<br>45 mg/vial, single-<br>use vials | Ixempra Kit<br>22065 | 4/16/2012          | 1                         | Extinguished         | 4/18/2023                     |                                  |   | 2/8/2022                                  |
| Ixazomib Citrate       | Capsules            | 2.3 mg, 3 mg and<br>4 mg                           | Ninlaro<br>208462    | 11/20/2019         | 1                         |                      |                               |                                  |   | 11/20/2029                                |
| Ketoconazole           | Foam                | 2%   | Extina<br>21738      | 7/30/2009          | 1                         | Eligible             | 6/29/2020                     | 8/25/2011                        | 8/25/2011                                 | 10/19/2018                                |
| Ketoprofen             | Capsules            | 25 mg, 50 mg and 75<br>mg                          | Orudis<br>18754      | Pre-MMA            |                           |                      |                               |                                  |   |   |
| Ketorolac Tromethamine | Injection           | 15 mg/mL and<br>30 mg/mL                           | Toradol<br>19698     | Pre-MMA            |                           |                      |                               |                                  |   |   |
| Ketorolac Tromethamine | Ophthalmic Solution | 0.45%  | Acuvail<br>22427     | 8/24/2011          | 1                         | Eligible             | 6/29/2020                     | 2/10/2014                        |   | 8/15/2029                                 |
| Ketorolac Tromethamine | Ophthalmic Solution | 0.4%   | Acular LS<br>21528   | 1/28/2005          | 1                         | Extinguished         | 6/29/2020                     | 11/5/2009                        |   | 5/5/2011                                  |
| Ketorolac Tromethamine | Tablets             | 10 mg  | Toradol<br>19645     | Pre-MMA            |                           |                      |                               |                                  |   |   |
| Ketorolac Tromethamine | Nasal Spray         | 15.75 mg/spray                                     | Sprix<br>22382       | 3/12/2012          | 1                         | Extinguished         | 3/10/2020                     |                                  |   | 12/25/2018                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                                   | STRENGTH  | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---|---|-----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Ketotifen Fumarate                                | Ophthalmic Solution                           | 0.025%  | Zaditor<br>21066      | 12/23/2004         | 1                         | Eligible       | 7/27/2020                     | 5/9/2006                         | 7/3/2006                                  | 1/13/2019                                 |
| Lacosamide  | Oral Solution                                 | 10 mg/mL  | Vimpat<br>22255       | 10/29/2012         | 3                         | Extinguished   | 4/18/2022                     |                                  |   | 3/17/2022                                 |
| Lacosamide  | Tablets                                       | 50 mg, 100 mg,<br>150 mg, and<br>200 mg                   | Vimpat<br>22253       | 10/29/2012         | 14                        | Extinguished   | 4/18/2022                     | 3/17/2022                        |   | 3/17/2022                                 |
| Lacosamide  | Injection                                     | 10 mg/mL, 20 mL   | Vimpat<br>22254       | 6/30/2016          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 3/17/2022                                 |
| Lactic Acid, Citric Acid and Potassium Bitartrate | Vaginal Gel                                   | 1.8%/1%/0.4%  | Phexxi<br>208352      | 2/28/2023          | 1                         |                |                               |                                  |   | 3/15/2033                                 |
| Lactulose   | Oral Syrup                                    | 10 g/15 mL  | Cephulac<br>17657     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Lactulose   | Oral Syrup                                    | 10 g/15 mL  | Chronulac<br>17884    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Lamivudine  | Tablets                                       | 100 mg  | Epivir-HBV            | 10/31/2007         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 5/18/2016                                 |
| Lamivudine  | Tablets                                       | 150 mg and 300 mg   | Epivir                | 10/16/2007         | 1                         | Extinguished   | 10/5/2021                     |                                  |   | 11/17/2009                                |
| Lamivudine and Zidovudine                         | Tablets                                       | 150 mg/300 mg   | Combivir              | 6/26/2007          | 1                         | Eligible       | 10/5/2021                     | 5/25/2011                        | 2/3/2012                                  | 5/18/2016                                 |
| Lamivudine  | Oral Solution                                 | 10 mg/mL  | Epivir                | 11/22/2011         | 1                         | Eligible       | 4/6/2021                      | 10/31/2014                       | 3/5/2015                                  | 3/20/2018                                 |
| Lamotrigine                                       | Tablets                                       | 25 mg, 100 mg,<br>150 mg and 200 mg                       | Lamictal<br>20241     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Lamotrigine                                       | Chewable Tablets                              | 2 mg, 5 mg and<br>25 mg                                   | Lamictal CD<br>20764  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Lamotrigine                                       | Orally Disintegrating Tablets                 | 25 mg, 50 mg,<br>100 mg, and<br>200 mg                    | Lamictal ODT<br>22251 | 12/21/2009         | 1                         | Deferred       | 10/5/2021                     | 7/15/2013                        |   | 1/4/2029                                  |
| Lamotrigine                                       | Extended-release Tablets                      | 25 mg, 50 mg,<br>100 mg, 200 mg, 250<br>mg, and<br>300 mg | Lamictal XR<br>22115  | 2/12/2014          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 6/14/2028                                 |
| Lansoprazole                                      | Delayed-release Pellets/Capsules              | 15 mg and 30 mg   | Prevacid<br>20406     | 12/05/2005         |                           |                |                               |                                  |   |   |
| Lansoprazole                                      | Delayed-release Orally Disintegrating Tablets | 15 mg and 30 mg   | Prevacid<br>21428     | 12/27/2006         | 1                         | Extinguished   | 10/5/2021                     | 10/15/2010                       |   | 5/10/2009                                 |
| Lanthanum Carbonate                               | Chewable Tablet                               | 500 mg, 750 mg and<br>1000 mg                             | Fosrenol<br>21468     | 10/27/2008         | 3                         | Deferred       | 7/16/2019                     | 8/11/2017                        | 8/30/2017                                 | 8/26/2024                                 |
| Lanthanum Carbonate                               | Oral Powder                                   | 750 mg and<br>1000 mg                                     | Fosrenol<br>204734    | 11/25/2015         | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 12/1/2030                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                             | DOSAGE FORM              | STRENGTH                   | RLD/NDA                                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------------------|--------------------------|----------------------------|--|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Lapatinib Ditosylate                  | Tablets                  | 250 mg                     | Tykerb<br>22059                        | 3/14/2011          | 1                         | Deferred       | 11/17/2020                    | 9/29/2020                        | 9/29/2020                                 | 11/19/2021                                |
| Latanoprost                           | Ophthalmic Solution      | 0.005%                     | Xalatan<br>20597                       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Latanoprost and Netarsudil Dimesylate | Ophthalmic Solution      | 0.005%/0.02%               | Rocklatan<br>208259                    | 12/20/2021         | 2                         |                |                               |                                  |   | 3/14/2034                                 |
| Latanoprostene Bunod                  | Ophthalmic Solution      | 0.024%                     | Vyzulta<br>207795                      | 3/31/2022          | 1                         |                |                               |                                  |   | 10/3/2025                                 |
| Lenalidomide                          | Capsules                 | 5 mg, 10 mg and 15 mg      | Revlimid<br>21880                      | 8/30/2010          | 1                         | Non-Forfeiture | 11/17/2020                    | 5/21/2021                        | 3/3/2022                                  | 4/27/2027                                 |
| Lenalidomide                          | Capsules                 | 25 mg                      | Revlimid<br>21880                      | 7/12/2010          | 1                         | Non-Forfeiture | 11/17/2020                    | 5/21/2021                        | 3/3/2022                                  | 4/27/2027                                 |
| Lenalidomide                          | Capsules                 | 2.5 mg and 20 mg           | Revlimid<br>21880                      | 7/12/2016          | 1                         | Non-Forfeiture | 11/17/2020                    | 10/14/2021                       | 9/7/2022                                  | 4/27/2027                                 |
| Lenvatinib                            | Capsules                 | 4 mg and 10 mg             | Lenvima<br>206947                      | 2/13/2019          | 2                         |                |                               |                                  |   | 7/27/2027                                 |
| Letrozole                             | Tablets                  | 2.5 mg                     | Femara<br>20726                        | 3/2/2006           | 1                         | Eligible       | 4/6/2021                      | 12/24/2008                       |   | 6/3/2011                                  |
| Leuprolide Acetate                    | Injection (depot)        | 7.5 mg/vial                | Lupron Depot<br>19732                  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levalbuterol Hydrochloride            | Inhalation Solution      | 0.0103%, 0.021% and 0.042% | Xopenex<br>20837                       | 6/20/2005          | 1                         | Eligible       | 10/5/2021                     | 4/9/2008                         |   | 3/21/2021                                 |
| Levalbuterol Hydrochloride            | Inhalation Solution      | 0.25%                      | Xopenex<br>20837                       | 5/23/2006          | 1                         | Eligible       | 10/5/2021                     | 3/20/2009                        |   | 3/21/2021                                 |
| Levalbuterol Tartrate                 | Inhalation Aerosol       | 0.045 mg/actuation         | Xopenex HFA<br>21730                   | 2/27/2012          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 10/8/2024                                 |
| Levetiracetam                         | Tablets                  | 250 mg, 500 mg and 750 mg  | Keppra<br>21035                        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levetiracetam                         | Tablets                  | 1000 mg                    | Keppra<br>21035                        | 1/24/2007          | 1                         |                |                               | 1/15/2009                        |   | 7/14/2008                                 |
| Levetiracetam                         | Extended-release Tablets | 500 mg and 750 mg          | Keppra XR<br>22285                     | 1/7/2011           | 3                         | Eligible       | 6/15/2020                     | 9/12/2011                        | 9/12/2011                                 | 9/17/2028                                 |
| Levetiracetam                         | Extended-release Tablets | 1000 mg                    | Keppra XR<br>22285                     | 1/7/2011           | 2                         | Extinguished   | 3/10/2020                     |                                  |   | 9/17/2028                                 |
| Levocetirizine Dihydrochloride        | Oral Solution            | 0.5 mg/mL                  | Xyzal<br>22157                         | 1/14/2009          | 1                         | Eligible       | 10/5/2021                     | 11/7/2011                        |   | 9/24/2012                                 |
| Levocetirizine Dihydrochloride        | Oral Solution            | 0.5 mg/mL                  | Xyzal Allergy<br>24 HR (OTC)<br>209090 | 1/4/2018           | 1                         | Deferred       | 10/5/2021                     |                                  |   |   |
| Levocetirizine Dihydrochloride        | Tablets                  | 5 mg                       | Xyzal<br>22064                         | 12/17/2007         | 1                         | Eligible       | 10/5/2021                     | 11/26/2010                       |   | 9/24/2012                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM               | STRENGTH   | RLD/NDA  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|---------------------------|--|--|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Levofloxacin   | Injection                 | 5 mg/mL; 50 mL, 100 mL and 150 mL vials  | Levaquin in Dextrose 5% in Plastic Container 20635 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levofloxacin   | Injection                 | 25 mg/mL   | Levaquin 20635                                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levofloxacin   | Ophthalmic Solution       | 0.5%   | Quixin 21199                                       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levofloxacin   | Oral Solution             | 25 mg/mL   | Levaquin 21721                                     | 7/30/2009          | 1                         | Eligible       | 10/5/2021                     | 6/20/2011                        |   | 2/26/2022                                 |
| Levofloxacin   | Tablets                   | 250 mg, 500 mg and 750 mg  | Levaquin 20634                                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levoleucovorin Calcium                               | Injection                 | 10 mg/mL, 17.5 mL vial and 25 mL vial  | Fusilev 20140                                      | 10/26/2011         | 1                         | Eligible       | 10/5/2021                     | 3/9/2015                         | 4/23/2015                                 | 12/31/2019                                |
| Levoleucovorin Calcium                               | Injection                 | 50 mg/vial   | Fusilev 20140                                      | 12/19/2013         | 1                         |                |                               |                                  |   |   |
| Levomilnacipran                                      | Extended-release Capsules | 20 mg, 40 mg, 80 mg and 120 mg   | Fetzima 204168                                     | 7/25/2017          | 6                         | Eligible       | 5/19/2020                     | 2/4/2019                         |   | 3/2/2031                                  |
| Levonorgestrel and Ethinyl Estradiol                 | Tablets                   | 0.09 mg/0.02 mg  | Lybrel 21864                                       | 10/5/2007          | 1                         | Non-Forfeiture | 10/5/2021                     | 6/6/2011                         |   |   |
| Levonorgestrel and Ethinyl Estradiol                 | Tablets                   | 0.15 mg/0.03 mg  | Seasonale 21544                                    | 3/29/2004          |                           |                |                               |                                  |   |   |
| Levonorgestrel and Ethinyl Estradiol                 | Tablets                   | 0.1 mg/0.02 mg   | Balcoltra 208612                                   | 7/14/2020          | 1                         | Extinguished   | 5/1/2023                      |                                  |   | 8/16/2021                                 |
| Levonorgestrel; Ethinyl Estradiol; Ethinyl Estradiol | Tablets                   | 0.1 mg/0.02 mg and 0.01 mg   | LoSeasonique 22262                                 | 11/16/2009         | 1                         | Eligible       | 10/5/2021                     | 10/26/2011                       |   | 6/15/2023                                 |
| Levonorgestrel; Ethinyl Estradiol; Ethinyl Estradiol | Tablets                   | 0.15 mg/0.03 mg/0.01 mg  | Seasonique 21840                                   | 1/22/2008          |                           |                |                               |                                  |   |   |
| Levonorgestrel; Ethinyl Estradiol; Ethinyl Estradiol | Tablets                   | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg   | Quartette 204061                                   | 7/10/2013          | 1                         | Extinguished   | 10/5/2021                     |                                  |   |   |
| Levothyroxine Sodium                                 | Tablets                   | 0.025 mg, 0.05 mg, 0.075 mg, 0.088 mg, 0.1 mg, 0.112 mg, 0.125 mg, 0.150 mg, 0.175 mg, 0.2 mg and 0.3 mg | Levoxyl 21301                                      | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME            | DOSAGE FORM         | STRENGTH  | RLD/NDA                     | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|----------------------|---------------------|---|-----------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Levothyroxine Sodium | for Injection       | 100 mcg/vial and 500 mcg/vial   | Levothyroxine Sodium 202231 | 4/14/2015          | 2                         | Eligible       | 6/18/2019                     | 6/29/2016                        | 4/2/2018                                  | 10/3/2032                                 |
| Levothyroxine Sodium | for Injection       | 200 mcg/vial  | Levothyroxine Sodium 202231 | 5/1/2015           | 1                         | Deferred       | 6/18/2019                     | 12/7/2015                        | 7/5/2016                                  | 10/3/2032                                 |
| Levothyroxine Sodium | Capsules            | 75 mcg and 150 mcg  | Tirosint 21924              | 12/29/2017         | 1                         | Deferred       | 1/12/2021                     | 10/28/2020                       |   | 3/14/2024                                 |
| Levothyroxine Sodium | Capsules            | 88 mcg, 100 mcg and 125 mcg   | Tirosint 21924              | 8/1/2019           | 1                         | Eligible       | 1/12/2021                     | 1/6/2021                         |   | 3/14/2024                                 |
| Levothyroxine Sodium | Capsules            | 112 mcg   | Tirosint 21924              | 12/18/2020         | 1                         | Eligible       | 7/25/2022                     | 4/16/2021                        |   | 3/14/2024                                 |
| Levothyroxine Sodium | Capsules            | 200 mcg   | Tirosint 21924              | 12/30/2021         | 1                         | Eligible       | 11/15/2022                    | 11/9/2022                        |   | 3/14/2024                                 |
| Levothyroxine Sodium | Capsules            | 137 mcg and 175 mcg   | Tirosint 21924              | 11/4/2022          | 1                         | Eligible       | 5/1/2023                      | 5/2/2023                         |   | 3/14/2024                                 |
| Levothyroxine Sodium | Oral Solution       | 13 mcg/mL<br>25 mcg/mL<br>50 mcg/mL<br>75 mcg/mL<br>88 mcg/mL<br>100 mcg/mL<br>112 mcg/mL<br>125 mcg/mL<br>137 mcg/mL<br>150 mcg/mL<br>175 mcg/mL<br>200 mcg/mL | Tirosint-Sol 206977         | 9/30/2022          | 1                         |                |                               |                                  |   | 2/28/2037                                 |
| Levothyroxine Sodium | Oral Solution       | 100 mcg/5 mL  | Thyquidity 214047           | 12/28/2022         | 1                         |                |                               |                                  |   | 8/6/2031                                  |
| Lidocaine            | Topical Patch       | 5%  | Lidoderm 20612              | 11/13/2009         | 1                         | Deferred       | 10/5/2021                     | 8/23/2012                        |   | 10/27/2015                                |
| Lidocaine            | Topical Patch       | 1.80%   | Ztlido 207962               | 3/17/2022          | 1                         |                |                               |                                  |   | 5/10/2031                                 |
| Lifitegrast          | Ophthalmic Solution | 5%  | Xiidra 208073               | 7/13/2020          | 4                         | Eligible       | 8/7/2023                      | 8/4/2023                         |   | 7/25/2033                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                | DOSAGE FORM              | STRENGTH  | RLD/NDA                            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|---|------------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Linacotide                               | Capsules                 | 145 mcg and 290 mcg                               | Linness 202811                     | 8/30/2016          | 4                         | Deferred       | 2/22/2021                     | 2/9/2021                         |   | 10/30/2031                                |
| Linacotide                               | Capsules                 | 72 mcg  | Linness 202811                     | 11/7/2017          | 1                         |                |                               |                                  |   | 8/16/2033                                 |
| Linagliptin                              | Tablets                  | 5 mg  | Tradjenta 201280                   | 5/4/2015           | 11                        | Deferred       | 12/14/2021                    | 8/31/2021                        |   | 6/4/2030                                  |
| Linagliptin and Metformin Hydrochloride  | Tablets                  | 2.5 mg/500 mg<br>2.5 mg/850 mg<br>2.5 mg/1000 mg  | Jentaduetto 201281                 | 5/4/2015           | 8                         | Deferred       | 9/7/2021                      | 8/30/2021                        |   | 6/4/2030                                  |
| Linagliptin and Metformin Hydrochloride  | Extended-release Tablets | 2.5 mg/1000 mg<br>5 mg/1000 mg                    | Jentaduetto XR 208026              | 3/28/2018          | 1                         |                |                               |                                  |   | 5/21/2030                                 |
| Linezolid                                | Injection                | 2 mg/mL, 100 mL bag                               | Zyvox 21131                        | 12/29/2009         | 1                         | Extinguished   | 10/5/2021                     | 7/16/2015                        |   | 11/18/2014                                |
| Linezolid                                | Injection                | 2 mg/mL, 300 mL bag                               | Zyvox 21131                        | 9/1/2009           | 1                         | Deferred       | 10/5/2021                     | 6/27/2012                        |   | 11/18/2014                                |
| Linezolid                                | Oral Suspension          | 100 mg/5 mL                                       | Zyvox 21132                        | 8/3/2009           | 1                         | Deferred       | 11/15/2022                    | 6/3/2015                         | 11/18/2015                                | 1/29/2021                                 |
| Linezolid                                | Tablets                  | 600 mg  | Zyvox 21130                        | 12/21/2005         | 1                         | Eligible       | 10/5/2021                     | 5/18/2015                        |   | 11/18/2014                                |
| Liraglutide                              | Injection                | 18 mg/3 mL prefilled syringe                      | Victoza 22341                      | 12/12/2016         | 1                         |                |                               |                                  |   | 1/9/2037                                  |
| Liraglutide                              | Injection                | 18 mg/3 mL prefilled syringe                      | Saxenda 206321                     | 8/16/2021          | 1                         |                |                               |                                  |   | 1/9/2037                                  |
| Lisdexamfetamine Dimesylate              | Capsules                 | 10 mg   | Vyvanse 21977                      | 4/9/2020           | 1                         | Extinguished   | 4/18/2023                     |                                  |   | 2/24/2023                                 |
| Lisdexamfetamine Dimesylate              | Capsules                 | 20 mg, 30 mg,<br>40 mg, 50 mg,<br>60 mg and 70 mg | Vyvanse 21977                      | 2/23/2011          | 6                         | Extinguished   | 4/18/2023                     |                                  |   | 2/24/2023                                 |
| Lisinopril                               | Oral Solution            | 1 mg/mL   | Qbrelis 208401                     | 10/24/2019         | 1                         | Extinguished   | 6/15/2021                     |                                  |   | 11/6/2035                                 |
| Loperamide Hydrochloride and Simethicone | Chewable Tablets         | 2 mg/125 mg                                       | Imodium Multi-Symptom Relief 20606 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Loperamide Hydrochloride and Simethicone | Tablets                  | 2 mg/125 mg                                       | Imodium Multi-Symptom Relief 21140 | 12/29/2004         |                           |                |                               |                                  |   |   |



**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                  | DOSAGE FORM                   | STRENGTH                       | RLD/NDA                  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-------------------------------|--------------------------------|--------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Lopinavir and Ritonavir                    | Tablets                       | 100 mg/25 mg and 200 mg/50 mg  | Kaletra 21906            | 12/23/2008         | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 11/10/2020                                |
| Lopinavir and Ritonavir                    | Oral Solution                 | 80 mg/20 mg per mL             | Kaletra 21251            | 6/19/2014          | 1                         | Deferred       | 2/11/2020                     | 12/27/2016                       | 1/23/2017                                 | 11/28/2021                                |
| Loratadine                                 | Syrup                         | 1 mg/mL                        | Claritin 20641           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Loratadine                                 | Tablets                       | 10 mg                          | Claritin 19658           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Loratadine                                 | Orally Disintegrating Tablets | 10 mg                          | Claritin RediTabs 20704  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Loratadine/ Pseudoephedrine                | Extended-release Tablets      | 5 mg/120 mg                    | Claritin D-12 hour 19670 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Loratadine/ Pseudoephedrine                | Extended-release Tablets      | 10 mg/240 mg                   | Claritin D-24 hour 20470 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Lorcaserin Hydrochloride                   | Extended-release Tablets      | 20 mg                          | Belviq XR 208524         | 12/13/2016         | 1                         | Extinguished   | 5/19/2020                     |                                  |   | 2/7/2033                                  |
| Lorcaserin Hydrochloride                   | Tablets                       | 10 mg                          | Belviq 22529             | 6/27/2016          | 4                         | Extinguished   | 5/19/2020                     |                                  |   | 2/7/2033                                  |
| Losartan Potassium                         | Tablets                       | 25 mg, 50 mg, and 100 mg       | Cozaar 20386             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Losartan Potassium and Hydrochlorothiazide | Tablets                       | 50 mg/12.5 mg and 100 mg/25 mg | Hyzaar 20387             | 5/24/2004          | 1                         | Eligible       | 10/5/2021                     | 4/6/2010                         |   | 9/4/2009                                  |
| Losartan Potassium and Hydrochlorothiazide | Tablets                       | 100 mg/12.5 mg                 | Hyzaar 20387             | 4/4/2006           | 1                         |                |                               |                                  |   |   |
| Loteprednol Etabonate                      | Ophthalmic Gel                | 0.38%                          | Lotemax SM 208219        | 11/14/2022         | 1                         |                |                               |                                  |   | 12/23/2036                                |
| Lovastatin and Niacin                      | Extended-release Tablets      | 20 mg/500 mg                   | Advicor                  | 9/22/2008          |                           |                |                               |                                  |   |   |
| Lovastatin and Niacin                      | Extended-release Tablets      | 20 mg/750 mg                   | Advicor                  | 12/17/2008         |                           |                |                               |                                  |   |   |
| Lovastatin and Niacin                      | Extended-release Tablets      | 20 mg/1000 mg                  | Advicor                  | 5/22/2008          |                           |                |                               |                                  |   |   |
| Lovastatin and Niacin                      | Extended-release Tablets      | 40 mg/1000 mg                  | Advicor                  | 11/19/2009         |                           |                |                               |                                  |   |   |
| Lubiprostone                               | Capsules                      | 8 mcg and 24 mcg               | Amitiza 21908            | 8/20/2012          | 1                         | Extinguished   | 11/30/2021                    | 6/27/2022                        | 1/4/2021                                  | 8/30/2022                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM                  | STRENGTH                                     | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|------------------------------|--|---------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Lumateperone Tosylate  | Capsules                     | 10.5 mg and 21 mg                            | Caplyta<br>209500   | 12/20/2023         | 6                         |                          |                               |                                  |   | 12/10/2040                                |
| Lumateperone Tosylate  | Capsules                     | 42 mg  | Caplyta<br>209500   | 12/20/2023         | 7                         |                          |                               |                                  |   | 12/10/2040                                |
| Lurasidone Hydrochloride   | Tablets                      | 20 mg, 40 mg,<br>60 mg, 80 mg, and<br>120 mg | Latuda<br>200603    | 10/28/2014         | 14                        | Extinguished<br>Eligible | 1/12/2021<br>8/27/2019        | 1/3/2019                         |   | 5/26/2026                                 |
| Lutetium Lu 177 Dotatate   | Injection                    | 10 mCi/mL                                    | Lutathera<br>208700 | 11/13/2023         | 1                         |                          |                               |                                  |   | 7/25/2038                                 |
| Macitentan   | Tablets                      | 10 mg  | Opsumit<br>204410   | 10/18/2017         | 11                        | Eligible                 | 5/4/2021                      | 4/6/2021                         |   | 4/18/2029                                 |
| Malathion  | Topical Lotion               | 0.50%  | Ovide<br>18613      | 3/16/2011          | 1                         | Deferred                 | 2/8/2022                      | 5/23/2012                        |   | 2/1/2027                                  |
| Maraviroc  | Tablets                      | 150 mg and<br>300 mg                         | Selzentry<br>22128  | 8/8/2011           | 2                         | Eligible                 | 2/22/2022                     | 2/7/2022                         | 2/7/2022                                  | 11/25/2022                                |
| Mefloquine Hydrochloride   | Tablets                      | 250 mg                                       | Lariam<br>19591     | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Megestrol Acetate  | Oral Suspension              | 40 mg/mL                                     | Megace<br>20264     | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Megestrol Acetate  | Oral Suspension              | 125 mg/mL                                    | Megace ES<br>21778  | 4/27/2011          | 1                         | Eligible                 | 10/5/2021                     | 8/27/2014                        | 7/1/2015                                  | 4/22/2024                                 |
| Meloxicam  | Oral Suspension              | 7.5 mg/5 mL                                  | Mobic<br>21530      | 12/17/2009         | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 9/25/2019                                 |
| Meloxicam  | Capsules                     | 5 mg and 10 mg                               | Vivlodex<br>207233  | 1/9/2017           | 1                         | Extinguished<br>Deferred | 3/9/2021<br>6/29/2020         | 6/1/2020                         | 12/22/2020                                | 3/31/2033                                 |
| Melphalan Hydrochloride  | Injection                    | 50 mg/vial                                   | Evomela<br>207155   | 9/8/2017           | 1                         | Eligible                 | 5/19/2020                     | 3/6/2020                         |   | 2/27/2033                                 |
| Memantine Hydrochloride  | Tablets                      | 5 mg and 10 mg                               | Namenda<br>21487    | 10/16/2007         | 14                        | Eligible                 | 2/8/2022                      | 1/30/2015                        |   | 4/11/2015                                 |
| Memantine Hydrochloride  | Extended-release<br>Capsules | 7 mg, 14 mg,<br>21 mg, and 28 mg             | Namenda XR<br>22525 | 6/10/2013          | 1                         | Extinguished             | 2/8/2022                      | 10/12/2016                       |   |   |
| Memantine Hydrochloride<br>Extended-release and<br>Donepezil Hydrochloride | Capsules                     | 14 mg/10 mg and<br>28 mg/10 mg               | Namzaric<br>206439  | 5/18/2015          | 1                         | Eligible                 | 2/9/2021                      | 1/27/2017                        |   | 12/5/2029                                 |
| Memantine Hydrochloride<br>Extended-release and<br>Donepezil Hydrochloride | Capsules                     | 21 mg/10 mg                                  | Namzaric<br>206439  | 9/23/2016          | 1                         | Deferred                 | 1/8/2024                      | 12/15/2023                       |   | 12/5/2029                                 |
| Memantine Hydrochloride<br>Extended-release and<br>Donepezil Hydrochloride | Capsules                     | 7 mg/10 mg                                   | Namzaric<br>206439  | 9/26/2016          | 1                         | Extinguished             | 2/9/2021                      |                                  |   | 12/5/2029                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                     | DOSAGE FORM               | STRENGTH               | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS              | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------|---------------------------|------------------------|---------------------|--------------------|---------------------------|-----------------------------|-------------------------------|----------------------------------|---|---|
| Mesalamine                    | Delayed-release Tablets   | 400 mg                 | Asacol 19651        | 6/22/2007          | 1                         | Extinguished                | 2/11/2020                     |                                  |   | 7/30/2013                                 |
| Mesalamine                    | Delayed-release Tablets   | 800 mg                 | Asacol HD 21830     | 7/13/2011          | 1                         | Deferred                    | 2/11/2020                     | 7/21/2017                        | 8/1/2016                                  | 11/15/2021                                |
| Mesalamine                    | Delayed-release Tablets   | 1.2 g                  | Lialda 22000        | 12/16/2009         | 1                         | Deferred                    | 2/11/2020                     | 6/5/2017                         | 7/18/2017                                 | 6/8/2020                                  |
| Mesalamine                    | Extended-release Capsules | 0.375 g                | Apriso 22301        | 4/3/2012           | 1                         | Extinguished                | 2/11/2020                     |                                  |   | 4/20/2018                                 |
| Mesalamine                    | Suppository               | 1000 mg                | Canasa 21252        | 5/24/2013          | 1                         | Eligible                    | 8/27/2019                     | 11/24/2015                       | 11/24/2015                                | 6/6/2028                                  |
| Mesalamine                    | Delayed-release Capsules  | 400 mg                 | Delzicol 204412     | 6/17/2014          | 1                         | Extinguished Non-Forfeiture | 6/18/2019<br>6/18/2019        |                                  |   | 4/13/2020                                 |
| Metaxalone                    | Tablets                   | 400 mg                 | Skelaxin 13217      | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Metaxalone                    | Tablets                   | 800 mg                 | Skelaxin 13217      | 11/4/2004          | 1                         | Non-Forfeiture              | 9/8/2020                      | 3/31/2010                        | 3/31/2010                                 | 12/3/2021                                 |
| Metformin Hydrochloride       | Extended-release Tablets  | 500 mg                 | Glucophage XR 21202 | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Metformin Hydrochloride       | Extended-release Tablets  | 750 mg                 | Glucophage XR 21202 | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Metformin Hydrochloride       | Extended-release Tablets  | 500 mg and 1000 mg     | Fortamet 21574      | 10/14/2008         | 1                         | Extinguished Eligible       | 4/17/2023<br>2/8/2022         | 6/29/2011                        |   | 3/17/2021                                 |
| Metformin Hydrochloride       | Extended-release Tablets  | 500 mg and 1000 mg     | Glumetza 21748      | 7/27/2009          | 1                         | Eligible                    | 7/16/2019                     | 7/19/2013                        | 2/1/2016                                  | 500mg:10/25/2021<br>1 g: 6/20/2020        |
| Metformin Hydrochloride       | Oral Solution             | 500 mg/5 mL            | Riomet 21591        | 2/2/2018           | 1                         | Eligible                    | 11/15/2022                    | 3/3/2020                         | 4/20/2020                                 | 8/7/2021                                  |
| Methylphenidate Hydrochloride | Injection                 | 12 mg/0.6 mL           | Relistor 21964      | 7/22/2015          | 1                         |                             |                               |                                  |   | 12/31/2030                                |
| Methylphenidate Hydrochloride | Injection                 | 8 mg/0.4 mL            | Relistor 21964      | 9/8/2015           | 1                         |                             |                               |                                  |   | 12/31/2030                                |
| Methylphenidate Hydrochloride | Tablets                   | 150 mg                 | Relistor 208271     | 9/6/2016           | 1                         |                             |                               |                                  |   | 3/10/2031                                 |
| Methylphenidate Hydrochloride | Extended-release Capsules | 10 mg                  | Ritalin LA 21284    | 5/21/2007          | 1                         | Extinguished                | 3/10/2020                     |                                  |   | 11/1/2019                                 |
| Methylphenidate Hydrochloride | Extended-release Capsules | 20 mg, 30 mg and 40 mg | Ritalin LA 21284    | 8/21/2006          |                           |                             |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                     | DOSAGE FORM                                    | STRENGTH   | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------|--|--|------------------------|--------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Methylphenidate Hydrochloride | Extended-release Capsules                      | 10 mg, 20 mg and 30 mg                                   | Metadate CD 21259      | 5/13/2005          | 1                         | Non-Forfeiture        | 9/8/2020                      | 7/19/2012                        | 9/27/2012                                 | 10/27/2020                                |
| Methylphenidate Hydrochloride | Extended-release Capsules                      | 40 mg  | Metadate CD 21259      | 3/15/2007          | 1                         | Non-Forfeiture        | 9/8/2020                      | 7/19/2012                        | 9/27/2012                                 | 10/27/2020                                |
| Methylphenidate Hydrochloride | Extended-release Chewable Tablets              | 20 mg, 30 mg and 40 mg                                   | Quillichew ER 207960   | 4/25/2016          | 1                         |                       |                               |                                  |   | 8/14/2033                                 |
| Methylphenidate Hydrochloride | Extended-release Tablets                       | 18 mg*, 27 mg, 36 mg and 54 mg                           | Concerta 21121         | 7/19/2005          |                           |                       |                               |                                  |   |   |
| Methylphenidate Hydrochloride | Oral Solution                                  | 5 mg/5 mL<br>10 mg/5 mL                                  | Methylin 21419         | 4/13/2010          | 1                         | Eligible              | 1/27/2020                     | 7/23/2010                        | 7/26/2010                                 | 10/7/2024                                 |
| Methylphenidate               | Transdermal System                             | 10 mg/9 hrs<br>15 mg/9 hrs<br>20 mg/9 hrs<br>30 mg/9 hrs | Daytrana 21514         | 4/13/2011          | 1                         | Extinguished          | 3/9/2021                      |                                  |   | 9/30/2018                                 |
| Methylphenidate Hydrochloride | Extended-release Oral Suspension               | 5 mg/mL  | Quillivant XR 202100   | 8/2/2013           |                           |                       |                               |                                  |   |   |
| Methylphenidate Hydrochloride | Extended-release Capsules                      | 60 mg  | Aptensio XR 205831     | 12/23/2015         | 1                         | Eligible              | 7/30/2019                     | 12/13/2018                       | 9/25/2020                                 | 12/16/2019                                |
| Methylphenidate Hydrochloride | Extended-release Capsules                      | 10 mg  | Aptensio XR 205831     | 12/24/2015         | 1                         | Eligible              | 7/30/2019                     | 12/13/2018                       | 9/25/2020                                 | 12/16/2019                                |
| Methylphenidate Hydrochloride | Extended-release Capsules                      | 15 mg, 20 mg, 40 mg and 50 mg                            | Aptensio XR 205831     | 12/28/2015         | 1                         | Eligible              | 7/30/2019                     | 12/13/2018                       | 9/25/2020                                 | 12/16/2019                                |
| Methylphenidate Hydrochloride | Extended-release Capsules                      | 30 mg  | Aptensio XR 205831     | 3/28/2016          | 1                         | Eligible              | 7/30/2019                     | 12/13/2018                       | 9/25/2020                                 | 12/16/2019                                |
| Methylphenidate               | Extended-release Orally Disintegrating Tablets | 8.6 mg, 17.3 mg and 25.9 mg                              | Cotempla XR-ODT 205489 | 9/1/2017           | 1                         | Eligible              | 7/13/2020                     | 6/19/2020                        |   | 6/28/2032                                 |
| Metoclopramide Hydrochloride  | Injection                                      | 5 mg/mL, 2 mL, 10 mL, 20 mL and 30 mL vials              | Reglan 17862           | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Metoclopramide Hydrochloride  | Orally Disintegrating Tablets                  | 5 mg and 10 mg   | Metozolv ODT 22246     | 8/24/2010          | 1                         | Extinguished Deferred | 4/18/2023<br>2/8/2022         | 8/15/2014                        |   | 7/11/2017                                 |
| Metoclopramide Hydrochloride  | Metered Nasal Spray                            | 15 mg/spray  | Gimoti 209388          | 12/30/2021         | 1                         |                       |                               |                                  |   | 5/16/2030                                 |
| Metoprolol Succinate          | Extended-release Tablets                       | 25 mg, 50 mg, 100 mg and 200 mg                          | Toprol XL 19962        | Pre-MMA            |                           |                       |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                 | DOSAGE FORM                   | STRENGTH                             | RLD/NDA                                  | DATE OF SUBMISSION             | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|-------------------------------|--------------------------------------|--|--------------------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Metronidazole             | Vaginal Gel                   | 0.75%                                | MetroGel-Vaginal 20208                   | 9/2/2004                       | 1                         | Extinguished             | 2/8/2022                      |                                  |   | 6/6/2006                                  |
| Metronidazole             | Topical Gel                   | 1%                                   | Metrogel 21789                           | 10/21/2008                     | 1                         | Eligible                 | 5/4/2021                      | 7/22/2011                        | 7/1/2013                                  | 2/21/2022                                 |
| Metronidazole             | Vaginal Gel                   | 1.30%                                | Nuvessa 205223                           | 3/30/2022                      | 1                         |                          |                               |                                  |   | 6/28/2032                                 |
| Micafungin Sodium         | For Injection                 | 50 mg/vial<br>100 mg/vial            | Mycamine 21506                           | 6/16/2014                      | 1                         | Eligible                 | 6/1/2020                      | 5/17/2019                        | 5/8/2020                                  | 1/8/2021                                  |
| Miconazole Nitrate        | Vaginal Cream and Suppository | 2% and 1.2 g                         | Monistat 1 Combination Pack 21308        | 12/5/2007                      | 1                         | Extinguished<br>Deferred | 4/18/2023<br>2/8/2022         | 6/2/2010                         |   | 11/28/2020                                |
| Midazolam                 | Nasal Spray                   | 5 mg/spray                           | Nayzilam 211321                          | 6/1/2021                       | 1                         |                          |                               |                                  |   | 1/18/2028                                 |
| Midazolam                 | Intravenous                   | 50 mg/50 mL and<br>100 mg/100 mL     | Midazolam in 0.9% Sodium Chloride 211844 | 9/29/2021                      | 1                         | Eligible                 | 4/18/2023                     | 4/17/2023                        | 7/6/2023                                  | 6/20/2038                                 |
| Midostaurin               | Capsules                      | 25 mg                                | Rydapt 207997                            | 4/28/2021                      | 4                         |                          |                               |                                  |   | 12/2/2030                                 |
| Mifepristone              | Tablets                       | 300 mg                               | Korlym 202107                            | 12/15/2017                     | 1                         | Eligible                 | 2/8/2022                      | 8/3/2020                         | 1/19/2024                                 | 8/15/2036                                 |
| Migalastat Hydrochloride  | Capsules                      | 123 mg                               | Galafold 208623                          | 8/10/2022                      | 3                         |                          |                               |                                  |   | 2/6/2039                                  |
| Milnacipran Hydrochloride | Tablets                       | 12.5 mg, 25 mg,<br>50 mg, and 100 mg | Savella 22256                            | 1/14/2013                      | 8                         | Deferred                 | 2/8/2022                      | 1/27/2016                        |   | 9/19/2029                                 |
| Minocycline Hydrochloride | Extended-release Tablet       | 45 mg, 90 mg and<br>135 mg           | Solodyn 50808                            | PIV received prior to 2/5/2009 |                           |                          |                               |                                  |   |   |
| Minocycline Hydrochloride | Extended-release Tablet       | 55 mg                                | Solodyn 50808                            | 12/2/2010                      | 1                         | Eligible                 | 12/13/2022                    | 11/30/2011                       | 2/22/2019                                 | 11/20/2025                                |
| Minocycline Hydrochloride | Extended-release Tablet       | 65 mg and 115 mg                     | Solodyn 50808                            | 11/19/2009                     | 1                         | Extinguished<br>Eligible | 6/18/2019<br>6/18/2019        | 5/18/2012                        | 2/20/2018                                 | 2/19/2018                                 |
| Minocycline Hydrochloride | Extended-release Tablet       | 80 mg                                | Solodyn 50808                            | 10/27/2010                     | 1                         | Non-Forfeiture           | 2/8/2022                      | 9/25/2014                        |   | 2/19/2018                                 |
| Minocycline Hydrochloride | Extended-release Tablet       | 105 mg                               | Solodyn 50808                            | 12/13/2010                     | 1                         | Non-Forfeiture           | 2/8/2022                      |                                  |   | 2/19/2018                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                       | DOSAGE FORM                   | STRENGTH  | RLD/NDA                  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-------------------------------|---|--------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Minocycline Hydrochloride                       | Injection                     | 100 mg/vial                                       | Minocin<br>NDA 50444     | 10/16/2020         | 1                         | Eligible       | 11/15/2022                    | 7/22/2022                        |   | 5/12/2031                                 |
| Minocycline Hydrochloride                       | Topical Aerosol Foam          | 4%  | Amzeeq<br>NDA 212379     | 5/11/2021          | 1                         |                |                               |                                  |   | 9/8/2037                                  |
| Minocycline Hydrochloride                       | Topical Aerosol Foam          | 1.50%   | Zilxi<br>213690          | 2/28/2022          | 1                         |                |                               |                                  |   | 10/1/2030                                 |
| Minoxidil                                       | Topical Aerosol Foam          | 5%  | Men's Rogaine<br>21812   | 4/6/2009           | 1                         | Eligible       | 2/8/2022                      | 4/28/2011                        |   | 4/20/2019                                 |
| Minoxidil                                       | Topical Aerosol Foam          | 5%  | Women's Rogaine<br>21812 | 2/4/2015           | 1                         | Eligible       | 4/18/2022                     | 7/27/2017                        |   | 4/20/2019                                 |
| Mirabegron                                      | Extended-release Tablets      | 25 mg   | Myrbetriq<br>202611      | 6/28/2016          | 6                         | Eligible       | 10/4/2022                     | 12/27/2019                       |   | 11/4/2023                                 |
| Mirabegron                                      | Extended-release Tablets      | 50 mg   | Myrbetriq<br>202611      | 6/28/2016          | 6                         | Deferred       | 10/4/2022                     | 9/28/2022                        |   | 11/4/2023                                 |
| Mirtazapine                                     | Tablets                       | 7.5 mg, 15 mg,<br>30 mg, and 45 mg                | Remeron<br>20415         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Mirtazapine                                     | Orally Disintegrating Tablets | 15 mg, 30 mg and 45 mg                            | Remeron SolTab<br>21208  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Mitomycin <b>New</b>                            | Powder for Injection          | 40 mg/vial  | Jelmyto<br>211728        | 12/28/2023         | 1                         |                |                               |                                  |   | 1/20/2031                                 |
| Modafinil                                       | Tablets                       | 100 mg and 200 mg                                 | Provigil<br>20717        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Moexipril Hydrochloride                         | Tablets                       | 7.5 mg and 15 mg                                  | Univasc<br>20312         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Moexipril Hydrochloride and Hydrochlorothiazide | Tablets                       | 7.5mg/12.5mg,<br>15 mg/25 mg and<br>15 mg/12.5 mg | Uniretic<br>20729        | 1/15/2004          | 1                         | Extinguished   | 2/8/2022                      | 3/7/2007                         |   | 2/24/2007                                 |
| Mometasone Furoate                              | Nasal Spray                   | 50 mcg/ Spray                                     | Nasonex<br>20762         | 8/7/2009           | 1                         | Deferred       | 2/8/2022                      | 3/22/2016                        | 3/22/2016                                 | 10/3/2017                                 |
| Mometasone Furoate                              | Topical Solution (Cream)      | 0.1%  | Elocon<br>19625          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Mometasone Furoate                              | Topical Solution (Lotion)     | 0.1%  | Elocon<br>19796          | 6/10/2004          | 1                         |                |                               | 4/6/2005                         |   | 11/21/2007                                |
| Montelukast                                     | Tablets                       | 10 mg   | Singulair<br>20829       | 2/20/2007          | 2                         | Extinguished   | 2/8/2022                      | 8/3/2012                         |   | 2/3/2012                                  |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                     | DOSAGE FORM               | STRENGTH                                   | RLD/NDA   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------|--|---|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Montelukast Sodium                            | Chewable Tablets          | 4 mg and 5 mg                              | Singulair 20830   | 12/26/2006         | 1                         | Extinguished   | 2/8/2022                      | 8/3/2012                         |   | 8/3/2012                                  |
| Montelukast Sodium                            | Oral Granules             | 4 mg                                       | Singular Granules 21409                                   | 10/17/2008         | 1                         | Extinguished   | 2/25/2020                     | 8/3/2012                         |   | 8/3/2012                                  |
| Morphine Sulfate                              | Extended-release Capsules | 30 mg, 60 mg, 90 mg and 120 mg             | Avinza 21260  | 6/4/2007           | 1                         | Deferred       | 3/10/2020                     | 1/16/2013                        |   | 11/25/2017                                |
| Morphine Sulfate                              | Extended-release Capsules | 45 mg and 75 mg                            | Avinza 21260  | 8/11/2009          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 11/25/2017                                |
| Morphine Sulfate                              | Extended-release Tablets  | 15 mg, 30 mg and 60 mg                     | Arymo ER 208603   | 12/29/2017         | 1                         | Extinguished   | 2/8/2022                      |                                  |   | 11/25/2017                                |
| Morphine Sulfate                              | Extended-release Tablets  | 15 mg, 30 mg, 60 mg and 100 mg             | Morphabond ER 206544                                      | 1/28/2019          | 1                         |                |                               |                                  |   | 8/21/2028                                 |
| Morphine Sulfate and Naltrexone Hydrochloride | Extended-release Capsules | 20 mg/0.8 mg                               | Embeda 22321  | 8/16/2018          | 1                         | Extinguished   | 2/8/2022                      |                                  |   | 11/7/2029                                 |
| Morphine Sulfate and Naltrexone Hydrochloride | Extended-release Capsules | 100 mg/4 mg                                | Embeda 22321  | 5/3/2010           | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 6/19/2027                                 |
| Morphine Sulfate and Naltrexone Hydrochloride | Extended-release Capsules | 60 mg/2.4 mg                               | Embeda 22321  | 5/25/2010          | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 6/19/2027                                 |
| Morphine Sulfate and Naltrexone Hydrochloride | Extended-release Capsules | 30 mg/1.2 mg<br>50 mg/2 mg<br>80 mg/3.2 mg | Embeda 22321  | 5/28/2010          | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 6/19/2027                                 |
| Moxifloxacin Hydrochloride                    | Ophthalmic Solution/Drops | 0.5%                                       | Vigamox 21598   | 12/22/2005         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 9/20/2019                                 |
| Moxifloxacin Hydrochloride                    | Ophthalmic Solution       | 0.5%                                       | Moxeza 22428  | 2/29/2012          | 1                         | Eligible       | 2/8/2022                      | 5/28/2015                        | 5/28/2015                                 | 9/20/2019                                 |
| Moxifloxacin Hydrochloride                    | Tablets                   | 400 mg                                     | Avelox 21085  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Moxifloxacin Hydrochloride                    | Injection                 | 1.6 mg/mL                                  | Avelox in Sodium Chloride 0.8% in plastic container 21277 | 2/7/2014           | 1                         | Deferred       | 10/8/2019                     | 5/5/2017                         | 10/3/2017                                 | 7/25/2020                                 |
| Mycophenolic Acid                             | Delayed-release Tablets   | 180 mg                                     | Myfortic 50791  | 6/3/2009           | 1                         | Extinguished   | 2/8/2022                      | 1/8/2014                         |   | 4/10/2017                                 |
| Mycophenolic Acid                             | Delayed-release Tablets   | 360 mg                                     | Myfortic 50791  | 2/2/2009           | 1                         | Non-Forfeiture | 2/8/2022                      | 1/8/2014                         | 1/8/2014                                  | 4/10/2017                                 |
| Mycophenolic Mofetil                          | For Oral Suspension       | 200 mg/mL                                  | Cellcept 50759  | 3/25/2011          | 1                         | Deferred       | 2/8/2022                      | 11/14/2014                       | 11/17/2014                                | 11/18/2014                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                                  | STRENGTH                                       | RLD/NDA                     | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|--|--|-----------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Nabumetone  | Tablets                                      | 500 mg and 750 mg                              | Relafen<br>19583            | Pre-MMA            |                           |                |                               |                                  |   |   |
| Naftifine Hydrochloride                                 | Gel  | 2%   | Naftin Gel<br>204286        | 2/4/2015           | 1                         | Deferred       | 8/13/2019                     | 4/10/2019                        | 4/12/2023                                 | 1/31/2033                                 |
| Naloxegol   | Tablets                                      | 12.5 mg and 25 mg                              | Movantik<br>204760          | 9/17/2018          | 2                         |                |                               |                                  |   | 4/2/2032                                  |
| Naloxone Hydrochloride                                  | Nasal Spray                                  | 2 mg/spray                                     | Narcan<br>208411            | 12/28/2017         | 1                         |                |                               |                                  |   | 3/16/2035                                 |
| Naloxone Hydrochloride                                  | Nasal Spray                                  | 4 mg/spray                                     | Narcan<br>208411            | 7/15/2016          | 1                         | Eligible       | 6/18/2019                     | 4/19/2019                        | 12/22/2021                                | 3/16/2035                                 |
| Naloxone Hydrochloride                                  | Nasal Spray                                  | 8 mg/spray                                     | Kloxxado<br>212045          | 3/30/2023          | 1                         |                |                               |                                  |   | 8/26/2034                                 |
| Naltrexone  | Extended-release<br>Injectable<br>Suspension | 380 mg/vial                                    | Vivitrol<br>21897           | 6/18/2020          | 1                         | Deferred       | 87/2023                       | 7/6/2023                         |   | 10/15/2029                                |
| Naltrexone Hydrochloride and<br>Bupropion Hydrochloride | Extended-release<br>Tablets                  | 8 mg/90 mg                                     | Contrave<br>200063          | 3/12/2015          | 1                         |                |                               |                                  |   | 2/2/2030                                  |
| Naproxen Sodium   | Extended-release<br>Tablets                  | 375 mg (base) and<br>500 mg (base)             | Naprelan<br>20353           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Naproxen Sodium   | Capsules                                     | 200 mg   | Naproxen<br>Sodium<br>21920 | 11/15/2017         | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 3/3/2026                                  |
| Naproxen and Esomeprazole<br>Magnesium                  | Delayed-release<br>Tablets                   | 375 mg/20 mg and<br>500 mg/20 mg               | Vimovo<br>22511             | 11/5/2010          | 1                         | Extinguished   | 2/25/2020                     |                                  |   | 2/28/2023                                 |
| Naproxen Sodium and<br>Sumatriptan Succinate            | Tablets                                      | 500 mg/85 mg                                   | Treximet<br>21926           | 7/23/2008          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 10/2/2025                                 |
| Nateglinide   | Tablets                                      | 60 mg and 120 mg                               | Starlix<br>21204            | 12/22/2004         |                           |                |                               |                                  |   |   |
| Nebivolol Hydrochloride                                 | Tablets                                      | 2.5 mg, 5 mg,<br>10 mg, and 20 mg              | Bystolic<br>21742           | 12/19/2011         | 7                         | Eligible       | 6/18/2019                     | 4/16/2015                        | 9/17/2021                                 | 12/17/2021                                |
| Nebivolol Hydrochloride and<br>Valsartan                | Tablets                                      | 5 mg/80 mg                                     | Byvalson<br>206302          | 6/9/2017           | 1                         | Deferred       | 10/4/2022                     | 9/19/2022                        |   | 10/4/2027                                 |
| Nefazodone Hydrochloride                                | Tablets                                      | 50 mg, 100 mg,<br>150 mg, 200 mg and<br>250 mg | Serzone<br>20152            | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nepafenac   | Ophthalmic<br>Suspension                     | 0.3%   | Ilevro<br>203491            | 12/21/2015         | 1                         |                |                               |                                  |   | 3/31/2032                                 |
| Neratinib Maleate                                       | Tablets                                      | 40 mg  | Nerlynx<br>208051           | 7/19/2021          | 1                         |                |                               |                                  |   | 12/29/2025                                |
| Netarsudil Mesylate                                     | Ophthalmic Solution                          | 0.02%  | Rhopressa<br>208254         | 12/20/2021         | 2                         |                |                               |                                  |   | 3/14/2034                                 |



**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                 | DOSAGE FORM              | STRENGTH                                    | RLD/NDA  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|--------------------------|---|--|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Nevirapine                | Extended-release Tablets | 400 mg                                      | Viramune XR 201152   | 6/21/2013          | 3                         | Eligible       | 12/13/2022                    | 4/3/2014                         | 4/15/2014                                 | 3/12/2029                                 |
| Niacin                    | Extended-release Tablets | 500 mg, 750 mg and 1000 mg                  | Niaspan 20381  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Niacin and Simvastatin    | Extended-release Tablets | 500 mg/20 mg                                | Simcor   | 2/12/2010          |                           |                |                               |                                  |   |   |
| Niacin and Simvastatin    | Extended-release Tablets | 750 mg/20 mg                                | Simcor   | 2/17/2010          |                           |                |                               |                                  |   |   |
| Niacin and Simvastatin    | Extended-release Tablets | 1000 mg/20 mg                               | Simcor   | 9/17/2009          |                           |                |                               |                                  |   |   |
| Niacin and Simvastatin    | Extended-release Tablets | 1000 mg/40 mg                               | Simcor   | 2/4/2011           |                           |                |                               |                                  |   |   |
| Niacin and Simvastatin    | Extended-release Tablets | 500 mg/40 mg                                | Simcor   | 2/9/2011           |                           |                |                               |                                  |   |   |
| Nicardipine Hydrochloride | Injection                | 2.5 mg/mL, 10 mL Ampoules                   | Cardene 19734  | 12/27/2006         | 1                         |                |                               |                                  |   |   |
| Nicardipine Hydrochloride | Injection                | 0.1 mg/mL, 200 mL<br>0.2mg/mL, 200 mL       | Cardene in 0.86% Sodium Chloride in plastic container and Cardene 0.83% Sodium Chloride in plastic container 19734 | 1/9/2013           | 1                         |                |                               |                                  |   | 12/26/2027                                |
| Nicotine                  | Transdermal System       | 7 mg/day,<br>14 mg/day<br>21 mg/day         | Habitrol 20076   | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nicotine                  | Transdermal System       | 7 mg/24 hrs<br>14 mg/24 hrs<br>21 mg/24 hrs | Nicoderm CQ 20165  | 5/30/2014          | 1                         | Extinguished   | 2/8/2022                      |                                  |   | 5/22/2021                                 |
| Nicotine Polacrilex       | Troche/Lozenge           | 2 mg and 4 mg                               | Commit   | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nicotine Polacrilex       | Troche/Lozenge (Mini)    | 2 mg and 4 mg                               | Nicorette 22360  | 12/2/2015          | 1                         | Eligible       | 10/8/2019                     | 2/7/2019                         | 4/4/2019                                  | 6/14/2029                                 |
| Nicotine Polacrilex       | Gum                      | 2 mg  | Nicorette  | 1/22/2013          |                           |                |                               |                                  |   |   |
| Nicotine Polacrilex       | Gum                      | 4 mg  | Nicorette  | 1/22/2013          |                           |                |                               |                                  |   |   |
| Nifedipine                | Capsules                 | 10 mg and 20 mg                             | Procardia 18482  | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                    | DOSAGE FORM              | STRENGTH   | RLD/NDA                      | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|--|------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Nifedipine                                   | Extended-release Tablets | 30 mg, 60 mg and 90 mg   | Adalat CC 20198              | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nifedipine                                   | Extended-release Tablets | 30 mg, 60 mg and 90 mg   | Procardia XL 19684           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nilotinib                                    | Capsules                 | 50 mg  | Tasigna 22068                | 10/17/2019         | 1                         | Deferred       | 1/8/2024                      | 1/5/2024                         |   | 4/7/2032                                  |
| Nilotinib                                    | Capsules                 | 150 mg and 200 mg  | Tasigna 22068                | 11/8/2013          | 1                         | Deferred       | 1/8/2024                      | 1/5/2024                         |   | 8/23/2028                                 |
| Nimodipine                                   | Oral Solution            | 6 mg/mL  | Nymalize 203340              | 11/29/2021         | 1                         |                |                               |                                  |   | 4/16/2038                                 |
| Nintedanib                                   | Capsules                 | 100 mg and 150 mg  | Ofev 205832                  | 10/15/2018         | 4                         |                |                               |                                  |   | 6/7/2029                                  |
| Nitric Oxide                                 | for Inhalation           | 100 ppm and 800 ppm  | INOmax 20845                 | 5/20/2014          | 1                         | Deferred       | 11/19/2019                    | 10/2/2018                        | 4/1/2019                                  | 1/6/2031                                  |
| Nisoldipine                                  | Extended-release Tablets | 8.5 mg and 17 mg   | Sular 20356                  | 3/2/2009           | 1                         | Eligible       | 2/8/2022                      | 1/26/2011                        | 1/28/2011                                 | 6/6/2012                                  |
| Nisoldipine                                  | Extended-release Tablets | 20 mg and 30 mg  | Sular 20356                  | 11/7/2007          | 1                         | Extinguished   | 2/8/2022                      | 7/25/2008                        |   | 6/8/2008                                  |
| Nisoldipine                                  | Extended-release Tablets | 25.5 mg and 34 mg  | Sular 20356                  | 11/28/2008         | 1                         | Eligible       | 2/8/2022                      | 1/26/2011                        | 1/28/2011                                 | 11/30/2014                                |
| Nisoldipine                                  | Extended-release Tablets | 40 mg  | Sular 20356                  | 6/11/2007          | 1                         | Extinguished   | 2/8/2022                      | 7/25/2008                        |   | 6/8/2008                                  |
| Nitrofurantoin Monohydrate/<br>Macrocrystals | Capsules                 | 75 mg/25 mg  | Macrobid 20064               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nitroglycerin                                | Sublingual Tablets       | 0.3 mg, 0.4 mg, and 0.6 mg   | Nitrostat 21134              | 10/19/2005         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 9/16/2018                                 |
| Nitroglycerin                                | Transdermal System       | 0.1 mg/hr  | Transderm-Nitro 20144        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nitroglycerin                                | Transdermal System       | 0.1 mg/hr<br>0.2 mg/hr<br>0.3 mg/hr<br>0.4 mg/hr<br>0.6 mg/hr<br>0.8 mg/hr | Nitro-dur 20145              | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nitroglycerin                                | Sublingual Spray         | 400 mcg/spray, 4.9 g and 12 g bottles                                      | Nitrolingual Pumpspray 18705 | 4/17/2012          | 1                         | Eligible       | 2/8/2022                      | 9/20/2013                        | 9/23/2013                                 | 3/14/2028                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME  | DOSAGE FORM        | STRENGTH   | RLD/NDA   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------|--|---|--------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Nizatidine   | Capsules           | 150 mg and 300 mg  | Axid 19508  | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Nizatidine   | Oral Solution      | 15 mg/mL   | Axid 21494  | 5/14/2008          | 1                         | Extinguished Eligible | 4/18/2023<br>2/22/2022        | 11/18/2009                       |   | 7/17/2022                                 |
| Norelgestromin and Ethinyl Estradiol   | Transdermal System | 0.15 mg/0.02 mg per 24 hours                                 | Ortho Evra 21180  | 3/22/2007          | 1                         | Extinguished          | 3/10/2020                     |                                  |   | 11/20/2015                                |
| Norepinephrine Bitartrate in 0.9 % Sodium Chloride                                   | Injection          | 4 mg/250 mL and 8 mg/250 mL                                  | Norepinephrine Bitartrate in 0.9 % Sodium Chloride 215700 | 9/29/2023          | 1                         |                       |                               |                                  |   | 4/26/2039                                 |
| Norethindrone Acetate/ Ethinyl Estradiol   | Tablets            | 1 mg/0.005 mg  | Femhrt 21065  | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Norethindrone Acetate/ Ethinyl Estradiol   | Tablets            | 1 mg/ 0.02 mg<br>1 mg/0.03 mg<br>1 mg /0.035 mg              | Estrostep Fe 20130  | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Norethindrone Acetate/ Ethinyl Estradiol   | Tablets            | 1 mg/0.02 mg<br>1 mg/ 0.03 mg and<br>1 mg /0.035 mg          | Estrostep 21 20130  | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Norethindrone Acetate/ Ethinyl Estradiol and Ferrous Fumarate                        | Tablets            | 1 mg/0.02 mg and 75 mg                                       | Loestrin 24 Fe 21871                                      | 4/17/2006          | 1                         | Extinguished          | 2/8/2022                      | 9/1/2009                         |   | 7/22/2014                                 |
| Norethindrone Acetate and Ethinyl Estradiol / Ethinyl Estradiol and Ferrous Fumarate | Tablets            | 1 mg/0.01 mg,<br>0.01 mg and 75 mg                           | Lo Loestrin Fe 22501                                      | 4/29/2011          | 1                         | Extinguished          | 2/8/2022                      |                                  |   | 2/2/2029                                  |
| Norethindrone and Ethinyl Estradiol and Ferrous Fumarate                             | Chewable Tablets   | 0.4 mg/0.035 mg  | Ovcon-35 Fe<br>Femcon Fe<br>NDA 21-490                    | 4/27/2007          | 1                         | Non-Forfeiture        | 2/8/2022                      | 8/5/2010                         | 3/25/2011                                 | 4/6/2019                                  |
| Norethindrone and Ethinyl Estradiol and Ferrous Fumarate                             | Chewable Tablets   | 0.8 mg/0.025 mg and 75 mg                                    | Generess Fe   | 8/5/2011           | 1                         | Eligible              | 2/8/2022                      | 4/23/2014                        | 4/1/2015                                  | 4/16/2019                                 |
| Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate                     | Chewable Tablets   | 1 mg/0.02 mg and 75 mg                                       | Minastrin 24 Fe 203667                                    | 4/23/2014          | 1                         | Eligible              | 10/8/2019                     | 5/24/2016                        | 3/15/2017                                 | 4/6/2019                                  |
| Norethindrone/ Ethinyl Estradiol   | Tablets            | 0.5 mg/ 0.035 mg,<br>0.75 mg/ 0.035 mg<br>and 1 mg /0.035 mg | Ortho-Novum 7/7/7, 21 and 28 day 18985                    | Pre-MMA            |                           |                       |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                               | DOSAGE FORM                   | STRENGTH  | RLD/NDA                               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-------------------------------|---|---------------------------------------|--------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Norgestimate/ Ethinyl Estradiol         | Tablets                       | 0.18 mg /0.025 mg, 0.215 mg /0.025 mg and 0.25 mg /0.025 mg   | Ortho Tri-Cyclen Lo, 28 day 21241     | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Norgestimate/ Ethinyl Estradiol         | Tablets                       | 0.18 mg /0.035 mg, 0.215 mg /0.035 mg and 0.25 mg /0.035 mg   | Ortho Tri-Cyclen, 21 and 28 day 19697 | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Nortriptyline Hydrochloride             | Capsules                      | 10 mg, 25 mg, 50 mg and 75 mg   | Pamelor 18013                         | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Obeticholic Acid                        | Tablets                       | 5 mg and 10 mg  | Ocaliva 207999                        | 5/27/2020          | 5                         | Eligible              | 6/12/2023                     | 5/30/2023                        |   | 4/26/2036                                 |
| Octreotide Acetate                      | Injection                     | 0.05 mg /mL, 0.1 mg /mL and 0.5 mg/mL, 1 mL vials   | Sandostatin (Preservative-free) 19667 | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Octreotide Acetate                      | Injection                     | 0.2 mg/mL and 1 mg /mL, 5 mL vials  | Sandostatin 19667                     | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Octreotide Acetate                      | Injection                     | 0.05 mg/mL (base), 0.1 mg/mL (base) and 0.5 mg/mL (base) packaged in 1 mL pre-filled syringes (preservative-free) | Octreotide Acetate Injection 19667    | 1/17/2008          | 1                         | Extinguished Eligible | 4/18/2023<br>2/8/2022         | 2/10/2011                        |   | 5/19/2015                                 |
| Ofloxacin                               | Otic Solution                 | 0.3%  | Floxin 20799                          | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Olanzapine                              | Tablets                       | 2.5 mg, 5 mg, 7.5 mg, 10 mg and 15 mg   | Zyprexa 20592                         | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Olanzapine                              | Tablets                       | 20 mg   | Zyprexa 20592                         | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Olanzapine                              | Orally Disintegrating Tablets | 5 mg, 10 mg, 15 mg and 20 mg  | Zyprexa Zydys 21086                   | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Olanzapine and Fluoxetine Hydrochloride | Capsules                      | 6 mg/25 mg<br>12 mg/25 mg<br>6 mg/50 mg<br>12 mg/50 mg  | Symbyax 21520                         | 1/10/2005          | 1                         | Extinguished          | 2/8/2022                      | 6/20/2012                        |   | 11/1/2017                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                    | DOSAGE FORM                   | STRENGTH                           | RLD/NDA                                    | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-------------------------------|------------------------------------|--|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Olaparib                                     | Tablets                       | 100 mg and 150 mg                  | Lynparza<br>208558                         | 11/1/2022          | 1                         |                |                               |                                  |   | 8/4/2031                                  |
| Olmesartan Medoxomil                         | Tablets                       | 5 mg, 20 mg and<br>40 mg           | Benicar<br>21286                           | 4/25/2006          | 1                         | Eligible       | 2/8/2022                      | 10/26/2016                       | 10/26/2016                                | 11/19/2021                                |
| Olmesartan Medoxomil and Hydrochlorothiazide | Tablets                       | 20 mg/12.5 mg                      | Benicar HCT<br>21532                       | 5/11/2007          | 1                         | Eligible       | 2/8/2022                      | 10/26/2016                       | 10/26/2016                                | 11/19/2021                                |
| Olmesartan Medoxomil and Hydrochlorothiazide | Tablets                       | 40 mg/12.5 mg and<br>40 mg/25 mg   | Benicar HCT<br>21532                       | 2/15/2007          | 1                         | Eligible       | 2/8/2022                      | 10/26/2016                       | 10/26/2016                                | 11/19/2021                                |
| Olopatadine Hydrochloride                    | Nasal Spray                   | 0.665 mg/ Spray                    | Patanase<br>21861                          | 6/29/2009          | 1                         | Extinguished   | 2/8/2022                      | 10/8/2014                        |   | 12/18/2010                                |
| Olopatadine Hydrochloride                    | Ophthalmic Solution           | 0.1%                               | Pataday Twice<br>Daily Relief OTC<br>20688 | 7/17/2006          | 1                         | Extinguished   | 4/7/2020                      | 12/7/2015                        |   | 6/6/2015                                  |
| Olopatadine Hydrochloride                    | Ophthalmic Solution           | 0.2%                               | Pataday Once<br>Daily Relief OTC<br>21545  | 9/8/2008           | 1                         | Eligible       | 6/18/2019                     | 7/13/2015                        | 6/8/2017                                  | 11/12/2023                                |
| Olopatadine Hydrochloride                    | Ophthalmic Solution           | 0.7%                               | Pataday Once<br>Daily Relief OTC<br>206276 | 9/10/2015          | 1                         | Non-forfeiture | 6/18/2019                     | 2/19/2020                        |   | 5/19/2032                                 |
| Omacetaxine Mepesuccinate                    | for Injection                 | 3.5 mg/vial                        | Synribo<br>203585                          | 10/26/2016         | 1                         | Extinguished   | 2/8/2022                      |                                  |   | 6/28/2023                                 |
| Omega-3-Acid Ethyl Esters                    | Capsules                      | 1 g                                | Lovaza<br>21654                            | 11/10/2008         | 3                         | Deferred       | 2/22/2022                     | 4/7/2014                         |   | 4/10/2017                                 |
| Omeprazole                                   | Delayed-release<br>Capsules   | 10 mg, 20 mg and 40<br>mg          | Prilosec<br>19810                          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Omeprazole and Sodium Bicarbonate            | Capsules                      | 20 mg/1100 mg and<br>40 mg/1100 mg | Zegerid<br>21849                           | 4/30/2007          | 1                         | Eligible       | 2/8/2022                      | 5/25/2010                        | 7/1/2010                                  | 7/16/2016                                 |
| Omeprazole and Sodium Bicarbonate            | Capsules                      | 20 mg/1100 mg                      | Zegerid OTC<br>22281                       | 4/20/2010          | 1                         | Extinguished   | 2/8/2022                      | 7/15/2016                        |   | 7/16/2016                                 |
| Omeprazole and Sodium Bicarbonate            | Powder for Oral<br>Suspension | 20mg/1680mg per<br>packet          | Zegerid<br>21636                           | 11/13/2007         | 1                         | Deferred       | 2/8/2022                      | 4/19/2013                        |   | 7/16/2016                                 |
| Omeprazole and Sodium Bicarbonate            | Powder for Oral<br>Suspension | 40 mg/1680 mg per<br>packet        | Zegerid<br>21636                           | 8/24/2007          | 1                         | Deferred       | 2/8/2022                      | 4/19/2013                        |   | 7/16/2016                                 |
| Omeprazole Magnesium                         | Delayed-release<br>Capsules   | 20 mg                              | Prilosec OTC<br>21229                      | 3/19/2007          | 1                         | Eligible       | 2/8/2022                      | 6/5/2009                         |   | 11/15/2019                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                 | DOSAGE FORM                   | STRENGTH                                | RLD/NDA                           | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS              | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|-------------------------------|---|-----------------------------------|--------------------|---------------------------|-----------------------------|-------------------------------|----------------------------------|---|---|
| Omeprazole Magnesium      | Delayed-release Tablets       | 20 mg                                   | Prilosec OTC 21229                | 3/30/2012          | 1                         | Eligible                    | 2/8/2022                      | 7/30/2015                        | 12/1/2017                                 | 11/15/2019                                |
| Omeprazole                | Delayed-release Tablets       | 20 mg                                   | Omeprazole 22032 (OTC)            | 6/3/2015           | 1                         | Extinguished Non-Forfeiture | 2/11/2020<br>2/11/2020        | 10/12/2018                       |   | 8/16/2025                                 |
| Ondansetron Hydrochloride | Injection                     | 2 mg/mL, 2 mL vials (Preservative-free) | Zofran 20007                      | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Ondansetron Hydrochloride | Injection                     | 2 mg/mL, 20 mL vials                    | Zofran 20007                      | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Ondansetron Hydrochloride | Injection                     | 0.64 mg/mL, 50 mL container (plastic)   | Zofran in Plastic Container 20403 | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Ondansetron Hydrochloride | Oral Solution                 | 4 mg/5 mL                               | Zofran 20605                      | 12/20/2004         | 1                         | Eligible                    | 2/22/2022                     | 12/26/2006                       |   | 5/20/2016                                 |
| Ondansetron Hydrochloride | Orally Disintegrating Tablets | 4 mg and 8 mg                           | Zofran ODT 20781                  | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Ondansetron Hydrochloride | Tablets                       | 4 mg, 8 mg, 16 mg and 24 mg             | Zofran 20103                      | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Orlistat                  | Capsules                      | 60 mg                                   | Alli 21887                        | 9/8/2010           | 1                         | Extinguished                | 2/8/2022                      |                                  |   | 1/6/2018                                  |
| Oseltamivir Phosphate     | Capsules                      | 30 mg and 45 mg                         | Tamiflu 21087                     | 8/2/2011           | 1                         | Eligible                    | 2/8/2022                      | 8/3/2016                         | 12/12/2016                                | 12/27/2016                                |
| Oseltamivir Phosphate     | Capsules                      | 75 mg                                   | Tamiflu 21087                     | 11/15/2010         | 1                         | Eligible                    | 2/8/2022                      | 8/3/2016                         | 12/12/2016                                | 12/27/2016                                |
| Oseltamivir Phosphate     | for Oral Suspension           | 6 mg/mL                                 | Tamiflu 21246                     | 6/18/2015          | 1                         | Extinguished                | 10/8/2019                     | 2/20/2018                        |   | 12/27/2016                                |
| Osimertinib Mesylate      | Tablets                       | 40 mg and 80 mg                         | Tagrisso 208065                   | 11/13/2019         | 3                         |                             |                               |                                  |   | 1/2/2035                                  |
| Ospemifene                | Tablets                       | 60 mg                                   | Osphena 203505                    | 12/29/2020         | 1                         | Eligible                    | 2/19/2024                     | 2/13/2024                        |   | 7/9/2028                                  |
| Oxaliplatin               | Injection                     | 5 mg/mL, 10 mL and 20 mL vials          | Eloxatin 21759                    | 2/9/2007           | 11                        | Eligible                    | 3/10/2020                     | 8/7/2009                         |   | 2/9/2017                                  |
| Oxaliplatin               | Injection                     | 5 mg/mL, 40 mL vials                    | Eloxatin 21759                    | 7/16/2007          | 1                         | Extinguished                | 3/10/2020                     |                                  |   | 8/7/2015                                  |
| Oxandrolone               | Tablets                       | 2.5 mg and 10 mg                        | Oxandrin 13718                    | 6/19/2006          | 1                         | Extinguished                | 2/8/2022                      |                                  |   | 12/5/2017                                 |
| Oxazepam                  | Capsules                      | 10 mg, 15 mg and 30 mg                  | Serax 15539                       | Pre-MMA            |                           |                             |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                 | DOSAGE FORM                         | STRENGTH                              | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-------------------------------------|---------------------------------------|------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Oxcarbazepine                             | Tablets                             | 150 mg, 300 mg and 600 mg             | Trileptal 21014        | 5/5/2006           | 1                         | Eligible                 | 2/8/2022                      | 10/9/2007                        |   | 2/12/2018                                 |
| Oxcarbazepine                             | Oral Suspension                     | 300 mg/5 mL                           | Trileptal 21285        | 12/26/2006         | 1                         | Eligible                 | 6/15/2021                     | 6/26/2009                        | 12/14/2009                                | 2/12/2018                                 |
| Oxcarbazepine                             | Extended-release Tablets            | 600 mg                                | Oxtellar XR 202810     | 3/20/2013          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 4/13/2027                                 |
| Oxcarbazepine                             | Extended-release Tablets            | 150 mg and 300 mg                     | Oxtellar XR 202810     | 4/12/2013          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 4/13/2027                                 |
| Oxybutynin                                | Transdermal System Extended-release | 3.9 mg/24 hrs                         | Oxytrol 21351          | 8/19/2008          | 1                         | Deferred                 | 2/8/2022                      | 3/4/2014                         |   | 4/26/2020                                 |
| Oxybutynin Chloride                       | Extended-release Tablets            | 5 mg, 10 mg and 15 mg                 | Ditropan XL 20897      | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Oxybutynin Chloride                       | Gel                                 | 10%                                   | Gelnique 22204         | 6/19/2014          | 1                         | Extinguished<br>Deferred | 6/15/2020<br>6/18/2019        | 5/31/2018                        |   | 4/26/2020                                 |
| Oxycodone                                 | Extended-release Tablets            | 10 mg, 20 mg, 40 mg, 80 mg and 160 mg | Oxycontin (NDA 020553) | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Oxycodone Hydrochloride                   | Extended-release Tablets            | 15 mg                                 | Oxycontin (NDA 020553) | 2/15/2007          | 2                         | Extinguished             | 2/8/2022                      |                                  |   | 4/16/2013                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets            | 30 mg and 60 mg                       | Oxycontin (NDA 020553) | 1/3/2007           | 1                         | Extinguished             | 2/8/2022                      |                                  |   | 4/16/2013                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets            | 10 mg                                 | Oxycontin (NDA 022272) | 10/25/2010         | 1                         | Extinguished             | 10/8/2019                     |                                  |   | 4/19/2025                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets            | 15 mg                                 | Oxycontin (NDA 022272) | 10/28/2010         | 1                         | Extinguished             | 10/8/2019                     |                                  |   | 4/19/2025                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets            | 20 mg                                 | Oxycontin (NDA 022272) | 10/29/2010         | 2                         | Extinguished             | 11/19/2019                    |                                  |   | 4/19/2025                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets            | 30 mg, 60 mg and 80 mg                | Oxycontin (NDA 022272) | 10/18/2010         | 1                         | Extinguished             | 6/18/2019                     |                                  |   | 4/19/2025                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets            | 40 mg                                 | Oxycontin (NDA 022272) | 10/4/2010          | 1                         | Extinguished             | 10/8/2019                     |                                  |   | 4/19/2025                                 |
| Oxycodone Hydrochloride                   | Tablets                             | 5 mg and 7.5 mg                       | Oxaydo 202080          | 2/7/2012           | 1                         | Extinguished             | 11/17/2020                    |                                  |   | 3/16/2025                                 |
| Oxycodone                                 | Extended-release Capsules           | 9 mg, 13.5 mg, 18 mg, 27 mg and 36 mg | Xtampza ER 208090      | 11/15/2017         | 1                         |                          |                               |                                  |   | 9/2/2036                                  |
| Oxycodone Hydrochloride and Acetaminophen | Extended-release Tablets            | 7.5 mg/325 mg                         | Xartemis XR            | 4/3/2014           | 1                         | Extinguished             | 2/9/2021                      |                                  |   | 12/21/2030                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                             | DOSAGE FORM                                  | STRENGTH   | RLD/NDA                  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS             | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF             | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------------------|--|--|--------------------------|--------------------|---------------------------|----------------------------|-------------------------------|----------------------------------|---|---|
| Oxymetazoline Hydrochloride           | Topical Cream                                | 1%   | Rhofade<br>208552        | 6/20/2019          | 1                         | Eligible                   | 11/2/2021                     | 10/4/2021                        |   | 6/11/2035                                 |
| Oxymorphone Hydrochloride             | Extended-release<br>Tablets                  | 5 mg, 10 mg, 20 mg<br>and 40 mg  | Opana ER                 | 11/23/2007         | 1                         | Eligible                   | 2/8/2022                      | 6/14/2010                        | 20 mg- 1/3/2013<br>5 mg, 10 mg and<br>40 mg -1/8/2013 | 7/3/2022                                  |
| Oxymorphone Hydrochloride             | Extended-release<br>Tablets                  | 7.5 mg and 15 mg   | Opana ER                 | 5/29/2008          | 1                         | Extinguished               | 2/8/2022                      | 12/13/2010                       |   | 7/3/2022                                  |
| Oxymorphone Hydrochloride             | Extended-release<br>Tablets                  | 30 mg  | Opana ER                 | 6/12/2008          | 1                         | Eligible                   | 2/8/2022                      | 7/22/2010                        | 1/8/2013  | 2/4/2023                                  |
| Oxymorphone Hydrochloride             | Extended-release<br>Tablets                  | 7.5 mg, 10 mg, and<br>15 mg  | Opana ER (NDA<br>201655) | 3/23/2012          | 1                         | Extinguished               | 3/10/2020                     |                                  |   | 7/10/2029                                 |
| Oxymorphone Hydrochloride             | Extended-release<br>Tablets                  | 5 mg   | Opana ER (NDA<br>201655) | 3/26/2012          | 1                         | Extinguished               | 2/8/2022                      |                                  |   | 7/10/2029                                 |
| Oxymorphone Hydrochloride             | Extended-release<br>Tablets                  | 20 mg, 30 mg and 40<br>mg  | Opana ER (NDA<br>201655) | 4/3/2012           | 1                         | Extinguished               | 2/8/2022                      |                                  |   | 7/10/2029                                 |
| Paclitaxel                            | Injection                                    | 6 mg/mL, 5 mL,<br>16.7 mL, 25 mL,<br>33.3 mL and<br>50 mL vials                      | Taxol<br>20262           | Pre-MMA            |                           |                            |                               |                                  |   |   |
| Paclitaxel Protein-Bound<br>Particles | For Injection<br>Suspension                  | 100 mg/vial  | Abraxane<br>21660        | 12/11/2015         | 1                         | Extinguished               | 9/4/2023                      |                                  |   | 10/27/2024                                |
| Palbociclib                           | Capsules                                     | 75 mg, 100 mg and<br>125 mg  | Ibrance<br>207103        | 2/4/2019           | 12                        | Extinguished               | 4/18/2023                     |                                  |   | 1/22/2023                                 |
| Palbociclib                           | Tablets                                      | 75 mg, 100 mg and<br>125 mg  | Ibrance<br>212436        | 11/24/2020         | 1                         | Deferred                   | 8/28/2023                     | 9/4/2023                         |   | 2/28/2034                                 |
| Paliperidone Palmitate                | Extended-release<br>Injectable<br>Suspension | 39 mg/0.25 mL,<br>78 mg/0.5 mL,<br>117 mg/0.75 mL,<br>156 mg/mL and<br>234 mg/1.5 mL | Invega Sustenna<br>22264 | 11/21/2017         | 1                         | Non-Forfeiture<br>Deferred | 1/22/2024<br>8/24/2021        | 7/6/2021                         |   | 1/26/2031                                 |
| Paliperidone Palmitate                | Extended-release<br>Injectable<br>Suspension | 546 mg/1.75 mL   | Invega Trinza<br>207946  | 6/24/2020          | 1                         |                            |                               |                                  |   | 4/5/2036                                  |
| Paliperidone Palmitate                | Extended-release<br>Injectable<br>Suspension | 819 mg/2.625 mL  | Invega Trinza<br>207946  | 4/30/2021          | 1                         |                            |                               |                                  |   | 4/5/2036                                  |



**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                  | DOSAGE FORM                            | STRENGTH  | RLD/NDA              | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|----------------------------|--|---|----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Paliperidone Palmitate     | Extended-release Injectable Suspension | 273 mg/0.875 mL and 410 mg/1.315 mL                                     | Invega Trinza 207946 | 7/14/2021          | 1                         |                |                               |                                  |   | 4/5/2036                                  |
| Palonosetron Hydrochloride | Injection                              | 0.05 mg/mL, 1.5 mL and 5 mL vials                                       | Aloxi 21372          | 5/27/2011          | 3                         | Extinguished   | 2/22/2022                     | 10/13/2015                       |   | 4/13/2015                                 |
| Pamidronate Disodium       | For Injection                          | 30 mg/vial<br>60 mg/vial<br>90 mg/vial                                  | Aredia 20036         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Pamidronate Disodium       | Injection                              | 30 mg/vial<br>60 mg/vial<br>90 mg/vial                                  | Aredia 20036         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Pantoprazole Sodium        | For Injection                          | 40 mg/vial  | Prontonix IV 20988   | 4/7/2005           | 1                         | Extinguished   | 8/27/2019                     |                                  |   | 11/17/2021                                |
| Pantoprazole Sodium        | Delayed-release Tablets                | 20 mg and 40 mg   | Protonix 20987       | 2/2/2004           |                           |                |                               |                                  |   |   |
| Pantoprazole Sodium        | for Delayed-release Oral Suspension    | 40 mg   | Protonix 22020       | 9/13/2019          | 1                         | Eligible       | 7/13/2020                     | 6/30/2020                        | 8/13/2020                                 | 6/7/2026                                  |
| Paricalcitol               | Injection                              | 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials | Zemplar 20819        | 11/28/2008         | 1                         | Eligible       | 3/10/2020                     | 7/27/2011                        |   | 10/8/2018                                 |
| Paricalcitol               | Capsules                               | 1 mcg and 2 mcg   | Zemplar 21606        | 10/14/2008         | 1                         | Eligible       | 2/22/2022                     | 9/27/2013                        | 9/30/2013                                 | 6/24/2014                                 |
| Paricalcitol               | Capsules                               | 4 mcg   | Zemplar 21606        | 8/25/2008          | 1                         | Eligible       | 2/22/2022                     | 9/27/2013                        | 9/30/2013                                 | 6/24/2014                                 |
| Paroxetine Hydrochloride   | Capsules                               | 10 mg and 20 mg   | Paxil 20885          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Paroxetine Hydrochloride   | Oral Suspension                        | 10 mg/5 mL  | Paxil 20710          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Paroxetine Hydrochloride   | Tablets                                | 10 mg, 20 mg, 30 mg and 40 mg   | Paxil 20031          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Paroxetine Hydrochloride   | Extended-release Tablets               | 25 mg   | Paxil CR 20936       | 9/9/2005           | 1                         | Eligible       | 2/22/2022                     | 6/29/2007                        | 5/14/2008                                 | 9/17/2017                                 |
| Paroxetine Hydrochloride   | Extended-release Tablets               | 37.5 mg   | Paxil CR 20936       | 5/19/2009          | 1                         | Eligible       | 2/22/2022                     | 4/14/2011                        | 5/5/2011                                  | 3/17/2017                                 |
| Paroxetine                 | Capsules                               | 7.5 mg  | Brisdelle 204516     | 4/7/2014           | 1                         | Extinguished   | 8/13/2019                     | 3/13/2019                        |   | 4/6/2029                                  |
| Patiromer Sorbitex Calcium | for Oral Suspension                    | 8.4 g, 16.8 g and 25.2 g  | Veltassa 205739      | 10/21/2019         | 2                         |                |                               |                                  |   | 10/8/2033                                 |
| Pemetrexed Disodium        | For Injection                          | 100 mg/vial   | Alimta 21462         | 7/1/2008           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 1/24/2017                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                | DOSAGE FORM                   | STRENGTH   | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-------------------------------|--|---------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Pemetrexed Disodium                      | For Injection                 | 500 mg/vial  | Alimta<br>21462     | 2/4/2008           | 2                         | Extinguished   | 3/10/2020                     |                                  |   | 1/24/2017                                 |
| Pemetrexed Disodium                      | For Injection                 | 1000 mg/vial   | Alimta<br>21462     | 6/27/2012          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 11/24/2021                                |
| Pemetrexed Disodium                      | For Injection                 | 750 mg/vial  | Alimta<br>21462     | 10/6/2016          | 1                         | Extinguished   | 2/22/2022                     |                                  |   | 11/24/2021                                |
| Perampanel                               | Tablets                       | 2 mg, 4 mg, 6 mg,<br>8 mg, 10 mg and<br>12 mg                  | Fycompa<br>202834   | 10/24/2016         | 2                         |                |                               |                                  |   | 7/1/2026                                  |
| Perampanel                               | Oral Suspension               | 0.5 mg/mL  | Fycompa<br>208277   | 12/20/2022         | 1                         |                |                               |                                  |   | 7/1/2026                                  |
| Pergolide Mesylate                       | Tablets                       | 0.05 mg, 0.25 mg<br>and 1 mg                                   | Permax<br>19385     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Perindopril Arginine and Amlodipine      | Tablets                       | 3.5 mg/2.5 mg,<br>7 mg/5 mg and<br>14 mg/10 mg                 | Prestalia<br>205003 | 11/4/2016          | 1                         | Extinguished   | 7/25/2022                     |                                  |   | 10/5/2029                                 |
| Perindopril Erbumine                     | Tablets                       | 2 mg, 4 mg and<br>8 mg   | Aceon<br>20184      | 6/6/2006           | 1                         | Extinguished   | 2/22/2022                     |                                  |   | 11/10/2009                                |
| Phentermine Hydrochloride                | Orally Disintegrating Tablets | 15 mg and 30 mg  | Suprenza<br>202088  | 10/19/2012         | 1                         | Deferred       | 2/22/2022                     | 6/28/2017                        |   | 7/23/2018                                 |
| Phentermine Hydrochloride                | Orally Disintegrating Tablets | 37.5 mg  | Suprenza<br>202088  | 3/22/2013          | 1                         | Deferred       | 2/22/2022                     | 6/28/2017                        |   | 7/23/2018                                 |
| Phentermine Hydrochloride and Topiramate | Extended-release Capsules     | 3.75 mg/23 mg<br>7.5 mg/46 mg<br>11.25 mg/69 mg<br>15 mg/92 mg | Qsymia<br>22580     | 7/18/2013          | 1                         | Extinguished   | 2/22/2022                     |                                  |   | 6/14/2020                                 |
| Phenylephrine and Ketorolac              | Injection                     | 1%/0.3%  | Omidria<br>205388   | 5/29/2015          | 1                         | Extinguished   | 8/13/2019                     |                                  |   | 7/30/2023                                 |
| Pilocarpine Hydrochloride                | Ophthalmic Solution           | 1.25%  | Vuity<br>214028     | 12/30/2022         | 1                         |                |                               |                                  |   | 4/24/2039                                 |
| Pimavanserin                             | Capsules                      | 34 mg  | Nuplazid<br>210793  | 4/29/2020          | 5                         | Eligible       | 1/22/2024                     | 1/16/2024                        |   | 8/27/2038                                 |
| Pimavanserin                             | Tablets                       | 10 mg  | Nuplazid<br>207318  | 4/29/2020          | 1                         | Eligible       | 1/22/2024                     | 1/16/2024                        |   | 6/3/2028                                  |
| Pioglitazone Hydrochloride               | Tablets                       | 15 mg, 30 mg and<br>45 mg                                      | Actos<br>21073      | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                                   | STRENGTH   | RLD/NDA                  | DATE OF SUBMISSION             | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS              | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---|--|--------------------------|--------------------------------|---------------------------|-----------------------------|-------------------------------|----------------------------------|---|---|
| Pioglitazone Hydrochloride and Glimepiride  | Tablets                                       | 30 mg/2 mg and 30 mg/4 mg                                | Duetact 21925            | 12/22/2009                     | 1                         | Deferred                    | 2/22/2022                     | 1/4/2013                         | 1/8/2013                                  | 6/8/2028                                  |
| Pioglitazone Hydrochloride and Metformin Hydrochloride  | Extended-release Tablets                      | 15 mg/1000 mg and 30 mg/1000 mg                          | Actoplus Met XR 22024    | 9/23/2011                      | 1                         | Extinguished                | 1/12/2021                     |                                  |   | 7/31/2026                                 |
| Pioglitazone Hydrochloride and Metformin Hydrochloride  | Tablets                                       | 15 mg/500 mg and 15 mg/850 mg                            | Actoplus Met 21824       | 3/6/2008                       | 1                         | Non-Forfeiture Extinguished | 2/22/2022                     | 2/25/2011                        | 8/17/2012                                 | 6/19/2016                                 |
| Piperacillin Sodium and Tazobactam Sodium   | For Injection                                 | 2.25 g/vial<br>3.375 g/vial<br>4.5 g/vial                | Zosyn 50684              | PIV received prior to 2/5/2009 |                           |                             |                               |                                  |   |   |
| Piperacillin Sodium and Tazobactam Sodium   | For Injection                                 | 12 g/1.5 g per vial (pharmacy bulk)                      | Zosyn 50684              | 12/6/2011                      | 1                         | Eligible                    | 2/22/2022                     | 10/29/2014                       | 1/24/2017                                 | 4/14/2023                                 |
| Piperacillin Sodium and Tazobactam Sodium   | For Injection                                 | 36 mg/4.5 g per vial (pharmacy bulk)                     | Zosyn 50684              | PIV received prior to 2/5/2009 | 1                         | Eligible                    | 12/1/2020                     | 9/15/2009                        | 10/29/2009                                | 4/14/2023                                 |
| Pirfenidone   | Capsules                                      | 267 mg   | Esbriet 22535            | 10/15/2018                     | 9                         | Eligible                    | 1/25/2022                     | 1/3/2022                         | 6/13/2022                                 | 8/30/2033                                 |
| Pirfenidone   | Tablets                                       | 267 mg and 801 mg  | Esbriet 208780           | 10/15/2018                     | 17                        | Eligible                    | 2/8/2022                      | 1/25/2022                        | 5/2/2022                                  | 8/30/2033                                 |
| Pirfenidone   | Tablets                                       | 534 mg   | Esbriet 208780           | 10/15/2018                     | 2                         | Eligible                    | 7/25/2022                     | 7/19/2022                        |   | 8/30/2033                                 |
| Pitavastatin Calcium  | Tablets                                       | 1 mg, 2 mg, and 4 mg                                     | Livalo 22363             | 8/5/2013                       | 7                         | Eligible                    | 7/25/2022                     | 12/20/2016                       | 11/2/2023                                 | 2/19/2024                                 |
| Pitolisant Hydrochloride  | Tablets                                       | 4.45 mg and 17.8 mg                                      | Wakix 211150             | 8/14/2023                      | 7                         |                             |                               |                                  |   | 3/7/2030                                  |
| Plecanatide   | Tablets                                       | 3 mg   | Trulance 208745          | 1/19/2021                      | 2                         |                             |                               |                                  |   | 6/5/2034                                  |
| Plerixafor  | Injection                                     | 24 mg/1.2 mL vials (20 mg/mL)                            | Mozobil 22311            | 12/17/2012                     | 3                         | Extinguished                | 87/2023                       |                                  |   | 7/23/2023                                 |
| Polyethylene Glycol 3350  | Powder for Oral Solution                      | 17g/Scoopful   | Miralax 22015            | Pre-MMA                        |                           |                             |                               |                                  |   |   |
| Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate, Potassium Chloride and Bisacodyl | For Oral Solution and Delayed-release Tablet  | 210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (1 Tablet Regimen) | Halflytely and Bisacodyl | 7/30/2010                      | 1                         | Eligible                    | 2/22/2022                     | 8/20/2014                        | 4/21/2015                                 | 10/22/2022                                |
| Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate, Potassium Chloride and Bisacodyl | For Oral Solution and Delayed-release Tablets | 210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (2 Tablet Regimen) | Halflytely and Bisacodyl | 1/28/2008                      | 1                         | Extinguished                | 2/22/2022                     |                                  |   | 10/22/2022                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM               | STRENGTH  | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS          | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------|---|------------------|--------------------|---------------------------|-------------------------|-------------------------------|----------------------------------|---|---|
| Polyethylene Glycol 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid                 | For Oral Solution         | 100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch | Moviprep 21881   | 11/27/2007         | 1                         | Eligible                | 9/8/2020                      | 1/25/2012                        | 8/31/2020                                 | 9/1/2024                                  |
| Polyethylene Glycol 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, Sodium Sulfate and Ascorbic Acid | For Oral Solution         | 140 g, 5.2 g, 2.2.g, 48.11 g, 9 g and 7.54 g per pouch    | Plenvu 209381    | 12/6/2018          | 1                         |                         |                               |                                  |   | 9/10/2033                                 |
| Pomalidomide  | Capsules                  | 1 mg, 2 mg, 3 mg and 4 mg                                 | Pomalyst 204026  | 2/8/2017           | 6                         | Non-Forfeiture Deferred | 12/14/2021<br>1/12/2021       | 10/3/2020                        |   | 6/21/2031                                 |
| Ponatinib Hydrochloride   | Tablets                   | 15 mg and 45 mg   | Iclusig 203469   | 3/31/2021          | 1                         | Eligible                | 8/7/2023                      | 7/14/2023                        |   | 12/12/2033                                |
| Ponatinib Hydrochloride   | Tablets                   | 10 mg and 30 mg   | Iclusig 203469   | 12/12/2022         | 1                         |                         |                               |                                  |   | 12/12/2033                                |
| Posaconazole  | Oral Suspension           | 40 mg/mL  | Noxafil 22003    | 2/28/2011          | 1                         | Extinguished            | 7/30/2019                     |                                  |   | 7/19/2019                                 |
| Posaconazole  | Delayed-release Tablets   | 100 mg  | Noxafil 205053   | 6/16/2014          | 1                         | Extinguished            | 7/30/2019                     |                                  |   | 7/19/2019                                 |
| Posaconazole  | Injection                 | 18 mg/mL, 16.7 mL vials                                   | Noxafil 205596   | 11/24/2015         | 1                         | Eligible                | 7/25/2022                     | 5/25/2022                        | 6/28/2023                                 | 7/4/2031                                  |
| Potassium Chloride  | Extended-release Capsules | 8 mEq and 10 mEq  | Micro K          | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Potassium Chloride  | Extended-release Tablets  | 10 mEq and 20 mEq   | K-Dur            | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Pralatrexate  | Injection                 | 20 mg/mL and 40 mg/2 mL                                   | Folotyn 22468    | 9/24/2013          | 4                         |                         |                               |                                  |   | 5/31/2025                                 |
| Pramipexole Dihydrochloride   | Tablets                   | 0.125 mg, 0.5 mg, 1 mg and 1.5 mg                         | Mirapex 20667    | 6/24/2005          | 1                         | Eligible                | 2/22/2022                     | 2/19/2008                        | 1/4/2010                                  | 3/25/2011                                 |
| Pramipexole Dihydrochloride   | Tablets                   | 0.25 mg   | Mirapex 20667    | 5/27/2005          | 1                         | Eligible                | 2/22/2022                     | 2/19/2008                        | 1/4/2010                                  | 3/25/2011                                 |
| Pramipexole Dihydrochloride   | Tablets                   | 0.75 mg   | Mirapex 20667    | 7/31/2008          | 1                         | Extinguished Eligible   | 4/18/2023<br>2/22/2022        | 4/9/2010                         |   | 10/8/2010                                 |
| Pramipexole Dihydrochloride   | Extended-release Tablets  | 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg                | Mirapex ER 22421 | 6/1/2010           | 1                         | Extinguished            | 2/8/2022                      |                                  |   | 4/26/2028                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                     | DOSAGE FORM                   | STRENGTH   | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF  | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------|-------------------------------|--|------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|--|---|
| Pramipexole Dihydrochloride   | Extended-release Tablets      | 2.25 mg and 3.75 mg  | Mirapex ER 22421 | 7/26/2011          | 1                         | Eligible       | 2/8/2022                      | 2/6/2014                         | 11/20/2015 - 2.25 mg<br>3.75 mg - 7/5/2016 | 4/26/2028                                 |
| Prasugrel Hydrochloride       | Tablets                       | 5 mg and 10 mg   | Effient 22307    | 7/10/2013          | 17                        | Eligible       | 6/29/2020                     | 7/12/2017                        | 8/15/2017                                  | 3/2/2022                                  |
| Pravastatin Sodium            | Tablets                       | 10 mg, 20 mg, 40 mg and 80 mg                                  | Pravachol 19898  | Pre-MMA            |                           |                |                               |                                  |  |   |
| Pravastatin Sodium            | Tablets                       | 30 mg  | Pravachol 19898  | 6/1/2005           | 1                         | Eligible       | 2/22/2022                     | 11/28/2006                       |  | 4/22/2014                                 |
| Prazosin Hydrochloride        | Capsules                      | 1 mg, 2 mg and 5 mg  | Minipress 17442  | Pre-MMA            |                           |                |                               |                                  |  |   |
| Prednisolone Sodium Phosphate | Oral Solution                 | 5 mg(base)/ 5 mL and 15 mg (base)/ 5 mL                        | Pediapred 19157  | Pre-MMA            |                           |                |                               |                                  |  |   |
| Prednisolone Sodium Phosphate | Orally Disintegrating Tablets | 10 mg, 15 mg and 30 mg   | Orapred 21959    | 7/22/2010          | 1                         | Eligible       | 8/27/2019                     | 4/10/2013                        | 12/8/2014                                  | 11/24/2019                                |
| Prednisone                    | Delayed-release Tablets       | 1 mg, 2 mg, and 5 mg   | Rayos 202020     | 11/26/2012         | 1                         | Deferred       | 2/22/2022                     | 4/25/2017                        |  | 4/23/2024<br>1/7/2028 - 5 mg              |
| Pregabalin                    | Capsules                      | 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg | Lyrica 21446     | 12/30/2008         | 8                         | Extinguished   | 12/13/2022                    |                                  |  | 12/30/2018                                |
| Pregablin                     | Oral Solution                 | 20 mg/mL   | Lyrica 22488     | 5/19/2010          | 1                         | Extinguished   | 7/25/2022                     |                                  |  | 12/30/2018                                |
| Pregabalin                    | Extended-release Tablets      | 330 mg   | Lyrica CR 209501 | 1/29/2018          | 1                         | Extinguished   | 4/20/2021                     | 4/12/2021                        |  | 11/2/2026                                 |
| Pregabalin                    | Extended-release Tablets      | 82.5 mg and 165 mg   | Lyrica CR 209501 | 2/2/2018           | 1                         | Extinguished   | 4/20/2021                     | 4/12/2021                        |  | 11/2/2026                                 |
| Propafenone                   | Extended-release Capsules     | 325 mg   | Rythmol SR 21416 | 11/07/2006         | 1                         | Deferred       | 7/25/2022                     | 10/18/2010                       | 1/3/2011                                   | 10/28/2014                                |
| Propafenone Hydrochloride     | Extended-release Capsules     | 225 mg and 425 mg  | Rythmol SR 21416 | 10/11/2006         | 1                         | Deferred       | 7/25/2022                     | 10/18/2010                       | 1/3/2011                                   | 10/28/2014                                |
| Propofol                      | Injection                     | 10 mg/mL ; 20 mL, 50 mL and 100 mL vials and 20 mL syringe     | Diprivan 19627   | Pre-MMA            |                           |                |                               |                                  |  |   |
| Propranolol Hydrochloride     | Extended-release Capsules     | 60 mg, 80 mg, 120 mg and 160 mg                                | Inderal LA 18553 | Pre-MMA            |                           |                |                               |                                  |  |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                       | DOSAGE FORM              | STRENGTH                                     | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|--------------------------|--|--------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Propranolol Hydrochloride                       | Oral Solution            | 4.28 mg/mL                                   | Hemangeol 205410   | 7/21/2022          | 1                         |                |                               |                                  |   | 10/16/2028                                |
| Quetiapine Fumarate                             | Extended-release Tablets | 400 mg                                       | Seroquel XR 22047  | 6/18/2008          | 1                         | Eligible       | 8/24/2020                     | 11/1/2016                        | 11/1/2016                                 | 5/28/2017                                 |
| Quetiapine Fumarate                             | Extended-release Tablets | 150 mg                                       | Seroquel XR 22047  | 11/17/2008         | 1                         | Eligible       | 8/24/2020                     | 5/9/2017                         | 11/1/2016                                 | 5/28/2017                                 |
| Quetiapine Fumarate                             | Extended-release Tablets | 200 mg and 300 mg                            | Seroquel XR 22047  | 6/12/2008          | 1                         | Eligible       | 8/24/2020                     | 5/9/2017                         | 11/1/2016                                 | 5/28/2017                                 |
| Quetiapine Fumarate                             | Extended-release Tablets | 50 mg  | Seroquel XR 22047  | 10/17/2008         | 1                         | Eligible       | 8/24/2020                     | 5/9/2017                         | 11/1/2016                                 | 5/28/2017                                 |
| Quetiapine Fumarate                             | Tablets                  | 25 mg  | Seroquel 20639     | 8/12/2005          | 1                         | Extinguished   | 8/24/2020                     | 3/27/2012                        |   | 9/26/2011                                 |
| Quetiapine Fumarate                             | Tablets                  | 50 mg, 150 mg and 400 mg                     | Seroquel 20639     | 2/12/2007          | 1                         | Extinguished   | 8/24/2020                     | 3/27/2012                        |   | 9/26/2011                                 |
| Quetiapine Fumarate                             | Tablets                  | 100 mg, 200 mg and 300 mg                    | Seroquel 20639     | 2/21/2006          | 1                         | Extinguished   | 8/24/2020                     | 3/27/2012                        |   | 9/26/2011                                 |
| Quinapril Hydrochloride                         | Tablets                  | 5 mg, 10 mg, 20 mg and 40 mg                 | Accupril 19885     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Quinapril Hydrochloride/<br>Hydrochlorothiazide | Tablets                  | 10 mg/12.5 mg<br>20 mg/12.5 mg<br>20mg/25 mg | Accuretic 20125    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Rabeprazole Sodium                              | Delayed-release Tablets  | 20 mg  | Aciphex 20973      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Raltegravir Potassium                           | Tablets                  | 400 mg                                       | Isentress 22145    | 10/12/2011         | 1                         |                |                               |                                  |   | 3/11/2029                                 |
| Raltegravir Potassium                           | Tablets                  | 600 mg                                       | Isentress HD 22145 | 10/21/2022         | 1                         |                |                               |                                  |   | 3/30/2032                                 |
| Raloxifene Hydrochloride                        | Tablets                  | 60 mg  | Evista 20815       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ramelteon                                       | Tablets                  | 8 mg   | Rozerem 21782      | 7/22/2009          | 2                         | Deferred       | 6/18/2019                     | 7/26/2013                        | 7/22/2019                                 | 7/22/2019                                 |
| Ramipril  | Capsules                 | 1.25 mg, 2.5 mg,<br>5 mg and 10 mg           | Altace 19901       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ranitidine                                      | Capsules                 | 150 mg and 300 mg                            | Zantac             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ranitidine                                      | Injection                | 25 mg/mL, 2 mL and<br>6 mL and 40 mL vials   | Zantac             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ranitidine                                      | Oral Solution            | 15 mg/mL                                     | Zantac             | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                       | DOSAGE FORM             | STRENGTH                              | RLD/NDA                            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-------------------------|---------------------------------------|------------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Ranitidine                                      | Tablets                 | 75 mg, 150 mg and 300 mg              | Zantac                             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ranitidine Hydrochloride                        | Tablets                 | 150 mg                                | Zantac 150 (NDA 21698/Product 002) | 10/30/2007         | 1                         | Extinguished   | 3/23/2021                     |                                  |   | 12/20/2010                                |
| Ranolazine                                      | Extended-release        | 500 mg and 1000 mg                    | Renexa 21526                       | 5/17/2010          | 1                         | Eligible       | 3/23/2021                     | 7/29/2013                        | 1/27/2019                                 | 5/27/2019                                 |
| Rasagiline Mesylate                             | Tablets                 | 0.5 mg and 1 mg                       | Azilect 21461                      | 5/17/2010          | 5                         | Eligible       | 3/23/2021                     | 9/12/2013                        | 1/2/2017                                  | 12/5/2026                                 |
| Regadenoson                                     | Injection               | 0.08 mg/mL, 5 mL vial                 | Lexiscan 22161                     | 4/10/2012          | 1                         | Extinguished   | 1/12/2021                     |                                  |   | 2/2/2027                                  |
| Regorafenib                                     | Tablets                 | 40 mg                                 | Stivarga 203085                    | 9/27/2016          | 2                         |                |                               |                                  |   | 2/16/2031                                 |
| Remifentanil Hydrochloride                      | for Injection           | 1 mg/vial, 2 mg/vial and 5 mg/vial    | Ultiva 20630                       | 12/27/2013         | 1                         | Extinguished   | 7/2/2019                      | 1/16/2018                        | 1/26/2018                                 | 9/10/2017                                 |
| Repaglinide                                     | Tablets                 | 0.5 mg*, 1 mg and 2 mg                | Prandin 20741                      | 2/10/2005          | 1                         | Eligible       | 3/23/2021                     | 7/11/2013                        | 7/24/2013                                 | 6/12/2018                                 |
| Repaglinide and Metformin Hydrochloride         | Tablets                 | 1 mg/500 mg and 2 mg/500 mg           | Prandimet 22386                    | 4/9/2009           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 6/12/2018                                 |
| Revefenacin                                     | Inhalation Solution     | 175 mcg/3 mL                          | Yupelri 210598                     | 11/9/2022          | 7                         |                |                               |                                  |   | 10/23/2039                                |
| Ribavirin                                       | Capsules                | 200 mg                                | Rebetol 20903                      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ribavirin                                       | for Inhalation Solution | 6 gm/vial                             | Virazole 18859                     | 5/22/2014          | 1                         | Eligible       | 3/23/2021                     | 10/6/2016                        | 12/15/2016                                | 11/21/2017                                |
| Ribociclib Succinate                            | Tablets                 | 200 mg                                | Kisqali 209092                     | 3/15/2021          | 4                         |                |                               |                                  |   | 4/14/2036                                 |
| Ribociclib Succinate and Letrozole (Copackaged) | Tablets                 | 200 mg and 2.5 mg                     | Kisqali Femara Co-Pack 209935      | 3/15/2021          | 4                         |                |                               |                                  |   | 4/14/2036                                 |
| Rifaximin                                       | Tablets                 | 550 mg                                | Xifaxan 21361                      | 12/18/2015         | 1                         | Non-Forfeiture | 8/24/2021                     |                                  |   | 10/2/2029                                 |
| Rifaximin                                       | Tablets                 | 200 mg                                | Xifaxan 21361                      | 1/28/2019          | 1                         |                |                               |                                  |   | 7/24/2029                                 |
| Riluzole  | Oral Suspension         | 50 mg/10 mL                           | Tiglutik Kit 209080                | 3/12/2021          | 1                         |                |                               |                                  |   | 3/12/2029                                 |
| Riociguat                                       | Tablets                 | 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg | Adempas 204819                     | 10/10/2017         | 3                         | Deferred       | 10/4/2022                     | 9/1/2022                         |   | 12/4/2026                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                 | DOSAGE FORM                         | STRENGTH                           | RLD/NDA              | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT       |
|---|-------------------------------------|------------------------------------|----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Risedronate Sodium                        | Tablets                             | 5 mg, 30 mg and 35 mg              | Actonel 20835        | 4/23/2004          | 1                         | Eligible       | 3/10/2020                     | 10/5/2007                        | 6/1/2015                                  | 6/10/2018 - 5 mg and 30 mg<br>7/17/2018 - 35 mg |
| Risedronate Sodium                        | Tablets                             | 75 mg                              | Actonel 20835        | 9/7/2007           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 6/10/2018                                       |
| Risedronate Sodium                        | Tablets                             | 150 mg                             | Actonel 20835        | 8/12/2008          | 1                         | Extinguished   | 3/10/2020                     | 6/13/2014                        |   | 5/6/2023  |
| Risedronate Sodium                        | Delayed-release Tablets             | 35 mg                              | Atelvia 22560        | 6/9/2011           | 1                         | Deferred       | 3/23/2021                     | 5/18/2015                        | 5/18/2015                                 | 1/9/2028  |
| Risedronate Sodium with Calcium Carbonate | Tablets                             | 35 mg; 500 mg                      | Actonel with Calcium | 12/18/2007         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 7/17/2018                                       |
| Risperidone                               | Oral Solution                       | 1 mg/mL                            | Risperdal 20588      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Risperidone                               | Tablets                             | 0.25 mg, 1 mg, 2 mg, 3 mg and 4 mg | Risperdal 20272      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Risperidone                               | Orally Disintegrating Tablets       | 0.25 mg                            | Risperdal 21444      | 4/11/2005          | 1                         | Eligible       | 3/23/2021                     | 4/30/2009                        | 6/1/2009                                  | 6/10/2017                                       |
| Risperidone                               | Orally Disintegrating Tablets       | 0.5 mg, 1 mg and 2 mg              | Risperdal 21444      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Risperidone                               | Orally Disintegrating Tablets       | 3 mg and 4 mg                      | Risperdal 21444      | 3/23/2005          | 1                         | Eligible       | 3/23/2021                     | 4/30/2009                        | 6/1/2009                                  | 6/10/2017                                       |
| Ritonavir                                 | Tablets                             | 100 mg                             | Norvir 22417         | 12/21/2010         | 1                         | Eligible       | 6/18/2019                     | 1/15/2015                        | 3/20/2018                                 | 5/10/2021                                       |
| Ritonavir                                 | Capsules                            | 100 mg                             | Norvir               | 10/31/2012         | 1                         | Extinguished   | 2/9/2021                      |                                  |   | 5/22/2020                                       |
| Rivastigmine Tartrate                     | Capsules                            | 1.5 mg, 3 mg, 4.5 mg and 6 mg      | Exelon 20823         | 4/21/2004          | 3                         | Eligible       | 3/23/2021                     | 10/22/2007                       |   | 2/11/2014                                       |
| Rivastigmine Tartrate                     | Oral Solution                       | 2 mg/mL                            | Exelon 21025         | 11/5/2004          | 1                         | Extinguished   | 8/27/2019                     |                                  |   | 2/11/2014                                       |
| Rivastigmine                              | Transdermal System Extended-release | 4.6 mg/24 hr and 9.5 mg/24 hr      | Exelon 22083         | 4/27/2011          | 1                         | Extinguished   | 3/23/2021                     |                                  |   | 1/8/2019  |
| Rivastigmine                              | Transdermal System Extended-release | 13.3 mg/24 hr                      | Exelon 22083         | 1/22/2013          | 1                         | Eligible       | 3/23/2021                     | 8/31/2015                        | 9/2/2015                                  | 1/8/2019  |
| Rivaroxaban                               | Tablets                             | 2.5 mg                             | Xarelto 22406        | 11/19/2018         | 4                         |                |                               |                                  |   | 11/13/2024                                      |



**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                 | DOSAGE FORM                   | STRENGTH  | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|-------------------------------|---|------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Rivaroxaban               | Tablets                       | 10 mg, 15 mg, and 20 mg                                     | Xarelto 22406    | 7/1/2015           | 8                         |                |                               |                                  |   | 8/28/2024                                 |
| Rivaroxaban               | Capsules                      | 10 mg, 15 mg and 20 mg                                      | Xarelto 22406    | 6/17/2022          | 1                         |                |                               |                                  |   | 2/17/2034                                 |
| Rizatriptan Benzoate      | Tablets                       | 5 mg and 10 mg  | Maxalt 20864     | 9/2/2004           | 1                         | Extinguished   | 3/23/2021                     | 12/31/2012                       |   | 2/11/2014                                 |
| Rizatriptan Benzoate      | Orally Disintegrating Tablets | 5 mg and 10 mg  | Maxalt-MLT 20865 | 2/17/2006          | 1                         | Eligible       | 3/23/2021                     | 12/31/2012                       | 12/31/2012                                | 2/11/2014                                 |
| Rofecoxib                 | Tablets                       | 12.5 mg, 25 mg and 50 mg                                    | Vioxx 21052      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Roflumilast               | Tablets                       | 500 mcg   | Daliresp 22522   | 3/2/2015           | 7                         | Eligible       | 6/18/2019                     | 7/13/2018                        | 10/19/2022                                | 3/8/2024                                  |
| Roflumilast               | Tablets                       | 250 mcg   | Daliresp 22522   | 1/25/2019          | 1                         | Eligible       | 9/20/2022                     | 9/7/2022                         | 10/20/2022                                | 3/8/2024                                  |
| Roflumilast               | Cream                         | 0.3%  | Zoryve 215985    | 12/27/2023         | 1                         |                |                               |                                  |   | 6/7/2037                                  |
| Romidepsin                | Injection                     | 10 mg/vial  | Istodax 22393    | 11/5/2013          | 1                         | Extinguished   | 11/2/2021                     | 10/12/2021                       |   | 8/22/2021                                 |
| Ropinirole Hydrochloride  | Tablets                       | 0.25 mg, 0.5 mg, 1 mg and 2 mg                              | Requip 20658     | 12/22/2004         | 1                         | Extinguished   | 3/10/2020                     | 5/5/2008                         |   | 5/19/2008                                 |
| Ropinirole Hydrochloride  | Tablets                       | 3 mg, 4 mg and 5 mg   | Requip 20658     | 2/4/2005           | 1                         | Extinguished   | 3/10/2020                     | 5/5/2008                         |   | 5/19/2008                                 |
| Ropinirole Hydrochloride  | Extended-release Tablets      | 2 mg  | Requip XL 22008  | 10/14/2008         | 1                         | Eligible       | 3/10/2020                     | 5/17/2012                        | 5/17/2012                                 | 6/6/2012                                  |
| Ropinirole Hydrochloride  | Extended-release Tablets      | 4 mg  | Requip XL 22008  | 10/31/2008         | 1                         | Eligible       | 3/10/2020                     | 5/17/2012                        | 5/17/2012                                 | 6/6/2012                                  |
| Ropinirole Hydrochloride  | Extended-release Tablets      | 6 mg  | Requip XL 22008  | 7/14/2009          | 1                         | Eligible       | 3/10/2020                     | 5/17/2012                        | 5/17/2012                                 | 6/6/2012                                  |
| Ropinirole Hydrochloride  | Extended-release Tablets      | 8 mg  | Requip XL 22008  | 11/3/2008          | 1                         | Eligible       | 3/10/2020                     | 5/17/2012                        | 5/17/2012                                 | 6/6/2012                                  |
| Ropinirole Hydrochloride  | Extended-release Tablets      | 3 mg  | Requip XL 22008  | 1/8/2009           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 6/6/2012                                  |
| Ropinirole Hydrochloride  | Extended-release Tablets      | 12 mg   | Requip XL 22008  | 2/5/2009           | 1                         | Eligible       | 3/10/2020                     | 5/17/2012                        | 5/17/2012                                 | 6/6/2012                                  |
| Ropivacaine Hydrochloride | Injection                     | 2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials | Naropin 20533    | 11/13/2006         | 1                         | Extinguished   | 3/23/2021                     | 7/17/2014                        |   | 9/23/2014                                 |
| Ropivacaine Hydrochloride | Injection                     | 2 mg/mL, 100 mL   | Naropin 20533    | 1/30/2015          | 1                         | Eligible       | 3/23/2021                     | 7/13/2016                        | 9/15/2016                                 | 11/28/2026                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                       | STRENGTH   | RLD/NDA         | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL   | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-----------------------------------|--|-----------------|--------------------|---------------------------|--------------------------|-------------------------------|------------------------------------|---|---|
| Ropivacaine Hydrochloride                         | Injection                         | 2 mg/mL, 200 mL  | Naropin 20533   | 9/3/2015           | 1                         | Extinguished             | 6/18/2019                     | 3/16/2018                          |   | 11/28/2026                                |
| Rosiglitazone Maleate                             | Tablets                           | 2 mg, 4 mg and 8 mg  | Avandia 21071   | Pre-MMA            |                           |                          |                               |                                    |   |   |
| Rosiglitazone Maleate and Metformin Hydrochloride | Tablets                           | 1 mg/ 500 mg,<br>2 mg/ 500mg<br>4 mg/ 500 mg<br>2 mg/ 1000 mg<br>4 mg/ 1000 mg   | Avandamet 21410 | 10/22/2004         | 1                         | Eligible                 | 3/23/2021                     | 5/7/2014<br>5/19/2017<br>1mg/500mg |   | 2/11/2017                                 |
| Rosuvastatin Calcium                              | Tablets                           | 5 mg, 10 mg, 20 mg and 40 mg   | Crestor 21366   | 8/13/2007          | 9                         | Non-Forfeiture           | 8/27/2019                     | 4/29/2016                          | 5/2/2016                                  | 8/4/2020                                  |
| Rotigotine  | Extended-release Transdermal Film | 1 mg/24 hr<br>2 mg/24 hr<br>3 mg/24 hr<br>4 mg/24 hr<br>6 mg/24 hr<br>8 mg/24 hr | Neupro 21829    | 11/26/2013         | 1                         |                          |                               |                                    |   | 9/1/2027                                  |
| Rufinamide  | Tablets                           | 100 mg   | Banzel 21911    | 11/14/2012         | 1                         | Extinguished<br>Deferred | 4/18/2023<br>9/6/2022         | 8/17/2022                          |   | 11/14/2022                                |
| Rufinamide  | Tablets                           | 200 mg and 400 mg  | Banzel 21911    | 11/14/2012         | 5                         | Eligible                 | 3/23/2021                     | 5/16/2016                          | 6/1/2021                                  | 11/14/2022                                |
| Rufinamide  | Oral Suspension                   | 40 mg/mL   | Banzel 201367   | 6/16/2014          | 1                         | Extinguished             | 10/8/2019                     |                                    |   | 11/14/2022                                |
| Ruxolitinib Phosphate                             | Cream                             | 1.5%   | Opzelura 215309 | 7/31/2023          | 1                         |                          |                               |                                    |   | 5/5/2041                                  |
| Ruxolitinib Phosphate                             | Tablets                           | 5 mg, 10 mg,<br>15 mg, 20 mg, and<br>25 mg                                       | Jakafi 202192   | 12/17/2015         | 1                         |                          |                               |                                    |   | 6/12/2028                                 |
| Sacubitril and Valsartan                          | Tablets                           | 24 mg/26 mg,<br>49 mg/51 mg<br>97 mg/103 mg                                      | Entresto 207620 | 7/8/2019           | 18                        |                          |                               |                                    |   | 5/27/2027                                 |
| Safinamide Mesylate                               | Tablets                           | 50 mg and 100 mg   | Xadago 2071454  | 3/22/2021          | 6                         | Eligible                 | 6/26/2023                     | 6/14/2023                          |   | 12/10/2028                                |
| Sapropterin Dihydrochloride                       | Tablets                           | 100 mg   | Kuvan 22181     | 6/5/2014           | 1                         | Eligible                 | 11/19/2019                    | 5/10/2019                          | 10/1/2020                                 | 11/16/2025                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME   | DOSAGE FORM                | STRENGTH   | RLD/NDA                 | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS       | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|----------------------------|--|-------------------------|--------------------|---------------------------|----------------------|-------------------------------|----------------------------------|---|---|
| Sapropterin Dihydrochloride                           | Powder for Oral Solution   | 100 mg per packet  | Kuvan<br>205065         | 11/9/2015          | 1                         | Eligible<br>Deferred | 1/27/2020<br>8/27/2019        | 8/20/2019                        | 10/1/2020                                 | 5/17/2025                                 |
| Sapropterin Dihydrochloride                           | Powder for Oral Solution   | 500 mg per packet  | Kuvan<br>205065         | 2/23/2017          | 1                         | Eligible             | 11/19/2019                    | 8/20/2019                        | 10/1/2020                                 | 11/1/2032                                 |
| Saxagliptin Hydrochloride                             | Tablets                    | 2.5 mg and 5 mg  | Onglyza<br>22350        | 7/31/2013          | 8                         | Eligible             | 8/7/2023                      | 7/31/2023                        | 7/31/2023                                 | 11/30/2028                                |
| Saxagliptin Hydrochloride and Metformin Hydrochloride | Extended-release Tablets   | 5 mg/500 mg<br>2.5 mg/1000 mg<br>5 mg/1000 mg                                      | Kombiglyze XR<br>200678 | 7/31/2013          | 3                         | Extinguished         | 8/7/2023                      |                                  |   | 7/31/2023                                 |
| Selexipag   | Tablets                    | 0.2 mg, 0.4 mg,<br>0.6 mg, 0.8 mg,<br>1 mg, 1.2 mg,<br>1.4 mg and 1.6 mg           | Uptravi<br>207947       | 12/23/2019         | 4                         | Eligible             | 1/10/2023                     | 12/21/2022                       |   | 8/1/2030                                  |
| Selexipag   | For Injection              | 1.8 mg/vial  | Uptravi<br>214275       | 7/29/2022          | 1                         |                      |                               |                                  |   | 8/1/2030                                  |
| Semaglutide   | Injection                  | 2 mg/1.5 mL and<br>4 mg/3 mL   | Ozempic<br>209637       | 12/6/2021          | 7                         |                      |                               |                                  |   | 6/21/2033                                 |
| Semaglutide   | Injection                  | 8 mg/3 mL  | Ozempic<br>209637       | 12/21/2022         | 1                         |                      |                               |                                  |   | 2/1/2032                                  |
| Semaglutide   | Injection                  | 0.25 mg/0.5 mL<br>0.5 mg/0.5 mL<br>1 mg/0.5 mL<br>1.7 mg/0.75 mL<br>2.4 mg/0.75 mL | Wegovy<br>215256        | 10/20/2022         | 1                         |                      |                               |                                  |   | 2/17/2041                                 |
| Sertraline Hydrochloride                              | Oral Concentrate           | 20 mg/mL   | Zoloft<br>20990         | 12/9/2003          | 1                         | Eligible             | 8/27/2019                     | 6/30/2006                        | 8/7/2007                                  | 10/11/2019                                |
| Sertraline Hydrochloride                              | Tablets                    | 25 mg, 50 mg and<br>100 mg   | Zoloft<br>19839         | Pre-MMA            |                           |                      |                               |                                  |   |   |
| Sertraline Hydrochloride                              | Tablets                    | 150 mg and 200 mg  | Zoloft<br>19839         | 11/9/2005          | 1                         | Eligible             | 8/24/2020                     | 2/6/2007                         |   | 8/13/2012                                 |
| Sevelamer Carbonate                                   | Powder for Oral Suspension | 0.8 g/packet and<br>2.4 g/packet   | Renvela<br>22318        | 12/30/2009         | 1                         | Extinguished         | 8/27/2019                     |                                  |   | 9/16/2014                                 |
| Sevelamer Carbonate                                   | Tablets                    | 800 mg   | Renvela<br>22127        | 12/4/2008          | 1                         | Extinguished         | 8/27/2019                     | 10/23/2017                       | 4/16/2014                                 | 9/16/2014                                 |
| Sevelamer Hydrochloride                               | Tablets                    | 400 mg and 800 mg  | Renagel<br>21179        | 5/22/2008          | 1                         | Extinguished         | 7/30/2019                     |                                  |   | 10/18/2020                                |
| Sevoflurane   | Inhalation                 | 100%, 250 mL   | Ultane<br>20478         | Pre-MMA            |                           |                      |                               |                                  |   |   |



**Paragraph IV Patent Certifications  
February 19, 2024**

| <b>DRUG NAME</b>  | <b>DOSAGE FORM</b>    | <b>STRENGTH</b>             | <b>RLD/NDA</b>              | <b>DATE OF SUBMISSION</b> | <b>NUMBER OF ANDAs SUBMITTED</b> | <b>180-DAY STATUS</b> | <b>180-DAY DECISION POSTING DATE</b> | <b>DATE OF FIRST APPLICANT APPROVAL</b> | <b>DATE OF FIRST COMMERCIAL MARKETING BY FTF</b> | <b>EXPIRATION DATE OF LAST QUALIFYING PATENT</b> |
|---|-----------------------|-----------------------------|-----------------------------|---------------------------|----------------------------------|-----------------------|--------------------------------------|---|--|--|
| Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid | Oral Solution         | 10 mg, 3.5 g, and 12 g      | Prepopik 202535             | 5/21/2014                 | 1                                | Extinguished          | 8/13/2019                            |   |  | 10/10/2028                                       |
| Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid | Oral Solution         | 10 mg, 3.5 g, and 12 g      | Clenpiq 209589              | 2/11/2019                 | 1                                |                       |                                      |   |  | 6/26/2034  |
| Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate       | Oral Solution         | 17.5 g/3.13 g/1.6 g         | Suprep Bowel Prep Kit 22372 | 11/8/2010                 | 1                                | Eligible              | 11/17/2020                           | 2/23/2017                               | 9/7/2022   | 3/7/2023   |
| Sodium Sulfate, Magnesium Sulfate and Potassium Chloride      | Tablets               | 1.479 g/0.225 g/0.188 g     | Sutab 213135                | 3/3/2023                  | 1                                |                       |                                      |   |  | 8/4/2037   |
| Sodium Oxybate  | Oral Solution         | 500 mg/mL                   | Xyrem 21196                 | 7/8/2010                  | 1                                | Eligible              | 7/2/2019                             | 1/17/2017                               |  | 6/16/2024  |
| Sodium Thiosulfate  | Intravenous Injection | 12.5 g/50 mL                | Sodium Thiosulfate 203923   | 4/29/2022                 | 1                                |                       |                                      |   |  | 3/29/2031  |
| Sodium Thiosulfate  | Intravenous Injection | 12.5 g/100 mL               | Pedmark 212937              | 10/7/2022                 | 1                                |                       |                                      |   |  | 7/1/2039   |
| Sodium Zirconium Cyclosilicate                                | for Oral Suspension   | 5 g/packet and 10 g/packet  | Lokelma 207078              | 5/18/2022                 | 5                                |                       |                                      |   |  | 10/14/2035                                       |
| Solifenacin Succinate   | Tablets               | 5 mg and 10 mg              | Vesicare 21518              | 4/8/2009                  | 1                                | Deferred              | 8/24/2020                            | 4/2/2014                                |  | 11/9/2018  |
| Solifenacin Succinate   | Oral Suspension       | 1 mg/mL                     | Vesicare LS 209529          | 5/27/2021                 | 1                                |                       |                                      |   |  | 5/18/2031  |
| Solriamfetol Hydrochloride                                    | Tablets               | 75 mg and 150 mg            | Sunosi 211230               | 6/20/2023                 | 6                                |                       |                                      |   |  | 3/19/2040  |
| Sofosbuvir  | Tablets               | 400 mg                      | Sovaldi 204671              | 12/6/2017                 | 2                                | Deferred              | 2/8/2022                             | 1/27/2022                               |  | 12/11/2030                                       |
| Sorafenib Tosylate  | Tablets               | 200 mg                      | Nexavar 21923               | 2/28/2014                 | 1                                | Eligible              | 11/17/2020                           | 9/10/2020                               |  | 2/11/2023  |
| Spirolactone  | Oral Suspension       | 25 mg/5 mL                  | Carospir 209478             | 12/31/2020                | 1                                | Eligible              | 9/18/2023                            | 9/5/2023                                | 10/31/2023                                       | 10/28/2036                                       |
| Sugammadex Sodium   | Injection             | 200 mg/2 mL and 500 mg/5 mL | Bridion 22225               | 12/16/2019                | 14                               | Deferred              | 6/12/2023                            | 6/9/2023                                |  | 1/27/2026  |
| Sumatriptan Succinate   | Injection             | 6 mg/0.5 mL, 0.5 mL vials   | Imitrex                     | 10/25/2004                | 1                                | Extinguished          | 8/24/2020                            | 10/9/2009                               |  | 8/6/2008   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                | DOSAGE FORM               | STRENGTH                                  | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS    | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--------------------------|---------------------------|---|--------------------|--------------------|---------------------------|-------------------|-------------------------------|----------------------------------|---|---|
| Sumatriptan Succinate    | Injection                 | 6 mg/0.5 mL, 0.5 mL (prefilled syringes)  | Imitrex            | 5/9/2006           | 1                         | Extinguished      | 3/10/2020                     |                                  |   | 8/6/2008                                  |
| Sumatriptan Succinate    | Tablets                   | 25 mg, 50 mg and 100 mg                   | Imitrex 20132      | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Sunitinib Malate         | Capsules                  | 12.5 mg, 25 mg, 37.5 mg and 50 mg         | Sutent 21938       | 1/26/2010          | 1                         | Extinguished      | 9/7/2021                      |                                  |   | 2/15/2021                                 |
| Tacrolimus               | Ointment                  | 0.03%                                     | Protopic 50777     | 11/22/2010         | 1                         | Extinguished      | 8/24/2020                     | 9/9/2014                         |   | 9/9/2014                                  |
| Tacrolimus               | Ointment                  | 0.10%                                     | Protopic 50777     | 9/9/2010           | 1                         | Extinguished      | 8/24/2020                     | 9/9/2014                         |   | 9/9/2014                                  |
| Tacrolimus               | Extended-release Capsules | 0.5 mg, 1 mg, and 5 mg                    | Astagraf XL 204096 | 9/24/2013          | 1                         | Extinguished      | 8/24/2020                     |                                  |   | 3/25/2019                                 |
| Tacrolimus               | Extended-release Tablets  | 0.75 mg, 1 mg and 4 mg                    | Envarsus XR 206406 | 3/31/2022          | 1                         |                   |                               |                                  |   | 5/30/2028                                 |
| Tadalafil                | Tablets                   | 2.5 mg                                    | Cialis 21368       | 10/14/2008         | 1                         | Eligible          | 6/18/2019                     | 5/22/2018                        | 9/27/2018                                 | 11/19/2020                                |
| Tadalafil                | Tablets                   | 5 mg, 10 mg and 20 mg                     | Cialis 21368       | 11/21/2007         | 1                         | Eligible          | 6/18/2019                     | 5/22/2018                        | 9/27/2018                                 | 11/19/2020                                |
| Tadalafil                | Tablets                   | 20 mg                                     | Adcirca 22332      | 10/15/2009         | 1                         | Eligible          | 6/18/2019                     | 8/3/2018                         | 8/8/2018                                  | 4/26/2020                                 |
| Tafamidis Meglumine      | Capsules                  | 20 mg                                     | Vyndaqel 211996    | 5/3/2023           | 1                         |                   |                               |                                  |   | 4/27/2024                                 |
| Tafamidis                | Capsules                  | 61 mg                                     | Vyndamax 212161    | 5/3/2023           | 3                         |                   |                               |                                  |   | 8/31/2035                                 |
| Tafuprost                | Ophthalmic Solution       | 0.0015%                                   | Zioptan 202514     | 2/10/2016          | 2                         | Eligible Deferred | 2/20/2023<br>12/14/2021       | 8/19/2019                        | 12/6/2022                                 | 12/18/2022                                |
| Tamoxifen Citrate        | Tablets                   | 10 mg and 20 mg                           | Nolvadex 17970     | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Tamsulosin Hydrochloride | Capsules                  | 0.4 mg                                    | Flomax 20579       | 12/20/2004         | 1                         | Extinguished      | 8/24/2020                     |                                  |   |   |
| Tapentadol Hydrochloride | Tablets                   | 50 mg, 75 mg, and 100 mg                  | Nucynta 22304      | 11/20/2012         | 4                         |                   |                               |                                  |   | 6/27/2025                                 |
| Tapentadol Hydrochloride | Extended-release Tablets  | 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg | Nucynta ER 200533  | 11/20/2012         | 2                         |                   |                               |                                  |   | 6/27/2025                                 |
| Tapentadol               | Oral Solution             | 20 mg/mL                                  | Nucynta 203794     | 12/20/2013         | 1                         |                   |                               |                                  |   | 6/27/2025                                 |
| Tasimelteon              | Capsules                  | 20 mg                                     | Hetlioz 205677     | 1/31/2018          | 3                         | Eligible Deferred | 1/10/2023<br>12/13/2022       | 12/12/2022                       | 12/29/2022                                | 5/17/2034                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                           | DOSAGE FORM      | STRENGTH                         | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS              | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------------|------------------|----------------------------------|-----------------------|--------------------|---------------------------|-----------------------------|-------------------------------|----------------------------------|---|---|
| Tavaborole                          | Topical Solution | 5%                               | Kerydin<br>204427     | 7/9/2018           | 13                        | Eligible                    | 11/17/2020                    | 10/13/2020                       | 10/19/2020                                | 5/26/2027                                 |
| Tazarotene                          | Topical Lotion   | 0.045%                           | Arazlo<br>211882      | 5/12/2022          | 1                         |                             |                               |                                  |   | 5/11/2038                                 |
| Teduglutide                         | Injection        | 5 mg/vial                        | Gattex Kit<br>203411  | 12/21/2016         | 1                         |                             |                               |                                  |   | 11/1/2025                                 |
| Telmisartan                         | Tablets          | 20 mg, 40 mg and 80 mg           | Micardis<br>20850     | 12/26/2006         | 1                         | Eligible                    | 8/24/2020                     | 1/8/2014                         | 1/8/2014                                  | 1/10/2020                                 |
| Telmisartan and Hydrochlorothiazide | Tablets          | 80 mg/12.5 mg and 40 mg/12.5 mg  | Micardis HCT<br>21162 | 12/31/2008         | 1                         | Extinguished                | 8/24/2020                     |                                  |   | 1/10/2020                                 |
| Temazepam                           | Capsules         | 7.5 mg                           | Restoril<br>18163     | 11/01/2006         | 1                         | Eligible                    | 8/24/2020                     | 9/8/2009                         |   | 5/18/2010                                 |
| Temozolomide                        | Capsules         | 5 mg, 20 mg, 100 mg and 250 mg   | Temodar<br>21029      | 3/20/2007          | 1                         | Eligible                    | 8/24/2020                     | 3/1/2010                         | 8/12/2013                                 | 8/11/2013                                 |
| Temozolomide                        | Capsules         | 140 mg and 180 mg                | Temodar<br>21029      | 3/24/2008          | 1                         | Eligible                    | 8/24/2020                     | 3/1/2010                         | 8/12/2013                                 | 8/11/2013                                 |
| Temsirolimus                        | Injection        | 25 mg/mL, 1.8 mL vial            | Torisel<br>22088      | 5/25/2011          | 1                         | Extinguished                | 3/10/2020                     |                                  |   | 4/18/2014                                 |
| Tenofovir Alafenamide Fumarate      | Tablets          | 25 mg                            | Vemlidy<br>208464     | 11/5/2019          | 6                         | Eligible                    | 4/18/2023                     | 3/30/2023                        |   | 8/15/2032                                 |
| Tenofovir Disoproxil Fumarate       | Tablets          | 300 mg                           | Viread<br>21356       | 1/26/2010          | 1                         | Eligible                    | 6/18/2019                     | 3/18/2015                        | 12/15/2017                                | 1/25/2018                                 |
| Tenofovir Disoproxil Fumarate       | Tablets          | 150 mg, 200 mg, and 250 mg       | Viread<br>21356       | 5/17/2012          | 1                         | Extinguished                | 6/18/2019                     |                                  |   | 1/25/2018                                 |
| Terazosin Hydrochloride             | Capsules         | 1 mg, 2 mg, 5 mg and 10 mg       | Hytrin<br>20347       | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Terazosin Hydrochloride             | Tablets          | 1 mg, 2 mg, 5 mg and 10 mg       | Hytrin<br>19057       | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Terbinafine Hydrochloride           | Tablets          | 250 mg                           | Lamisil<br>20539      | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Terfenadine                         | Tablets          | 60 mg                            | Seldane               | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Teriflunomide                       | Tablets          | 7 mg and 14 mg                   | Aubagio<br>202992     | 9/12/2016          | 21                        | Eligible                    | 6/18/2019                     | 7/27/2018                        | 3/12/2023                                 | 2/4/2034                                  |
| Teriparatide                        | Injection        | 250 mcg/mL, 2.4 mL prefilled Pen | Forteo<br>21318       | 7/27/2015          | 1                         | Extinguished Non-Forfeiture | 11/16/2023<br>11/16/2023      | 11/16/2023                       |   | 3/25/2025                                 |
| Testosterone                        | Gel              | 1%                               | Androgel              | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Testosterone                        | Gel              | 1%                               | Testim<br>21454       | 8/21/2008          | 1                         | Extinguished                | 3/10/2020                     |                                  |   | 6/11/2008                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                 | DOSAGE FORM                | STRENGTH                         | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|----------------------------|----------------------------------|------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Testosterone              | Gel                        | 1% (pump)                        | Androgel               | 12/19/2008         | 1                         | Extinguished   | 8/24/2020                     |                                  |   | 3/1/2021                                  |
| Testosterone              | Gel                        | 1.62% (pump)                     | Androgel               | 4/6/2012           | 1                         | Eligible       | 10/8/2019                     | 8/4/2015                         | 10/12/2018                                | 8/30/2020                                 |
| Testosterone              | Gel                        | 1.62% (1.25 g and 2.5 g packets) | Androgel               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Testosterone              | Gel                        | 10 mg/actuation                  | Fortesta 21463         | 8/14/2012          | 1                         | Deferred       | 8/24/2020                     | 8/5/2015                         |   | 11/9/2018                                 |
| Testosterone              | Topical Solution           | 30 mg/1.5 mL                     | Axiron 22504           | 1/29/2013          | 1                         | Extinguished   | 8/24/2020                     | 8/7/2017                         |   | 2/19/2017                                 |
| Testosterone Undecanoate  | Injection                  | 250 mg/mL                        | Aveed 22219            | 6/11/2014          | 1                         |                |                               |                                  |   | 3/14/2027                                 |
| Thalidomide               | Capsules                   | 50 mg and 100 mg                 | Thalomid 20785         | 12/18/2006         | 1                         | Extinguished   | 8/13/2019                     |                                  |   | 10/23/2020                                |
| Thalidomide               | Capsules                   | 200 mg                           | Thalomid 20785         | 9/25/2006          | 1                         | Extinguished   | 8/13/2019                     |                                  |   | 10/23/2020                                |
| Thalidomide               | Capsules                   | 150 mg                           | Thalomid 20785         | 2/3/2014           | 1                         |                |                               |                                  |   | 12/9/2023                                 |
| Tiagabine Hydrochloride   | Tablets                    | 2 mg and 4 mg                    | Gabitril 20646         | 2/1/2005           | 1                         | Eligible       | 8/24/2020                     | 11/4/2011                        |   | 6/10/2017                                 |
| Tiagabine Hydrochloride   | Tablets                    | 12 mg and 16 mg                  | Gabitril 20646         | 1/24/2014          | 1                         | Extinguished   | 8/24/2020                     | 10/13/2017                       |   | 6/10/2017                                 |
| Ticagrelor                | Tablets                    | 90 mg                            | Brilinta 22433         | 7/20/2015          | 16                        | Eligible       | 11/19/2019                    | 9/4/2018                         |   | 4/17/2030                                 |
| Ticagrelor                | Tablets                    | 60 mg                            | Brilinta 22433         | 9/30/2015          | 3                         | Eligible       | 8/13/2019                     | 9/4/2018                         |   | 4/17/2030                                 |
| Ticlopidine Hydrochloride | Tablets                    | 250 mg                           | Ticlid                 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Tigecycline               | For Injection              | 50 mg per vial                   | Tygacil                | 6/15/2009          | 1                         | Extinguished   | 8/24/2020                     | 5/27/2015                        |   | 4/9/2016                                  |
| Timolol Maleate           | Ophthalmic Solution        | 0.25% and 0.5%                   | Timoptic               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Timolol Maleate           | Ophthalmic Solution        | 0.5%                             | Istalol 21516          | 10/19/2012         | 1                         | Eligible       | 8/10/2020                     | 4/17/2015                        | 4/17/2015                                 | 11/16/2018                                |
| Tiopronin                 | Delayed-release Tablets    | 100 mg and 300 mg                | Thiola EC 211843       | 10/11/2022         | 2                         | Eligible       | 3/6/2023                      | 2/24/2023                        |   | 11/14/2038                                |
| Tiotropium Bromide        | Inhalation Powder Capsules | 18 mcg                           | Spiriva 21395          | 5/11/2018          | 1                         | Deferred       | 6/26/2023                     | 6/20/2023                        | 8/16/2023                                 | 4/19/2030                                 |
| Tiotropium Bromide        | Inhalation Aerosol         | 2.5 mcg per actuation            | Spiriva Respimat 21936 | 3/7/2023           | 1                         |                |                               |                                  |   | 4/16/2031                                 |



**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                | DOSAGE FORM               | STRENGTH                          | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS                             | 180-DAY DECISION POSTING DATE    | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--------------------------|---------------------------|-----------------------------------|------------------------|--------------------|---------------------------|--|----------------------------------|----------------------------------|---|---|
| Tirofiban Hydrochloride  | Injection                 | 12.5 mg/250 mL                    | Aggrastat 20913        | 10/3/2018          | 1                         | Extinguished<br>Non-Forfeiture<br>Deferred | 5/2/2023<br>2/6/2023<br>5/4/2021 | 4/8/2021                         |   | 5/1/2023                                  |
| Tirofiban Hydrochloride  | Injection                 | 5 mg/100 mL                       | Aggrastat 20913        | 8/29/2019          | 1                         | Extinguished<br>Deferred                   | 5/2/2023<br>2/6/2023             | 2/7/2023                         |   | 5/1/2023                                  |
| Tizanidine Hydrochloride | Capsules                  | 2 mg, 4 mg and 6 mg               | Zanaflex 21447         | 8/10/2007          | 1                         | Deferred                                   | 8/10/2020                        | 2/3/2012                         | 2/3/2012                                  | 11/28/2021                                |
| Tobramycin               | Inhalation Solution       | 300 mg/5 mL                       | Tobi 50753             | 6/29/2009          | 1                         | Extinguished                               | 8/10/2020                        | 10/10/2013                       |   | 10/19/2014                                |
| Tobramycin               | Inhalation Solution       | 300 mg/4 mL                       | Bethkis 201820         | 8/31/2017          | 1                         | Extinguished<br>Eligible                   | 4/18/2023<br>7/2/2019            | 6/26/2019                        |   | 9/22/2022                                 |
| Tofacitinib              | Tablets                   | 5 mg                              | Xeljanz 203214         | 11/7/2016          | 3                         | Eligible                                   | 3/20/2023                        | 3/13/2023                        |   | 12/8/2025                                 |
| Tofacitinib              | Tablets                   | 10 mg                             | Xeljanz 203214         | 7/24/2019          | 1                         | Eligible                                   | 7/13/2021                        | 6/1/2021                         |   | 12/8/2025                                 |
| Tofacitinib              | Extended-release Tablets  | 11 mg                             | Xeljanz XR 208246      | 11/7/2016          | 1                         | Extinguished                               | 8/10/2020                        |                                  |   | 3/25/2023                                 |
| Tofacitinib              | Extended-release Tablets  | 22 mg                             | Xeljanz XR 208246      | 12/28/2020         | 1                         | Eligible                                   | 8/24/2021                        | 8/19/2021                        |   | 3/14/2034                                 |
| Tofacitinib              | Oral Solution             | 1 mg/mL                           | Xeljanz 213082         | 11/12/2021         | 1                         | Eligible                                   | 10/16/2023                       | 9/25/2023                        |   | 12/8/2025                                 |
| Tolterodine Tartrate     | Extended-release Capsules | 2 mg and 4 mg                     | Detrol LA 21228        | 7/30/2007          | 1                         | Extinguished                               | 8/10/2020                        | 11/22/2016                       |   | 11/11/2019                                |
| Tolterodine Tartrate*    | Tablets                   | 1 mg and 2 mg                     | Detrol 20771           |                    |                           |  |                                  |                                  |   |   |
| Tolvaptan                | Tablets                   | 30mg                              | Samsca 22275           | 9/23/2013          | 1                         | Extinguished<br>Non-Forfeiture             | 6/15/2020<br>6/15/2020           |                                  |   | 5/19/2020                                 |
| Tolvaptan                | Tablets                   | 15 mg                             | Samsca 22275           | 10/10/2013         | 1                         | Non-Forfeiture                             | 5/19/2020                        | 2/15/2022                        | 3/10/2022                                 | 9/1/2026                                  |
| Tolvaptan                | Tablets                   | 60 mg                             | Samsca 22275           | 3/26/2018          | 1                         | Eligible                                   | 6/15/2020                        | 5/19/2020                        |   | 9/1/2026                                  |
| Tolvaptan                | Tablets                   | 15 mg, 30 mg, 45 mg, 60 mg, 90 mg | Jynarque 204441        | 4/8/2021           | 1                         |  |                                  |                                  |   | 4/7/2030                                  |
| Topiramate               | Capsules                  | 15 mg and 25 mg                   | Topamax Sprinkle 20844 | 9/7/2005           | 1                         | Eligible                                   | 8/10/2020                        | 4/15/2009                        | 4/15/2009                                 | 9/1/2019                                  |
| Topiramate               | Tablets                   | 25 mg, 100 mg and 200 mg          | Topamax 20505          | 12/26/2001         |                           |  |                                  |                                  |   |   |
| Topiramate               | Tablets                   | 50 mg                             | Topamax 20505          | 9/8/2005           | 1                         | Extinguished                               | 8/10/2020                        | 3/27/2009                        |   | 9/26/2008                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                                | DOSAGE FORM               | STRENGTH                                 | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS                       | 180-DAY DECISION POSTING DATE        | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|---------------------------|--|--------------------|--------------------|---------------------------|--------------------------------------|--------------------------------------|----------------------------------|---|---|
| Topiramate                               | Extended-release Capsules | 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg | Qudexy XR 205122   | 12/24/2015         | 1                         | Extinguished Non-Forfeiture          | 12/1/2020<br>8/27/2019               |                                  |   | 3/19/2033                                 |
| Topiramate                               | Extended-release Capsules | 200 mg                                   | Trokendi XR 201635 | 4/3/2014           | 1                         | Extinguished                         | 3/6/2023                             |                                  |   | 3/18/2029                                 |
| Topiramate                               | Extended-release Capsules | 25 mg, 50 mg, and 100 mg                 | Trokendi XR 201635 | 5/12/2014          | 1                         | Extinguished Non-Forfeiture Deferred | 3/20/2023<br>3/20/2023<br>11/19/2019 | 11/24/2017                       | 1/4/2023                                  | 3/18/2029                                 |
| Topiramate                               | Oral Solution             | 25 mg/mL                                 | Epronita 214679    | 10/6/2022          | 1                         |                                      |                                      |                                  |   | 8/21/2040                                 |
| Torsemide                                | Tablets                   | 5 mg, 10 mg, 20 mg, and 100 mg           | Demadex 20136      | Pre-MMA            |                           |                                      |                                      |                                  |   |   |
| Trabectedin                              | Powder for Injection      | 1 mg/vial                                | Yondelis 207953    | 4/23/2020          | 2                         |                                      |                                      |                                  |   | 1/7/2028                                  |
| Tramadol Hydrochloride                   | Tablets                   | 50 mg                                    | Ultram 20281       | Pre-MMA            |                           |                                      |                                      |                                  |   |   |
| Tramadol Hydrochloride                   | Extended-release Tablets  | 100 mg                                   | Ultram ER 21692    | 1/8/2007           | 1                         | Eligible                             | 8/10/2020                            | 11/13/2009                       | 11/13/2009                                | 5/10/2014                                 |
| Tramadol Hydrochloride                   | Extended-release Tablets  | 200 mg                                   | Ultram ER 21692    | 3/28/2007          | 1                         | Eligible                             | 8/10/2020                            | 11/13/2009                       | 11/13/2009                                | 5/10/2014                                 |
| Tramadol Hydrochloride                   | Extended-release Tablets  | 300 mg                                   | Ultram ER 21692    | 9/25/2007          | 1                         | Extinguished                         | 8/10/2020                            | 9/20/2011                        |   | 5/10/2014                                 |
| Tramadol Hydrochloride                   | Extended-release Tablets  | 100 mg, 200 mg and 300 mg                | Ryzolt 21745       | 6/18/2009          | 1                         | Eligible                             | 8/10/2020                            | 12/30/2011                       | 12/30/2011                                | 6/29/2020                                 |
| Trametinib Dimethyl Sulfoxide            | Tablets                   | 0.5 mg and 2 mg                          | Mekinist 204114    | 9/28/2023          | 1                         |                                      |                                      |                                  |   | 1/28/2032                                 |
| Trandolapril                             | Tablets                   | 1 mg, 2 mg and 4 mg                      | Mavik 20528        | 10/4/2004          | 1                         | Extinguished                         | 8/10/2020                            | 6/12/2007                        |   | 6/12/2007                                 |
| Trandolapril and Verapamil Hydrochloride | Extended-release Tablets  | 2 mg/180 mg and 2 mg/240 mg              | Tarka 20591        | 11/9/2007          | 1                         | Eligible                             | 8/10/2020                            | 5/26/2010                        |   | 2/24/2015                                 |
| Trandolapril and Verapamil Hydrochloride | Extended-release Tablets  | 1 mg/240 mg                              | Tarka 20591        | 2/20/2008          | 1                         | Eligible                             | 8/10/2020                            | 8/30/2010                        | 9/20/2010                                 | 2/24/2015                                 |
| Trandolapril and Verapamil Hydrochloride | Extended-release Tablets  | 4 mg/ 240 mg                             | Tarka 20591        | 7/24/2007          | 1                         | Eligible                             | 8/10/2020                            | 5/5/2010                         |   | 2/24/2015                                 |
| Tranexamic Acid                          | Tablets                   | 650 mg                                   | Lysteda 22430      | 5/24/2011          | 2                         | Eligible                             | 8/10/2020                            | 12/27/2012                       | 1/3/2013                                  | 3/4/2025                                  |
| Travoprost                               | Ophthalmic Solution       | 0.003%                                   | Izba 204822        | 12/30/2015         | 1                         | Extinguished                         | 8/10/2020                            |                                  |   | 10/10/2029                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                           | DOSAGE FORM                 | STRENGTH  | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------------|-----------------------------|---|------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Travoprost                          | Ophthalmic Solution         | 0.004%  | Travatan<br>21257      | 11/28/2008         | 1                         | Extinguished   | 8/10/2020                     |                                  |   | 12/22/2014                                |
| Travoprost (Preserved)              | Ophthalmic Solution         | 0.004%  | Travatan Z<br>21994    | 2/19/2009          | 1                         | Extinguished   | 8/13/2019                     |                                  |   | 12/2/2014                                 |
| Trazodone Hydrochloride             | Tablets                     | 150 mg  | Desyrel<br>18207       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Trazodone Hydrochloride             | Extended-release<br>Tablets | 150 mg and 300 mg                                 | Oleptro<br>22411       | 10/18/2010         | 1                         | Extinguished   | 8/10/2020                     |                                  |   | 6/29/2020                                 |
| Treprostinil Sodium                 | Injection                   | 10 mg/mL,<br>20 mL vial                           | Remodulin<br>21272     | 12/2/2011          | 1                         | Eligible       | 6/18/2019                     | 11/30/2017                       | 3/25/2019                                 | 3/29/2029                                 |
| Treprostinil Sodium                 | Injection                   | 1 mg/mL, 2.5 mg/mL,<br>and 5 mg/mL, 20 mL<br>vial | Remodulin<br>21272     | 12/7/2012          | 1                         | Eligible       | 6/18/2019                     | 11/30/2017                       | 3/25/2019                                 | 3/29/2029                                 |
| Treprostinil Sodium                 | Inhalation Solution         | 0.6 mg/mL,<br>2.9 mL ampules                      | Tyvaso<br>22387        | 4/13/2015          | 1                         | Extinguished   | 12/14/2021                    |                                  |   | 12/15/2028                                |
| Treprostinil                        | Extended-release<br>Tablets | 2.5 mg  | Orenitram<br>203496    | 12/24/2015         | 1                         |                |                               |                                  |   | 1/22/2031                                 |
| Treprostinil                        | Extended-release<br>Tablets | 0.25 mg and 1 mg                                  | Orenitram<br>203496    | 5/19/2016          | 1                         |                |                               |                                  |   | 1/22/2031                                 |
| Treprostinil                        | Extended-release<br>Tablets | 0.125 mg and 5 mg                                 | Orenitram<br>203496    | 12/28/2020         | 1                         |                |                               |                                  |   | 8/11/2031                                 |
| Trientine Tetrahydrochloride        | Tablets                     | 300 mg  | Cuvrior<br>215760      | 6/21/2023          | 1                         |                |                               |                                  |   | 5/3/2039                                  |
| Tretinoin                           | Cream                       | 0.025%, 0.05% and<br>0.1%                         | Retin-A                | Pre-MMA            |                           |                |                               |                                  |   |   |
| Tretinoin                           | Gel                         | 0.025%  | Retin-A<br>17579       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Tretinoin                           | Gel                         | 0.04%   | Retin-A Micro<br>20475 | 12/20/2010         | 1                         | Eligible       | 8/10/2020                     | 7/17/2013                        |   | 9/21/2016                                 |
| Tretinoin                           | Gel                         | 0.1%  | Retin-A Micro<br>20475 | 7/8/2010           | 1                         | Eligible       | 8/10/2020                     | 7/17/2013                        | 7/31/2013                                 | 9/21/2016                                 |
| Triamcinolone Acetonide             | Nasal Spray                 | 0.055 mg/Spray                                    | Nasacort AQ            | 12/29/2005         | 1                         | Deferred       | 8/10/2020                     | 7/30/2009                        |   | 7/3/2016                                  |
| Triamterene/<br>Hydrochlorothiazide | Tablets                     | 37.5 mg/25 mg and<br>75 mg/50 mg                  | Maxzide<br>19129       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Trifarotene                         | Cream                       | 0.005%  | Aklief<br>211527       | 10/4/2023          | 2                         |                |                               |                                  |   | 5/30/2033                                 |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                         | DOSAGE FORM               | STRENGTH  | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-----------------------------------|---------------------------|---|--------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Trifluridine and Tipiracil        | Tablets                   | 15 mg/6.14 mg and 20 mg/8.19 mg                 | Lonsurf 207981     | 9/23/2019          | 4                         | Deferred       | 6/26/2023                     | 6/13/2023                        |   | 6/17/2034                                 |
| Trospium Chloride                 | Extended-release Capsules | 60 mg   | Sanctura XR 22103  | 3/2/2009           | 1                         | Deferred       | 8/10/2020                     | 10/12/2012                       | 10/12/2012                                | 2/1/2025                                  |
| Ubrogepant <b>New</b>             | Tablets                   | 50 mg and 100 mg                                | Ubrelvy 211765     | 12/26/2023         | 4                         |                |                               |                                  |   | 12/22/2041                                |
| Ulipristal Acetate                | Tablets                   | 30 mg   | Ella 22474         | 8/13/2014          | 1                         | Eligible       | 8/10/2020                     | 2/13/2017                        |   | 6/12/2030                                 |
| Unoprostone Isopropyl             | Ophthalmic Solution       | 0.15%   | Rescula 21214      | 5/12/2014          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 7/9/2021                                  |
| Upadacitinib                      | Extended-release Tablets  | 15 mg   | Rinvoq 211675      | 8/16/2023          | 5                         |                |                               |                                  |   | 3/9/2038                                  |
| Upadacitinib                      | Extended-release Tablets  | 30 mg   | Rinvoq 211675      | 8/16/2023          | 4                         |                |                               |                                  |   | 3/9/2038                                  |
| Upadacitinib                      | Extended-release Tablets  | 45 mg   | Rinvoq 211675      | 8/16/2023          | 3                         |                |                               |                                  |   | 3/9/2038                                  |
| Valacyclovir Hydrochloride        | Tablets                   | 500 mg and 1000 mg                              | Valtrex 20487      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Valbenazine Tosylate              | Capsules                  | 40 mg and 80 mg                                 | Ingrezza 209241    | 4/12/2021          | 4                         |                |                               |                                  |   | 8/10/2040                                 |
| Valbenazine Tosylate              | Capsules                  | 60 mg   | Ingrezza 209241    | 2/14/2022          | 1                         |                |                               |                                  |   | 8/10/2040                                 |
| Valganciclovir Hydrochloride      | for Oral Solution         | 50 mg/mL  | Valcyte 22257      | 3/21/2011          | 1                         | Extinguished   | 1/2/2020                      |                                  |   | 3/29/2015                                 |
| Valganciclovir Hydrochloride      | Tablets                   | 450 mg  | Valcyte 21304      | 12/27/2005         | 1                         | Extinguished   | 7/27/2020                     |                                  |   | 7/28/2014                                 |
| Valsartan                         | Tablets                   | 40 mg, 80 mg, 160 mg and 320 mg                 | Diovan 21283       | 12/28/2004         | 1                         | Non-Forfeiture | 7/27/2020                     | 6/26/2014                        | 7/7/2014                                  | 6/18/2017                                 |
| Valsartan and Hydrochlorothiazide | Tablets                   | 80 mg/12.5 mg<br>160 mg/12.5 mg<br>160 mg/25 mg | Diovan HCT 20818   | 12/2/2005          | 1                         | Eligible       | 7/27/2020                     | 9/21/2012                        | 9/21/2012                                 | 6/18/2017                                 |
| Valsartan and Hydrochlorothiazide | Tablets                   | 320 mg/12.5 mg and 320 mg/25 mg                 | Diovan HCT 20818   | 2/7/2007           | 1                         | Eligible       | 7/27/2020                     | 9/21/2012                        | 9/21/2012                                 | 6/18/2017                                 |
| Vancomycin Hydrochloride          | For Oral Solution         | 25 mg/mL and 50 mg/mL                           | Firvanq Kit 208910 | 5/18/2020          | 1                         | Eligible       | 12/13/2022                    | 11/14/2022                       | 8/29/2023                                 | 3/13/2035                                 |
| Vardenafil Hydrochloride          | Tablets                   | 2.5 mg  | Levitra 21400      | 9/4/2009           | 1                         | Deferred       | 7/27/2020                     | 5/3/2012                         | 10/3/2018                                 | 10/31/2018                                |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                 | DOSAGE FORM                      | STRENGTH                                      | RLD/NDA                               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS             | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|----------------------------------|---|---------------------------------------|--------------------|---------------------------|----------------------------|-------------------------------|----------------------------------|---|---|
| Vardenafil Hydrochloride  | Tablets                          | 5 mg and 10 mg                                | Levitra<br>21400                      | 7/10/2009          | 1                         | Deferred                   | 7/27/2020                     | 5/3/2012                         | 10/3/2018                                 | 10/31/2018                                |
| Vardenafil Hydrochloride  | Tablets                          | 20 mg   | Levitra<br>21400                      | 3/5/2009           | 1                         | Deferred                   | 7/27/2020                     | 5/3/2012                         | 10/3/2018                                 | 10/31/2018                                |
| Vardenafil Hydrochloride  | Orally Disintegrating<br>Tablets | 10 mg   | Staxyn<br>200179                      | 12/22/2011         | 1                         | Extinguished<br>Eligible   | 6/18/2019<br>6/18/2019        | 4/23/2015                        |   | 10/31/2018                                |
| Varenicline Tartrate      | Tablets                          | 0.5 mg and 1 mg                               | Chantix<br>21928                      | 5/10/2010          | 5                         | Deferred                   | 9/7/2021                      | 8/11/2021                        | 9/21/2021                                 | 8/3/2022                                  |
| Varenicline Tartrate      | Nasal Spray                      | 0.03 mg/spray                                 | Tyvaya<br>213978                      | 4/21/2023          | 1                         |                            |                               |                                  |   | 10/19/2035                                |
| Vasopressin               | Injection                        | 20 units/mL, 1 mL                             | Vasopressin<br>204485                 | 3/23/2018          | 1                         | Non-Forfeiture<br>Deferred | 12/28/2021<br>12/28/2021      | 12/15/2021                       | 1/18/2022                                 | 1/30/2035                                 |
| Vasopressin               | Injection                        | 200 units/10 mL                               | Vasopressin<br>204485                 | 6/29/2018          | 1                         | Non-Forfeiture             | 2/6/2023                      |                                  |   | 1/30/2035                                 |
| Vasopressin               | Injection                        | 20 units/100 mL                               | Vasopressin<br>204485                 | 12/20/2022         | 1                         | Eligible                   | 1/8/2024                      | 12/6/2023                        |   | 1/30/2035                                 |
| Vasopressin               | Injection                        | 40 units/100 mL and<br>60 units/100 mL        | Vasopressin<br>204485                 | 2/28/2022          | 1                         |                            |                               |                                  |   | 1/30/2035                                 |
| Vecuronium Bromide        | For Injection                    | 10 mg/vial and<br>20 mg/vial                  | Norcuron<br>18776                     | Pre-MMA            |                           |                            |                               |                                  |   |   |
| Venetoclax                | Tablets                          | 10 mg, 50 mg and<br>100 mg                    | Venclexta<br>208573                   | 4/13/2020          | 2                         |                            |                               |                                  |   | 1/29/2032                                 |
| Venlafaxine Hydrochloride | Tablets                          | 25 mg, 37.5 mg,<br>50 mg, 75 mg and<br>100 mg | Effexor<br>20151                      | 11/03/2005         | 1                         |                            |                               | 8/3/2006                         | 6/15/2006                                 | 6/13/2008                                 |
| Venlafaxine Hydrochloride | Extended-release<br>Tablets      | 37.5 mg, 75 mg and<br>150 mg                  | Effexor XR<br>20699                   | 5/3/2007           | 1                         | Extinguished               | 7/27/2020                     |                                  |   | 3/20/2017                                 |
| Venlafaxine Hydrochloride | Extended-release<br>Tablets      | 37.5 mg, 75 mg and<br>150 mg                  | Venlafaxine<br>Hydrochloride<br>22104 | 2/12/2009          | 1                         | Eligible                   | 7/27/2020                     | 8/18/2010                        | 6/15/2006                                 | 3/20/2017                                 |
| Venlafaxine Hydrochloride | Extended-release<br>Tablets      | 225 mg  | Venlafaxine<br>Hydrochloride<br>22104 | 1/10/2011          | 1                         | Extinguished               | 7/27/2020                     | 1/8/2019                         |   | 3/20/2017                                 |
| Verapamil Hydrochloride   | Extended-release<br>Capsules     | 100 mg and 200 mg                             | Verelan PM<br>20943                   | 7/20/2006          | 1                         | Extinguished               | 7/27/2020                     | 8/9/2007                         |   | 6/19/2007                                 |
| Verapamil Hydrochloride   | Extended-release<br>Capsules     | 120 mg, 180 mg and<br>240 mg                  | Verelan SR                            | Pre-MMA            |                           |                            |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
February 19, 2024**

| DRUG NAME                 | DOSAGE FORM                 | STRENGTH                           | RLD/NDA           | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|-----------------------------|------------------------------------|-------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Verapamil Hydrochloride   | Extended-release Tablets    | 180 mg                             | Isoptin SR        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Verapamil Hydrochloride   | Extended-release Tablets    | 240 mg                             | Covera HS 20552   | Pre-MMA            |                           |                |                               |                                  |   |   |
| Verapamil Hydrochloride   | Extended-release Capsules   | 300 mg                             | Verelan PM 20943  | 5/19/2006          | 1                         | Extinguished   | 7/27/2020                     | 8/9/2007                         |   | 6/17/2007                                 |
| Vilazodone Hydrochloride  | Tablets                     | 10 mg, 20 mg, and 40 mg            | VIIBRYD 22567     | 1/21/2015          | 5                         | Eligible       | 7/27/2020                     | 9/13/2019                        | 6/4/2022                                  | 6/5/2022                                  |
| Vincristine Sulfate       | Injection                   | 1 mg/mL, 1 mL, 2 mL and 5 mL vials | Oncovin 14103     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Voriconazole              | For Injection               | 200 mg/vial                        | Vfend 21267       | 9/12/2008          | 1                         | Eligible       | 7/27/2020                     | 5/30/2012                        | 5/30/2012                                 | 6/2/2018                                  |
| Voriconazole              | Oral Suspension             | 40 mg/mL                           | Vfend 21630       | 10/8/2010          | 1                         | Eligible       | 7/27/2020                     | 5/28/2013                        | 9/25/2013                                 | 5/24/2016                                 |
| Voriconazole              | Tablets                     | 50 mg and 200 mg                   | Vfend 21266       | 4/14/2008          | 1                         | Eligible       | 7/27/2020                     | 4/22/2010                        | 2/15/2011                                 | 5/24/2016                                 |
| Vortioxetine              | Tablets                     | 5 mg, 10 mg, 15 mg and 20 mg       | Trintellix 204447 | 10/2/2017          | 15                        | Deferred       | 10/5/2021                     | 9/17/2021                        |   | 6/30/2031                                 |
| Voxelotor                 | Tablets                     | 300 mg and 500 mg                  | Oxbryta 213137    | 11/27/2023         | 2                         |                |                               |                                  |   | 10/12/2037                                |
| Voxelotor                 | Tablets for Oral Suspension | 300 mg                             | Oxbryta 216157    | 11/27/2023         | 1                         |                |                               |                                  |   | 12/2/2036                                 |
| Zafirlukast               | Tablets                     | 10 mg and 20 mg                    | Accolate 20547    | 2/29/2008          | 1                         | Eligible       | 7/27/2020                     | 11/18/2010                       | 11/18/2010                                | 3/18/2014                                 |
| Zaleplon                  | Capsules                    | 5 mg and 10 mg                     | Sonata 20859      | 6/21/2005          | 1                         | Extinguished   | 7/27/2020                     | 6/6/2008                         |   | 6/6/2008                                  |
| Zanubrutinib              | Capsules                    | 80 mg                              | Brukisa 213217    | 11/14/2023         | 2                         |                |                               |                                  |   | 1/19/2043                                 |
| Zidovudine                | Capsules                    | 100 mg                             | Retrovir 19665    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ziprasidone Hydrochloride | Capsules                    | 20 mg, 40 mg, 60 mg and 80 mg      | Geodon 20825      | 2/7/2005           | 5                         | Eligible       | 7/27/2020                     | 3/2/2012                         | 3/2/2012                                  | 5/27/2019                                 |
| Zoledronic Acid           | Injection                   | 0.05 mg/mL, 100 mL vial            | Reclast 21817     | 8/29/2008          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 9/2/2012                                  |
| Zoledronic Acid           | Injection                   | 0.8 mg (base) /mL                  | Zometa 21223      | 6/11/2008          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 9/2/2012                                  |
| Zoledronic Acid           | Injection                   | 4 mg/100 mL, 100 mL vial           | Zometa 21223      | 1/31/2012          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 2/5/2028                                  |

**Paragraph IV Patent Certifications  
February 19, 2024**

| <b>DRUG NAME</b>                                | <b>DOSAGE FORM</b>          | <b>STRENGTH</b>    | <b>RLD/NDA</b>      | <b>DATE OF SUBMISSION</b> | <b>NUMBER OF ANDAs SUBMITTED</b> | <b>180-DAY STATUS</b> | <b>180-DAY DECISION POSTING DATE</b> | <b>DATE OF FIRST APPLICANT APPROVAL</b> | <b>DATE OF FIRST COMMERCIAL MARKETING BY FTF</b> | <b>EXPIRATION DATE OF LAST QUALIFYING PATENT</b> |
|---|-----------------------------|--------------------|---------------------|---------------------------|----------------------------------|-----------------------|--------------------------------------|---|--|--|
| Zolmitriptan                                    | Nasal Spray                 | 2.5 mg/spray       | Zomig<br>21450      | 6/9/2016                  | 1                                | Extinguished          | 7/27/2020                            |   |  | 11/28/2020                                       |
| Zolmitriptan                                    | Nasal Spray                 | 5 mg/spray         | Zomig<br>21450      | 11/14/2013                | 1                                | Extinguished          | 1/12/2021                            |   |  | 11/28/2020                                       |
| Zolpidem Tartrate                               | Extended-release<br>Tablets | 6.25 mg            | Ambien CR<br>21774  | 2/24/2006                 | 1                                | Non-Forfeiture        | 7/27/2020                            | 10/13/2010                              | 10/13/2010                                       | 6/1/2020   |
| Zolpidem Tartrate                               | Extended-release<br>Tablets | 12.5 mg            | Ambien CR<br>21774  | 1/19/2006                 | 1                                | Non-Forfeiture        | 7/27/2020                            | 12/3/2010                               | 12/6/2020  | 6/1/2020   |
| Zolpidem Tartrate                               | Sublingual Tablets          | 5 mg and 10 mg     | Edluar<br>21997     | 4/29/2010                 | 1                                | Extinguished          | 7/27/2020                            | 8/1/2016                                |  | 9/24/2018  |
| Zolpidem Tartrate                               | Sublingual Tablets          | 1.75 mg and 3.5 mg | Intermezzo<br>22328 | 4/10/2012                 | 1                                | Eligible              | 7/27/2020                            | 6/3/2015                                | 3/23/2016  | 4/15/2027  |
| * ANDA withdrawn or<br>exclusivity relinquished |                             |                    |                     |                           |                                  |                       |                                      |   |  |  |